Conditions: Non-Small Cell Lung Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 504
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether Nivolumab improves life expectancy compared to Docetaxel in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who have failed prior platinum-based doublet chemotherapy.

Detailed description:

Arms:
arm 1: Nivolumab Intravenous infusion specified dose on specified days arm 2: Docetaxel Intravenous infusion specified dose on specified days

Interventions: intervention 1: Nivolumab intervention 2: Docetaxel
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document:
Prot_000.pdf: 
Page:
1
Protocol Number:
CA209078
IND Number:
100,052
Ex-US
Non-IND
EUDRACT Number
2015-001893-16
Date:
22-Mar-2013
Revised Date:
13-Dec-2017
Clinical Protocol CA209078
An Open-label Randomized Multinational Phase 3 Trial of Nivolumab versus Docetaxel in 
Previously Treated Subjects with Advanced or Metastatic Non-small Cell Lung Cancer
(CheckMate 078: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 078)
Revised Protocol Number: 05
Incorporates amendment(s) 05
Study Director/Medical Monitor
Xiaoqing Zhang
This document is the confidential and proprietary information of Bristol-Myers Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS-sponsored 
study. Any permitted disclosures will be made only on a confidential "need to know" basis 
within your organization or to your independent ethics committee(s). Any other use, 
copying, disclosure or dissemination of this information is strictly prohibited unless 
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Revised Protocol No: 05
Date: 13-Dec-2017
2
expressly authorized in writing by BMS. Any supplemental information (eg, amendments) 
that may be added to this document is also confidential and proprietary to BMS and must 
be kept in confidence in the same manner as the contents of this document. Any person 
who receives this document without due authorization from BMS is requested to return it 
to BMS or promptly destroy it. All other rights reserved. References to BMS in this 
protocol may apply to partners to which BMS has transferred obligations, eg, a Contract 
Research Organization (CRO).
Replace all previous version(s) of the protocol with this revised protocol and please provide a 
copy of this revised protocol to all study personnel under your supervision, and archive the 
previous versions.
7.0
Approved
930067687
7.0
v






Clinical Protocol
CA209078
BMS-936558
nivolumab
SYNOPSIS
Clinical Protocol CA209078
(CheckMate 078: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 078)
Protocol Title: An Open-label Randomized Multinational Phase 3 Trial of Nivolumab versus Docetaxel in 
Previously Treated Subjects with Advanced or Metastatic Non-small Cell Lung Cancer
Investigational Product(s), Dose and Mode of Administration, Duration of Treatment with Investigational 
Product(s): For subjects randomized to nivolumab, they will be dosed intravenously over 60 minutes at 3 mg/kg 
every 2 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol. For 
subjects randomized to docetaxel, they will be dosed intravenously over 60 minutes at 75 mg/m² every 3 weeks until 
disease progression, unacceptable toxicity, or other reasons specified in the protocol.
Amendment 05 Update:
Optional Switch of Arm B Subjects Receiving Docetaxel Treatment to Nivolumab 3mg/kg Q2 Weeks (Arm A) 
Under Amendment 05, subjects treated with docetaxel will have the option to switch to intravenous nivolumab 
3 mg/kg every 2 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol. 
Study Phase:  3
Research Hypothesis: The treatment effect of nivolumab is consistent between the study population and subjects 
from global pivotal trials (CheckMate 057 and CheckMate 017) and nivolumab increases OS as compared with 
docetaxel, in subjects with advanced or metastatic NSCLC who have failed prior platinum-based doublet 
chemotherapy.
Objectives: 
Primary:  

To demonstrate that the OS benefit of nivolumab in this study population with advanced or metastatic NSCLC 
after failure of prior platinum-based chemotherapy is consistent with benefit observed in global studies 
CheckMate 057 and CheckMate 017.

To compare the OS of nivolumab versus docetaxel in subjects with advanced or metastatic NSCLC after failure 
of prior platinum-based chemotherapy.
Secondary: Secondary objectives include the following:

To compare the objective response rate (ORR) of nivolumab versus docetaxel.

To compare the progression-free survival (PFS) of nivolumab versus docetaxel.

To compare the time to treatment failure (TTF) of nivolumab versus docetaxel

To evaluate clinical efficacy (OS, ORR, and PFS) in different subgroups, including squamous and 
non-squamous NSCLC subgroups, PD-L1 positive and PD-L1 negative protein expression subgroups, and 
Chinese and non-Chinese subgroups.

To evaluate the rate of treatment related selected AEs and SAEs in nivolumab and docetaxel arms.

To evaluate the proportion of subjects exhibiting disease-related symptom deterioration by Week 12 and by 
Week 24, as measured by the Lung Cancer Symptom Scale (LCSS), in nivolumab and docetaxel arms.
Revised Protocol No: 05
Date: 13-Dec-2017
5
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Study Design:  This is an open-label, randomized, Phase 3 study in adult (18 years old) male and female subjects 
with advanced or metastatic NSCLC after failure of prior platinum-doublet chemotherapy. Approximately 
500 subjects, will be randomized to nivolumab vs docetaxel in a 2:1 ratio.
Subjects will undergo screening evaluations to determine eligibility within 28 days prior to randomization. Subjects 
will be assigned in a 2:1 ratio to one of two treatment arms (see Study Design and Duration schema in Figure 1 
below). Randomization will be stratified and balanced according to the following factors: histology (squamous vs
non-squamous)/ PD-L1 Status (positive vs negative/unevaluable)/ ECOG Performance status (0 vs 1).
Approximately 100 PD-L1 unevaluable subjects will be randomized
Figure 1: 
Study Design
Stage IIIb/IV 
or recurrent 
NSCLC
EGFR Wild 
Type
Disease 
progression 
after 
platinum-
based doublet 
chemotherapy
Nivolumab  
3 mg/kg q 2 weeks until 
disease progression or 
unacceptable toxicity
Docetaxel 
75 mg/m² q 3 weeks until 
disease progression or 
unacceptable toxicity
A
B
R
Primary endpoint: 
OS
Secondary endpoints:
• ORR
• PFS
• TTF
• Efficacy in different  
subgroups (Squamous/non-
squamous, PD-L1 +/-, 
Chinese/non-Chinese )
• Rates of treatment selected 
AEs and SAEs
• Rate of disease related 
symptom deterioration 
measured by LCSS
2:1
Amendment 05 Update: Subjects currently receiving treatment with nivolumab (Arm A) will continue to be treated 
and monitored as specified in the protocol.
With this amendment, all subjects randomized to Arm B docetaxel treatment who meet eligibility criteria may enter 
the Nivolumab Crossover Extension Phase, according to the schema below. These subjects will follow the 
assessment schedules outlined in Table 5.1-7 of the protocol.
Subjects treated with docetaxel who have ended study treatment will be able to receive treatment with nivolumab via 
the crossover extension phase of the study, assuming basic inclusion/exclusion criteria are met (including a 3-week 
washout period for prior systemic anti-cancer therapy). Details are provided in Sections 3.3.1 and 3.3.2.
Subjects currently receiving treatment with docetaxel should continue to be treated and monitored as specified in the 
protocol as long as they are continuing to derive benefit from docetaxel in the judgment of the investigator. These 
subjects may receive nivolumab once they are discontinued from docetaxel therapy, assuming basic 
inclusion/exclusion criteria are met (including a 3-week washout period from last dose of docetaxel).
Figure -2:
Nivolumab Crossover Extension Phase Schema for Subjects Previously Randomized 
to Docetaxel
Treatment beyond investigator-assessed RECIST 1.1-defined progression may be considered for subjects meeting 
criteria according to Section 4.5.4. Treatment beyond progression for subjects in the nivolumab crossover extension 
Revised Protocol No: 05
Date: 13-Dec-2017
6
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
phase must be approved by the BMS Medical Monitor prior to subjects receiving additional study drug. Criteria for 
discontinuation of treatment beyond progression are described in Section 4.5.4. Subjects who discontinue study 
therapy for reasons other than progression should continue to be scanned until disease progression is documented.
Study Population: Subjects must meet all eligibility criteria specified in Sections 3.3.1 and 3.3.2 of the protocol, 
including the following:
Key Inclusion Criteria (See Protocol Section 3.3.1 for full list of criteria)
1.
Subjects with histologically- or cytologically-documented NSCLC who present with Stage IIIB/IV disease 
(according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in 
Thoracic Oncology), or with recurrence of progressive disease following multimodal therapy (radiation therapy, 
surgical resection or definitive chemoradiation therapy for locally advanced disease)
2.
Subjects must have experienced disease progression during or after one prior platinum-containing doublet 
chemotherapy (carboplatin or cisplatin) regimen for advanced or metastatic disease.

Subjects who received maintenance therapy (non-progressors with platinum-based doublet chemotherapy) 
and progressed are eligible. 

Subjects who received platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy 
given for locally advanced disease and developed recurrent or metastatic disease within 6 months of 
completing therapy are eligible. 

Subjects with recurrent disease > 6 months after platinum containing adjuvant, neoadjuvant or definite 
chemoradiation therapy given for locally advanced disease, who also subsequently progressed during or 
after a platinum- doublet regimen given to treat the recurrence, are eligible.
3.
Subjects must have measurable disease disease by CT or MRI per RECIST 1.1 criteria (per Appendix 2). 
Radiographic Tumor Assessment performed within 28 days prior to randomization.
a)
Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease 
progression in that site.
4.
Males and Females 18 years of age.
5.
ECOG performance status of 1.
6.
A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 10 unstained slides 
(submission of less than 10 unstained slides may be acceptable after approval by BMS Medical Monitor) of
tumor sample (archival or recent) must be available for biomarker evaluation at a central laboratory. In order to 
be randomized; subjects will be classified as PD-L1 positive, PD-L1 negative or PD-L1 unevaluable. Biopsy 
should be excisional, incisional or core needle. Fine needle biopsies, drainage of pleural effusions with 
cytospins or punch biopsies are not considered adequate for biomarker review and randomization. Biopsies of 
bone lesions that do not have a soft tissue component or decalcified bone tumor samples are also not acceptable
7.
Prior palliative radiotherapy to non-CNS lesions must have been completed at least 2 weeks prior to 
randomization. Subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy 
within 4 weeks of randomization are strongly encouraged to receive palliative radiotherapy prior to 
randomization
Key Exclusion Criteria (See Protocol Section 3.3.2 for full list of criteria) 
1.
Subjects with carcinomatous meningitis.
2.
Subjects with active CNS metastases are excluded. Subjects are eligible if CNS metastases are adequately 
treated and subjects are neurologically returned to baseline (except for residual signs or symptoms related to the 
CNS treatment) for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, 
or on a stable or decreasing dose of 10 mg daily prednisone (or equivalent).
3.
Subjects with an active, known or suspected autoimmune disease are excluded. Subjects with type I diabetes 
mellitus, hypothyroidism only requiring hormone replacement, skin disorder (such as vitiligo, psoriasis or 
alopecia) not requiring systemic treatment or conditions not expected to recur in the absence of an external 
trigger are permitted to enroll
Revised Protocol No: 05
Date: 13-Dec-2017
7
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
4.
Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone 
equivalent) or other immunosuppressive medications within 14 days prior to randomization. Inhaled or topical 
steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the 
absence of active autoimmune disease.
5.
Prior therapy with anti-tumor vaccines or other immuno-stimulatory antitumor agents.
6.
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including 
ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
7.
Prior treatment with docetaxel.
8.
Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus antibody (HCV Ab) indicating 
acute or chronic infection.
9.
Active Tuberculosis (TB) infection based on chest X-ray, sputum tests, and clinical examination. Patients with a 
history of active TB infection within last 1 year are excluded even if it was treated; Patients with a history of 
active TB infection greater than 1 year ago are eligible if there is no evidence of active TB in current status in 
the investigator’s opinion
10. Subjects with EGFR mutation regardless of mutation type are excluded. Non squamous subjects with unknown 
EGFR mutation status must be tested for EGFR mutation (use of PCR based test is strongly encouraged). If the 
EGFR mutation is positive, subject is excluded.
11. Subjects with known ALK translocation are excluded
Amendment 05 Update: Specific eligibility criteria for subjects originally randomized to the Arm B docetaxel 
treatment and now entering the Nivolumab Crossover Extension Phase are included in Section 3.3.1.1 and 
Section 3.3.2.1.
Study Drug: includes both Investigational [Medicinal] Products (IP/IMP) and Non-investigational 
[Medicinal] Products (Non-IP/Non-IMP) as listed:
Study Drug for CA209078
Medication 
Potency 
IP/Non-IP 
Nivolumab
10 mg/ml
IP
Docetaxel
40 mg/ml
IP
Docetaxel
20 mg/ml
IP
Dexamethasone
4 mg
Non IP
Study Assessments: This is an open-label, multinational, randomized, Phase 3 study in adult (18 years old) male 
and female subjects with advanced or metastatic NSCLC after failure of prior platinum-doublet chemotherapy. 
Subjects will be randomized to nivolumab vs docetaxel in a 2:1 ratio.
Overall survival (OS) is the primary endpoint of this study.  The final analysis will be performed when a total of 
382 OS events have occurred. There will be one interim analysis of OS (DMC monitored) when at least 291 OS 
events have been observed (76% of total events). A Time To treatment Failure (TTF) interim analysis (DMC 
monitored) will be conducted after the first approximately 380 randomized patients have been followed for at least 
8 months.
Amendment 05 Update: The schedule of study assessments for subjects randomized to the Arm B docetaxel 
treatment and now entering the Nivolumab Crossover Extension Phase are included in the protocol in Section 5.1.
Revised Protocol No: 05
Date: 13-Dec-2017
8
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Statistical Considerations:
Sample Size: The sample size is calculated in order to compare the overall survival (OS) between subjects 
randomized to receive nivolumab and subjects randomized to receive docetaxel. Approximately 500 subjects will be 
randomized to the nivolumab and docetaxel arms in a 2:1 ratio. At least 382 deaths will be required for the final 
analysis of OS. A formal OS interim analysis will be conducted when at least 291 OS events (76% information 
fraction) have been observed. In absence of cross over (no use of anti-PD-1/PD-L1 agents as subsequent therapy in 
the docetaxel arm), average hazard ratios, calculated from the simulations, are 0.70 and 0.67 at interim and final 
analysis of OS, respectively. To compare OS between nivolumab and docetaxel, the weighted log-rank test will be 
used. The weighted log-rank test will provide 98% power (cumulative) at final analysis and 86% at interim OS, 
using a 2-sided overall type 1 error of 5%. The impact of crossover on power is described in Section 8.1. 
Significance levels at interim and final analysis of OS are calculated using the Lan-DeMets error spending function.
Accrual information used in the simulations had the same pattern as the actual data at time of the protocol 
amendment (500 subjects were accrued in 11 months). Heterogeneity of treatment effects among histology and 
PD-L1 status subgroups was considered for the calculation of overall power and number of events at interim and 
final analyses of OS. Exponential distributions of OS times are assumed in the Docetaxel arm, with median OS of 
10 months for the Squamous (SQ) and 12 months for the Non Squamous (NSQ) population. For the SQ subjects 
from nivolumab arm, a hazard ratio of 0.6 (mOS nivolumab vs docetaxel: 16.7 vs 10 months) and exponential 
distribution of OS times are assumed. For NSQ subjects from nivolumab arm, piecewise exponential models are 
used to model survival function. For the NSQ PD-L1 positive subjects, a 4-month delay effect (exponential 
distribution with mOS of 12 months) followed by an exponential distribution with mOS of 24 months was used in 
the model, providing an overall mOS of 20 months. For the NSQ PD-L1 negative subjects, the piecewise 
exponential model considered for the first 2 months an exponential distribution with mOS of 5 months; and beyond 
Month 2, an exponential distribution with mOS of OS 18 months, providing an overall mOS of 12.8 months.
In absence of cross-over, interim and final analyses of OS are projected to occur approximately at 24 months 
(13 months of minimum follow-up) and 37 months (26 months of minimum follow-up) respectively.
At both IA OS and FA OS, a consistency check will be performed first followed by a superiority test (hierarchical 
testing). Consistency was defined if the observed HR for OS maintains at least 50% of the risk reduction of death in 
the global studies after adjusting for the patient distribution and the use of anti-PD-1/PD-L1 agents in the docetaxel 
arm. Probability of Technical Success (PTS) of the consistency check is 95% and 98% at IA and FA OS, in absence 
of cross over.
Time to Treatment failure (TTF) interim analysis is expected to occur approximately16 months after study initiation. 
TTF will be compared across treatment groups using a weighted log rank test, population for TTF analysis is the 
first ~380 randomized subjects with minimum 8 months follow-up. With one-sided type 1 error of 0.025, the power 
for the weighted log rank test of TTF is ~95% per simulations using data observed in global pivotal studies 
(CheckMate 057 and 017), adjusted for the proportion of squamous and non-squamous population in this study. 
Estimated median HR for TTF is 0.7.
Endpoints:
Primary Endpoint and Analyses:
The primary endpoint for the study is OS. It is defined as the time from randomization to the date of death. A subject 
who has not died will be censored at last known date alive. OS will be followed continuously while patients are on 
the study drug and every 3 months via in-person or phone contact after subjects go off the study drug.
At both the interim OS analysis and final OS analysis, a 2-step hierarchical testing will be performed. First, a check 
for consistency with global data in HR for OS will be performed. This is to mitigate loss of power due to 
confounding effects of cross-over (subjects receiving anti PD-1/PD-L1 agents in the comparator arm). Consistency 
in OS benefit is defined as maintaining 50% of the risk reduction of death from CheckMate 057 and CheckMate 017 
after adjusting for the patient distribution and the use of anti-PD-1/PD-L1 agents in the docetaxel arm.
If consistency in OS with global data is demonstrated, superiority for OS will be tested. The distribution of OS in 
two randomized arms will be compared at the interim and final analyses via a two-sided (adjusted for the interim), 
weighted log-rank test stratified by the stratification factors used for randomization as determined per IVRS, ie, 
histology (squamous vs non-squamous)/ PD-L1 Status (positive vs negative/non evaluable)/ ECOG Performance 
status (0 vs 1). The weighted log-rank test will use G (rho = 0, gamma = 1) weights, in the terminology of Fleming 
Revised Protocol No: 05
Date: 13-Dec-2017
9
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
and Harrington. The hazard ratio (HR) and the corresponding 100x (1- alpha)% confidence interval (CI) (adjusted 
for the interim) will be estimated in a stratified Cox proportional hazards model using randomized arm as a single 
covariate with the same stratification factors mentioned above. The OS curves for each randomized arm will be 
estimated using the Kaplan-Meier (KM) product-limit method. Two-sided, 95% confidence intervals for median OS 
will be computed by Brookmeyer and Crowley method. Survival rates at 6, 12, and 18 months will also be estimated 
using KM estimates on the OS curve for each randomized arm. Associated two-sided 95% CIs will be calculated 
using the Greenwood formula.
This study design includes one interim analysis for the OS when at least 291 deaths have been observed, which is 
projected to occur approximately 24 months after study initiation. This formal comparison of OS will allow for early 
stopping for superiority and the stopping boundaries will be derived based on the actual number of deaths using 
O’Brien and Fleming α spending function in EAST v5.4. If the interim analysis is performed exactly at 291 OS 
events (76% of total events), the DMC can recommend to stop the study for superiority if the p-value was < 0.020.
The nominal significance level for the final analysis after 382 OS events will be 0.044.
Secondary Endpoints and Analyses:
If superiority in OS is demonstrated at either interim or final analysis, a hierarchical hypothesis testing approach for 
the secondary endpoints of ORR and PFS will be used to preserve an overall type I error rate at 0.05 for efficacy 
claims. The secondary efficacy endpoints will be tested in the following hierarchical order: ORR first, then PFS.
ORR is defined as the proportion of all randomized subjects whose best overall response (BOR) is either a complete 
response (CR) or partial response (PR) per RECIST 1.1 criteria. ORR will be compared using a two-sided 5% level 
Cochran-Mantel Haenszel (CMH) test stratified by the same stratification factors used for randomization. An 
associated odds ratio and 95% CI will be calculated. The ORR and its corresponding 95% exact CI will also be 
calculated by Clopper-Pearson for each treatment arm. The difference in ORR between the two treatment arms along 
with the two-sided 95% CI will be estimated using the following Cochran-Mantel-Haenszel (CMH) method of 
weighting, adjusting for the stratification factors.
PFS is defined as the time from randomization to the date of the first documented tumor progression (per 
RECIST 1.1 criteria) or death due to any cause. Clinical deterioration in the absence of unequivocal evidence of 
progression (per RECIST 1.1) is not considered progression for purposes of determining PFS. Subjects who die 
without a reported prior progression will be considered to have progressed on the date of their death. Subjects who 
did not have disease progression or die will be censored on the date of their last evaluable tumor assessment. 
Subjects who did not have any on study tumor assessments and did not die will be censored at the randomization 
date. Subjects who started any subsequent anti-cancer therapy without a prior reported progression will be censored 
at the last evaluable tumor assessment prior to or on initiation of the subsequent anti-cancer therapy. The distribution 
of PFS in two randomized arms will be compared using a two-sided, log-rank test stratified by the same 
stratification factors used for randomization. The HR and the corresponding two-sided 95% CI will be estimated in a 
stratified Cox proportional hazards model using randomized arm as a single covariate. The PFS curves for each 
randomized arm will be estimated using the KM product-limit method. Two-sided, 95% confidence intervals for 
median PFS will be computed by Brookmeyer and Crowley method. 
The efficacy analyses methods for OS, ORR and PFS will also be evaluated in different subgroups, including 
squamous and non-squamous subgroups, PD-L1 positive and PD-L1 negative protein expression subgroups, and 
Chinese and non-Chinese subgroups. The analyses methods described above for OS, ORR and PFS will be repeated 
for each of the subgroups. However, the formal comparison between treatment groups will not be performed for 
these subgroups, ie, the stratified log-rank test for OS and PFS, and the CMH test for ORR described above.
Time to Treatment Failure (TTF) is defined as the minimum of the time from randomization to disease progression 
(RECIST 1.1 or Clinical), death or last dose date if a subject discontinued from treatment for any reasons other than 
“maximum clinical benefit” or “administrative reasons by sponsor”. TTF is considered as event at the randomization 
date for subjects who were randomized but not treated. Clinical progression date is considered for time to treatment 
failure only when treatment is discontinued due to clinical disease progression. For nivolumab subjects treated 
beyond RECIST 1.1 progression, the event will be at RECIST 1.1 progression date. TTF is censored at the last dose 
date for subjects who discontinued treatment (without RECIST 1.1 progression) due to maximum clinical benefit or 
administrative reason by sponsor. TTF is censored at the last dose date for subjects who continued on treatment 
without progression or death. The distribution of TTF will be compared in the two randomized arms, using the first 
Revised Protocol No: 05
Date: 13-Dec-2017
10
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
~380 randomized subjects with minimum 8 months follow-up (TTF population), via a 1-sided, unstratified weighted 
log-rank test. The one-sided weighted log-rank p-value will be reported using G (rho = 0, gamma = 1) weights, in 
the terminology of Harrington and Fleming. The FH method (with rho = 0 and gamma = 1) leads to a loss of power 
when treatment effect is not delayed but has higher power when a delay of more than 2 months is observed, which is 
expected for TTF, based on data from global studies CheckMate 017 and 057. TTF will also be compared using a 
regular log rank test. The hazard ratio (HR) and the corresponding 1-sided 97.5% CI upper bound will be estimated 
in an unstratified Cox proportional hazards model using randomized arm as a single covariate. The TTF curves for 
each treatment group will be estimated using the Kaplan-Meier (KM) product-limit method. Two-sided, 95% 
confidence intervals for median will be constructed based on a log-log transformed CI for the survivor function S(t). 
The DMC will review the safety and efficacy data from the TTF interim analysis. There is no alpha spending nor
penalty for TTF analysis: this interim analysis is considered as a bridging strategy. If TTF is statistically significant 
at 1-sided 0.025 level, safety and ORR will be described (no formal comparison) using the TTF population. TTR 
and DOR will be evaluated for responders (i.e. subjects with confirmed CR or PR) of the TTF population. Exposure 
and safety (including death summary) will be summarized on the Treated subjects among TTF population.
Regardless of whether TTF is positive or negative, study will continue to the planned OS Interim/Final analysis.
Disease-Related Symptom deterioration Rate by Week 12 and by Week 24 is defined as the proportion of 
randomized subjects who had 10 points or more increase from baseline in Average Symptom Burden Index (ASBI) 
score at any time between randomization and Week 12/ Week 24 respectively. The disease-related symptom 
deterioration rates and corresponding 95% exact CIs will be calculated by Clopper-Pearson method for each 
randomized arm.
Safety Analyses:
Safety will be summarized and listed for all treated subjects using the NCI CTCAE version 4.0 by treatment arm. 
All treatment emergent AEs, drug-related AEs, SAEs and drug-related SAEs will be tabulated using worst grade per 
NCI CTCAE v4.0 criteria by system organ class and preferred term. On-study lab parameters including hematology, 
coagulation, chemistry, liver function and renal function will be summarized using worst grade per NCI CTCAE 
v4.0 criteria.
Frequency, management and resolution of IMAEs will be analyzed. A tabular summary and comparative analysis 
between treatment arms of the incidence of overall IMAEs (by preferred term) and serious IMAEs will be 
performed. A descriptive analysis of IMAEs including time-to onset, severity, duration, action taken with the study 
drug, dosing delays of the study drug, corticosteroid details, re-challenge information and outcome of the AE
Amendment 05 Update: Arm B subjects receiving docetaxel treatment at the time of Amendment 05 will continue 
to be monitored as specified in the protocol. They may continue to receive treatment with docetaxel or switch to 
nivolumab 3mg/kg given every 2 weeks.
Revised Protocol No: 05
Date: 13-Dec-2017
11
7.0
Approved
930067687
7.0
v


TABLE OF CONTENTS 
TITLE PAGE ................................................................................................................ 
DOCUMENT HISTORY .............................................................................................. 
SYNOPSIS .................................................................................................................... 
TABLE OF CONTENTS .............................................................................................. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2 Research Hypothesis ......................................................................................... 
1.3 Objectives(s) ..................................................................................................... 
1.3.1 Primary Objectives .................................................................................. 
1.3.2 Secondary Objectives ............................................................................... 
 
 
 
 
 
 
1.4.2.2 Docetaxel ........................................................................................ 
1.4.2.3 Safety of Docetaxel ......................................................................... 
1.4.3 Nivolumab Clinical Results in NSCLC .................................................... 
1.4.3.1 Clinical Pharmacology Summary ................................................... 
1.4.3.2 Safety Summary ............................................................................... 
1.4.3.3 Anti-tumor Activity Summary .......................................................... 
 
2 ETHICAL CONSIDERATIONS ............................................................................... 
2.1 Good Clinical Practice ...................................................................................... 
2.2 Institutional Review Board/Independent Ethics Committee ............................. 
2.3 Informed Consent.............................................................................................. 
3 INVESTIGATIONAL PLAN .................................................................................... 
3.1 Study Design and Duration ............................................................................... 
3.2 Post Study Access to Therapy ........................................................................... 
3.3 Study Population ............................................................................................... 
3.3.1 Inclusion Criteria ..................................................................................... 
3.3.1.1 Inclusion Criteria for Entering the Nivolumab Crossover Extension 
Phase-Subjects Previously Randomized to Docetaxel .......................... 
1
3
5
12
16
17
17
17
18
19
19
20
21
21
22
22
22
23
23
23
23
23
24
25
25
26
27
27
28
28
30
33
33
33
34
34
35
35
40
40
40
43
Clinical Protocol
BMS-936558
CA209078
nivolumab
Revised Protocol No: 05
Date: 13-Dec-2017
12
7.0
Approved
930067687
7.0
v


3.3.2 Exclusion Criteria .................................................................................... 
3.3.2.1 Exclusion Criteria for Entering the Nivolumab Crossover Extension 
Phase-Subjects Previously Randomized to Docetaxel .......................... 
3.3.3 Women of Childbearing Potential ........................................................... 
3.4 Concomitant Treatments ................................................................................... 
3.4.1 Prohibited and/or Restricted Treatments................................................. 
3.4.1.1 Strong CYP3A4 inhibitors............................................................... 
3.4.2 Other Restrictions and Precautions ......................................................... 
3.4.3 Permitted Therapy ................................................................................... 
3.4.3.1 Palliative local therapy ................................................................... 
3.5 Discontinuation of Subjects Following any Treatment with Study Drug ......... 
3.6 Post Study Drug Study Follow up .................................................................... 
3.6.1 Withdrawal of Consent ............................................................................ 
3.6.2 Lost to Follow-Up .................................................................................... 
4 STUDY DRUG .......................................................................................................... 
4.1 Investigational Product ..................................................................................... 
4.2 Non-investigational Product ............................................................................. 
4.3 Storage and Dispensing..................................................................................... 
4.4 Method of Assigning Subject Identification ..................................................... 
4.4.1 Treatment Arms ........................................................................................ 
4.5 Selection and Timing of Dose for Each Subject ............................................... 
4.5.1 Dose Delay Criteria ................................................................................. 
4.5.1.1 Nivolumab Dose Delay Criteria ..................................................... 
4.5.1.2 Docetaxel Dose Delay Criteria ....................................................... 
4.5.2 Dose Reductions....................................................................................... 
4.5.2.1 Nivolumab Dose Reductions ........................................................... 
4.5.2.2 Docetaxel Dose Reductions ............................................................ 
4.5.3 Criteria to Resume Dosing....................................................................... 
4.5.3.1 Criteria to Resume Treatment with Nivolumab .............................. 
4.5.3.2 Criteria to Resume Treatment with Docetaxel ................................ 
4.5.4 Treatment Beyond Disease Progression .................................................. 
4.5.5 Treatment Discontinuation Criteria ........................................................ 
4.5.5.1 Nivolumab Dose Discontinuation ................................................... 
4.5.5.2 Docetaxel Dose Discontinuation .................................................... 
4.5.6 Treatment of Nivolumab-Related Infusion Reactions .............................. 
4.5.7 Management Algorithms for Immuno-Oncology Agents ......................... 
4.6 Blinding/Unblinding ......................................................................................... 
4.7 Treatment Compliance ...................................................................................... 
4.8 Destruction of Study Drug ................................................................................ 
4.9 Return of Study Drug ........................................................................................ 
5 STUDY ASSESSMENTS AND PROCEDURES ..................................................... 
5.1 Flow Chart/Time and Events Schedule ............................................................. 
5.1.1 Retesting During Screening ..................................................................... 
5.2 Study Materials ................................................................................................. 
5.3 Safety Assessments ........................................................................................... 
5.3.1 Imaging Assessment for the Study............................................................ 
44
46
47
48
48
48
49
49
49
50
50
51
51
51
53
53
53
54
55
55
56
56
57
57
57
57
58
58
58
59
60
60
62
62
64
64
64
64
65
66
66
82
82
82
85
Clinical Protocol
BMS-936558
CA209078
nivolumab
Revised Protocol No: 05
Date: 13-Dec-2017
13
7.0
Approved
930067687
7.0
v


5.4 Efficacy Assessments ........................................................................................ 
5.4.1 Primary Efficacy Assessment ................................................................... 
5.4.2 Secondary Efficacy Assessments .............................................................. 
 
 
 
 
 
 
 
 
5.8.3 Healthcare Resource Utilization .............................................................. 
5.9 Results of Central Assessments ........................................................................ 
6 ADVERSE EVENTS ................................................................................................. 
6.1 Serious Adverse Events .................................................................................... 
6.1.1 Serious Adverse Event Collection and Reporting .................................... 
6.2 Nonserious Adverse Events .............................................................................. 
6.2.1 Nonserious Adverse Event Collection and Reporting .............................. 
6.3 Laboratory Test Result Abnormalities .............................................................. 
6.4 Pregnancy .......................................................................................................... 
6.5 Overdose ........................................................................................................... 
6.6 Potential Drug Induced Liver Injury (DILI) ..................................................... 
6.7 Other Safety Considerations ............................................................................. 
6.7.1 Adverse Events of Interest ........................................................................ 
7 DATA MONITORING COMMITTEE AND OTHER EXTERNAL COMMITTEES
................................................................................................................................. 
8 STATISTICAL CONSIDERATIONS....................................................................... 
8.1 Sample Size Determination ............................................................................... 
8.2 Populations for Analyses .................................................................................. 
8.3 Endpoints .......................................................................................................... 
8.3.1 Primary Endpoint(s) ................................................................................ 
8.3.2 Secondary Endpoint(s) ............................................................................. 
8.3.2.1 Objective Response Rate ................................................................. 
8.3.2.2 Progression Free Survival .............................................................. 
8.3.2.3 Time to Treatment Failure .............................................................. 
8.3.2.4 Rate of Disease-related Symptom Deterioration ............................ 
8.3.2.5 Rates of Treatment Related Selected AEs and SAEs ....................... 
. 
8.4 Analyses ............................................................................................................ 
8.4.1 Demographics and Baseline Characteristics........................................... 
8.4.2 Efficacy Analyses ..................................................................................... 
8.4.2.1 Methods of Primary Endpoint ......................................................... 
 
8.4.3 Safety Analyses......................................................................................... 
8.4.4 Pharmacokinetic Analyses ....................................................................... 
 
85
85
85
86
87
88
88
88
88
88
89
90
90
90
91
92
93
93
93
93
94
94
94
95
96
96
96
98
99
99
99
99
100
100
100
101
101
102
102
102
102
102
103
104
104
Clinical Protocol
BMS-936558
CA209078
nivolumab
Revised Protocol No: 05
Date: 13-Dec-2017
14
7.0
Approved
930067687
7.0
v


 
 
8.5 Interim Analyses ............................................................................................... 
9 STUDY MANAGEMENT ........................................................................................ 
9.1 Compliance ....................................................................................................... 
9.1.1 Compliance with the Protocol and Protocol Revisions ........................... 
9.1.2 Monitoring ............................................................................................... 
9.1.2.1 Source Documentation .................................................................... 
9.1.3 Investigational Site Training.................................................................... 
9.2 Records ............................................................................................................. 
9.2.1 Records Retention .................................................................................... 
9.2.2 Study Drug Records ................................................................................. 
9.2.3 Case Report Forms .................................................................................. 
9.3 Clinical Study Report and Publications ............................................................ 
10 GLOSSARY OF TERMS ........................................................................................ 
11 LIST OF ABBREVIATIONS .................................................................................. 
 
 
 
APPENDIX 2 RECIST 1.1 GUIDELINES .................................................................. 
 
APPENDIX 3 MANAGEMENT OF SAFETY ALGORITHMS FOR IMMUNO-
ONCOLOGY AGENTS ......................................................................................... 
 
105
105
106
107
107
107
107
108
108
108
108
108
109
110
111
112
116
125
126
134
Clinical Protocol
BMS-936558
CA209078
nivolumab
Revised Protocol No: 05
Date: 13-Dec-2017
15
7.0
Approved
930067687
7.0
v














Clinical Protocol
CA209078
BMS-936558
nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2
Research Hypothesis 
The treatment effect of nivolumab is consistent between the study population and subjects from 
global pivotal trials (CheckMate 057 and CheckMate 017) and nivolumab increases OS as 
Revised Protocol No: 05
Date: 13-Dec-2017
22
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
compared with docetaxel, in subjects with advanced or metastatic NSCLC who have failed prior 
platinum-based doublet chemotherapy.
1.3
Objectives(s)
1.3.1
Primary Objectives

To demonstrate that the OS benefit of nivolumab in this study population with advanced or 
metastatic NSCLC after failure of prior platinum-based chemotherapy is consistent with 
benefit observed in global studies CheckMate 057 and CheckMate 017

To compare the OS of nivolumab versus docetaxel in subjects with advanced or metastatic
NSCLC after failure of prior platinum-based chemotherapy.
1.3.2
Secondary Objectives

To compare the objective response rate (ORR) of nivolumab versus docetaxel.

To compare the progression free survival (PFS) of nivolumab versus docetaxel.

To compare the time to treatment failure (TTF) of nivolumab versus docetaxel

To evaluate clinical efficacy (OS, ORR, and PFS) in different subgroups, including 
squamous and non-squamous NSCLC subgroups, PD-L1 positive and PD-L1 negative 
protein expression subgroups, and Chinese and non-Chinese subgroups.

To evaluate rates of treatment related selected AEs and SAEs in nivolumab and docetaxel
arms.

To evaluate the proportion of subjects exhibiting disease-related symptom deterioration by 
Week 12 and by Week 24, as measured by LCSS, in nivolumab and docetaxel arms.
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No: 05
Date: 13-Dec-2017
23
7.0
Approved
930067687
7.0
v






Clinical Protocol
CA209078
BMS-936558
nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.2.2
Docetaxel 
Docetaxel (Taxotere) is a cytotoxic microtubule inhibiting antineoplastic agent in the taxane 
class that is indicated as single agent treatment for locally advanced or metastatic NSCLC after 
failure of prior platinum-based chemotherapy. Docetaxel is recommended to be administered in a 
facility equipped to manage possible complications such as anaphylaxis. The dosing is 
recommended at 75 mg/m² administered intravenously over one hour on an every 3-week 
schedule. Per the Taxoterelabel, the premedication regimen should be oral corticosteroids such 
Revised Protocol No: 05
Date: 13-Dec-2017
26
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
as dexamethasone at a dose of 8 mg BID for 3 days starting one day prior to administration and 
continued for one day after infusion.87
1.4.2.3
Safety of Docetaxel 
The major adverse events related to docetaxel are primarily hematologic. The key Grade 3 to 4 
hematologic toxicities include neutropenia (30 - 67%), anemia (2 - 5%) and thrombocytopenia 
(< 1 - 2%). Non-hematologic adverse events related to docetaxel include febrile neutropenia 
(4.7 - 12.7%), asthenia (47 - 55%), alopecia (35%), nausea (26 - 36%), diarrhea (12 - 36%), 
peripheral neuropathy (15 - 24%), vomiting (17%), and fluid retention (5 - 16%).23,24,25,88,89
Warnings related to docetaxel include treatment-related mortality increases with abnormal liver 
function at higher doses, should not be given to subjects if the total bilirubin is greater than 
institutional upper limit of normal (ULN), or if AST and/or ALT is greater than 1.5x ULN 
concomitant with alkaline phosphatase greater than 2.5x ULN, should not be given if the 
neutrophil count of the subject is less than 1500 cell/mm³, should not be given if subjects have a 
history of severe hypersensitivity to docetaxel or drugs formulated with polysorbate 80, and may 
cause severe fluid retention.87
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No: 05
Date: 13-Dec-2017
27
7.0
Approved
930067687
7.0
v












Clinical Protocol
CA209078
BMS-936558
nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
ETHICAL CONSIDERATIONS
2.1
Good Clinical Practice
This study will be conducted in accordance with Good Clinical Practice (GCP), as defined by the 
International Conference on Harmonisation (ICH) and in accordance with the ethical principles 
underlying European Union Directive 2001/20/EC and the United States Code of Federal 
Regulations, Title 21, Part 50 (21CFR50).
The study will be conducted in compliance with the protocol. The protocol and any amendments 
and the subject informed consent will receive Institutional Review Board/Independent Ethics 
Committee (IRB/IEC) approval/favorable opinion prior to initiation of the study.
All potential serious breaches must be reported to BMS immediately. A serious breach is a 
breach of the conditions and principles of GCP in connection with the study or the protocol, 
which is likely to affect, to a significant degree, the safety or physical or mental integrity of the 
subjects of the study or the scientific value of the study.
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
Revised Protocol No: 05
Date: 13-Dec-2017
33
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
 
 
2.2
Institutional Review Board/Independent Ethics Committee 
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, subject recruitment materials 
(eg, advertisements), and any other written information to be provided to subjects. The 
investigator or BMS should also provide the IRB/IEC with a copy of the Investigator Brochure 
or product labeling information to be provided to subjects and any updates. 
The investigator or BMS should provide the IRB/IEC with reports, updates and other 
information (e.g., expedited safety reports, amendments, and administrative letters) according to 
regulatory requirements or institution procedures.
2.3
Informed Consent
Investigators must ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate. 
In situations where consent cannot be given to subjects, their legally acceptable representatives
(as per country guidelines) are clearly and fully informed about the purpose, potential risks, and 
other critical issues regarding clinical studies in which the subject volunteers to participate. 
BMS will provide the investigator with an appropriate (i.e., Global or Local) sample informed 
consent form which will include all elements required by ICH, GCP and applicable regulatory 
requirements. The sample informed consent form will adhere to the ethical principles that have 
their origin in the Declaration of Helsinki.
Investigators must:
1. Provide a copy of the consent form and written information about the study in the language 
in which the subject is most proficient prior to clinical study participation. The language 
must be non-technical and easily understood. 
2. Allow time necessary for subject or subject's legally acceptable representative to inquire 
about the details of the study.
3. Obtain an informed consent signed and personally dated by the subject or the subject's 
legally acceptable representative and by the person who conducted the informed consent 
discussion. 
4. Obtain the IRB/IEC’s written approval/favorable opinion of the written informed consent 
form and any other information to be provided to the subjects, prior to the beginning of the 
study, and after any revisions are completed for new information.
5. If informed consent is initially given by a subject’s legally acceptable representative or legal 
guardian, and the subject subsequently becomes capable of making and communicating his 
or her informed consent during the study, consent must additionally be obtained from the 
subject.
6. Revise the informed consent whenever important new information becomes available that is 
relevant to the subject's consent. The investigator, or a person designated by the investigator, 
Revised Protocol No: 05
Date: 13-Dec-2017
34
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
should fully inform the subject or the subject's legally acceptable representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
subject's willingness to continue participation in the study. This communication should be 
documented. 
The confidentiality of records that could identify subjects must be protected, respecting the 
privacy and confidentiality rules applicable to regulatory requirements, the subjects' signed ICF 
and, in the US, the subjects’ signed HIPAA Authorization.
The consent form must also include a statement that BMS and regulatory authorities have direct 
access to subject records. 
Subjects unable to give their written consent (eg, stroke or subjects with or severe dementia) may 
only be enrolled in the study with the consent of a legally acceptable representative. The subject 
must also be informed about the nature of the study to the extent compatible with his or her
understanding, and should this subject become capable, he or she should personally sign and date 
the consent form as soon as possible. The explicit wish of a subject who is unable to give his or 
her written consent, but who is capable of forming an opinion and assessing information to 
refuse participation in, or to be withdrawn from, the clinical study at any time should be 
considered by the investigator.
The rights, safety, and well-being of the study subjects are the most important considerations and 
should prevail over interests of science and society.
3
INVESTIGATIONAL PLAN
3.1
Study Design and Duration
This is an open-label, multinational randomized Phase 3 study in adult (18 years old) male and 
female subjects with advanced or metastatic NSCLC after failure of prior platinum-doublet 
chemotherapy. Subjects will undergo screening evaluations to determine eligibility prior to 
randomization. Subjects will be assigned to one of two treatment arms in a 2:1 ratio of 
nivolumab to docetaxel (see Study Design and Duration in Figure 3.1-1 below). Randomization 
will be stratified according to the following factors: histology (squamous vs non-squamous)/ 
PD-L1 Status (positive vs negative/ unevaluable)/ ECOG Performance status (0 vs 1).
Approximately 100 PD-L1 unevaluable subjects will be randomized
The study design schematic is presented in Figure 3.1-1.
Revised Protocol No: 05
Date: 13-Dec-2017
35
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Figure 3.1-1:
Study Design
Stage IIIb/IV 
or recurrent 
NSCLC
EGFR Wild 
Type
Disease 
progression 
after 
platinum-
based doublet 
chemotherapy
Nivolumab  
3 mg/kg q 2 weeks until 
disease progression or 
unacceptable toxicity
Docetaxel 
75 mg/m² q 3 weeks until 
disease progression or 
unacceptable toxicity
A
B
R
Primary endpoint: 
OS
Secondary endpoints:
• ORR
• PFS
• TTF
• Efficacy in different  
subgroups (Squamous/non-
squamous, PD-L1 +/-, 
Chinese/non-Chinese )
• Rates of treatment selected 
AEs and SAEs
• Rate of disease related 
symptom deterioration 
measured by LCSS
2:1
Treatment should be initiated within 3 business days of randomization. Nivolumab or docetaxel 
(depending on randomized treatment arm) will be administered as an IV infusion over 
60 minutes on Treatment Day 1. A treatment cycle is defined as 2 weeks for nivolumab and 
3 weeks for docetaxel.
Amendment 05 Update: The Data Monitoring Committee (DMC) for the CA209078 study 
convened on 21-Nov-2017 to evaluate the data from a planned formal Interim Analysis of overall 
survival (OS). The DMC declared superiority for OS in subjects receiving nivolumab as 
compared to docetaxel. As a result of the DMC assessment, this protocol amendment is being 
implemented to provide a mechanism for eligible subjects randomized to the docetaxel treatment 
Arm B to receive subsequent nivolumab therapy as part of a nivolumab crossover extension 
phase. In order to receive subsequent therapy with nivolumab, all subjects who received prior 
docetaxel and qualify for subsequent treatment with nivolumab, must sign an informed consent 
and will enter the nivolumab crossover extension phase of the study.
This study will consist of 3 phases: screening, treatment, follow-up in the original protocol and 
in the nivolumab crossover extension.
Screening for Original Study:

Begins by establishing subject’s initial eligibility and signing of the informed consent form 
(ICF).

Subject is enrolled using the Interactive Voice Response System (IVRS) to obtain a subject 
ID.

Tumor tissue (archival or recent tumor biopsy) must be available and received by the central 
lab for PD-L1 IHC testing for a subject to be randomized. Subjects must consent to allow the 
acquisition of tumor tissue by study personnel for performance of the correlative studies. 
(Table 5.1-1)

EGFR mutation positive subjects (squamous or non squamous) are excluded from the study. 
Historical EGFR mutation status is accepted. If no historical EGFR status is available for non 
Revised Protocol No: 05
Date: 13-Dec-2017
36
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
squamous subjects, the test can be done locally or centrally using PCR as the recommended 
method. (IHC and VeriStrat testing are not qualified test methods. Other tests involving 
circulating tumor cell or DNA have not been validated and therefore are not acceptable 
methods). Non squamous subjects with unknown EGFR mutation status must be tested prior 
to randomization

Baseline disease or tumor assessments should be performed within 28 days prior to 
randomization (according to Table 5.1-1).

Subject is assessed for study eligibility within the required timeframe found in Table 5.1-1.
Treatment for Original Study:

Begins with the randomization call to the IVRS. The subject is randomly assigned to one of 
the treatment arms. Treatment should begin within 3 business days of randomization. 

All of the laboratories and vital signs will be collected within 3 calendar days prior to dosing
of each cycle (according to Table 5.1-2 or Table 5.1-3). Adverse event assessments should be 
documented at each clinic visit.

Biomarker, PK and immunogenicity samples will be done according to Table 5.1-2, Table 
5.1-3, Table 5.1-4, and Table 5.5-1. 

Patient-reported outcome (PRO) instruments will be completed after randomization (prior to 
the first dose of study therapy), and prior to study procedures and dosing on Day 1 of each 
visit, according to Table 5.1-2 or Table 5.1-3.

Study drug is administered as an IV infusion on Treatment Day 1 of each cycle (frequency is 
dependent on the treatment arm) until disease progression (or until discontinuation of study 
therapy in patients receiving nivolumab beyond progression), discontinuation due to toxicity, 
withdrawal of consent, or the study ends.

Subjects will be evaluated for response according to the RECIST 1.1 criteria. The first on 
treatment radiographic assessment will be obtained in both treatment arms at Week 6 
(7 days). The subsequent radiographic assessments will be conducted every 6 weeks 
(7 days) for the first 12 months (Week 48), then every 12 weeks (14 days) until disease 
progression (or until discontinuation of study therapy in patients receiving nivolumab beyond 
progression), lost to follow-up, withdrawal of study consent. Any subject who develops an 
objective tumor response per RECIST 1.1 (Complete Response or Partial Response) is 
required to undergo confirmatory scans at the next scheduled tumor assessment in the first 
year, and at least 4 weeks apart in the second and following year.

This phase ends when the subject is discontinued from study therapy. Please refer to 
Section 3.5 for a complete list of reasons for discontinuation. 
Follow-up for Original Study:

Begins when the decision to discontinue a subject from study therapy is made (no further 
treatment with study therapy).

Subjects will be followed for drug related toxicities until these toxicities resolve, return to 
baseline or are deemed irreversible. All adverse events will be documented for a minimum of 
100 days after the last dose of study medication

Subjects who discontinue study therapy for reasons other than disease progression will 
continue to have radiographic assessments every 6 weeks (7 days) for the first 12 months 
Revised Protocol No: 05
Date: 13-Dec-2017
37
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
then every 12 weeks (14 days) until disease progression, lost to follow-up, withdrawal of 
study consent or death. 

After completion of the first two follow-up visits, subjects will be followed for overall 
survival every 3 months until death, lost to follow-up, or withdrawal of study consent.
PRO instruments will be completed at a frequency according to Table 5.1-4.
The total duration of the study from start of randomization to final analysis of OS is expected to 
be 37 months (11 months accrual + 26 months of follow-up). 
This study will end when survival follow-up is complete. The current plan is to continue survival 
follow-up for approximately 5 years after the last subject’s first visit.
Amendment 05 Update for Nivolumab Crossover Extension
Screening for Nivolumab Crossover Extension

Subjects currently receiving treatment with nivolumab (Arm A) will continue to be treated 
and monitored as specified in the protocol.

With Amendment 05, all subjects randomized to docetaxel treatment (Arm B) who meet 
eligibility criteria may enter the Nivolumab Crossover Extension Phase, according to the 
schema in Figure 3.1-2. These subjects will follow the assessment schedules outlined in 
Table 5.1-5 of the protocol.

Subjects treated with docetaxel who have ended study treatment will be able to receive 
treatment with nivolumab via the crossover extension phase of the study, assuming basic 
inclusion/exclusion criteria are met (including a 3-week washout period for prior systemic 
anti-cancer therapy). Details are provided in Section 3.3.1.1 and Section 3.3.2.1.

Subjects currently receiving treatment with docetaxel should continue to be treated and 
monitored as specified in the protocol as long as they are continuing to derive benefit from 
docetaxel in the judgment of the investigator. These subjects may receive nivolumab once 
they are discontinued from docetaxel therapy, assuming basic inclusion/exclusion criteria are 
met (including a 3-week washout period from last dose of docetaxel).
Figure 3.1-2:
Nivolumab Crossover Extension Phase Schema for Subjects 
Previously Randomized to Docetaxel
Treatment beyond investigator-assessed RECIST 1.1-defined progression may be considered for 
subjects meeting criteria according to Section 4.5.4. Treatment beyond progression for subjects 
in the nivolumab crossover extension phase must be approved by the BMS Medical Monitor 
prior to subjects receiving additional study drug. Criteria for discontinuation of treatment beyond 
progression are described in Section 4.5.4. Subjects who discontinue study therapy for reasons 
other than progression should continue to be scanned until disease progression is documented.
Revised Protocol No: 05
Date: 13-Dec-2017
38
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Treatment for Nivolumab Crossover Extension:

Begins with the call to the IVRS. The subject is assigned to the Nivolumab Crossover 
Extension Phase. Treatment should begin within 3 business days of crossover. 

All of the laboratories and vital signs will be collected within 3 calendar days prior to dosing 
of each cycle (according to Table 5.1-6). Adverse event assessments should be documented 
at each clinic visit.

Patient-reported outcome (PRO) instruments will be completed after enrollment (prior to the 
first dose of study therapy), and prior to study procedures and dosing on Day 1 of each visit, 
according schedule in Table 5.1-5.

Nivolumab is administered as an IV infusion on Treatment Day 1 of each cycle until disease 
progression (or until discontinuation of study therapy in patients receiving nivolumab beyond 
progression), discontinuation due to toxicity, withdrawal of consent, or the study ends.

Subjects will be evaluated for response according to the RECIST 1.1 criteria. The first on 
treatment radiographic assessment will be obtained in both treatment arms at Week 6 
(7 days). The subsequent radiographic assessments will be conducted every 6 weeks 
(7 days) for the first 12 months (Week 48), then every 12 weeks (14 days) until disease 
progression (or until discontinuation of study therapy in patients receiving nivolumab beyond 
progression), lost to follow-up, withdrawal of study consent. Any subject who develops an 
objective tumor response per RECIST 1.1 (Complete Response or Partial Response) is 
required to undergo confirmatory scans at the next scheduled tumor assessment in the first 
year, and at least 4 weeks apart in the second and following year.

This phase ends when the subject is discontinued from study therapy. Please refer to 
Section 3.5 for a complete list of reasons for discontinuation. 
Follow-up for Nivolumab Crossover Extension:

Begins when the decision to discontinue a subject from study therapy is made (no further 
treatment with study therapy).

Subjects will be followed for drug related toxicities until these toxicities resolve, return to 
baseline or are deemed irreversible. All adverse events will be documented for a minimum of 
100 days after the last dose of study medication. Two follow-up visits for safety within the 
first 100 days from the last dose of nivolumab therapy are included according to Table 5.1-7
and Section 5.3.

Subjects who discontinue study therapy for reasons other than disease progression will 
continue to have radiographic assessments every 6 weeks (7 days) for the first 12 months 
then every 12 weeks (14 days) until disease progression, lost to follow-up, withdrawal of 
study consent or death. 

After completion of the first two follow-up visits, subjects will be followed for overall 
survival every 3 months until death, lost to follow-up, or withdrawal of study consent.
PRO instruments will be completed at a frequency according to Table 5.1-7.
This study will end when survival follow-up is complete. The current plan is to continue survival 
follow-up for approximately 5 years after the last subject’s first visit.
Revised Protocol No: 05
Date: 13-Dec-2017
39
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
3.2
Post Study Access to Therapy
At the conclusion of the study, subjects who continue to demonstrate clinical benefit will be 
eligible to receive BMS supplied study drug consistent with the original study drug assignment 
Study drug will be provided via an extension of the study, a rollover study requiring approval by 
responsible health authority and ethics committee or through another mechanism at the discretion 
of BMS. BMS reserves the right to terminate access to BMS supplied study drug if any of the 
following occur: a) the marketing application is rejected by responsible health authority; b) the 
study is terminated due to safety concerns; c) the subject can obtain medication from a 
government sponsored or private health program; or d) therapeutic alternatives become available 
in the local market.
3.3
Study Population
For entry into the study, the following criteria MUST be met.
3.3.1
Inclusion Criteria
1. Signed Written Informed Consent
a) Subjects must have signed and dated an IRB/IEC approved written informed consent 
form in accordance with regulatory and institutional guidelines. This must be obtained 
before the performance of any protocol related procedures that are not part of normal 
subject care.
b) Subjects must be willing and able to comply with scheduled visits, treatment schedule, 
laboratory tests and other requirements of the study.
2. Target Population
a) ECOG performance status of 1 (see Appendix 1).
b) Subjects with histologically- or cytologically-documented NSCLC who present with 
Stage IIIB/ Stage IV disease (according to Version 7 of the International Association for 
the Study of Lung Cancer Staging Manual in Thoracic Oncology), or with recurrent or 
progressive disease following multimodal therapy (radiation therapy, surgical resection or 
definitive chemoradiation therapy for locally advanced disease).
c) Subjects must have experienced disease progression during or after one prior 
platinum-containing doublet chemotherapy (carboplatin or cisplatin) regimen for 
advanced or metastatic disease.
i)
Subjects who received maintenance therapy (non-progressors with platinum-based 
doublet chemotherapy) and progressed are eligible
ii) Subjects who received platinum-containing adjuvant, neoadjuvant or definitive 
chemoradiation therapy given for locally advanced disease and developed recurrent or 
metastatic disease within 6 months of completing therapy are eligible. 
iii) Subjects with recurrent disease > 6 months after platinum containing adjuvant,
neoadjuvant or definite chemoradiation therapy given for locally advanced disease, 
Revised Protocol No: 05
Date: 13-Dec-2017
40
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
who also subsequently progressed during or after a platinum- doublet regimen given 
to treat the recurrence, are eligible.
d) Subjects have measurable disease by CT or MRI per RECIST 1.1 criteria (per 
Appendix 2); Radiographic Tumor Assessment performed within 28 days prior to
randomization.
i)
Target lesions may be located in a previously irradiated field if there is documented 
(radiographic) disease progression in that site.
e) A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 
10 unstained slides (submission of less than 10 unstained slides may be acceptable after 
approval by BMS Medical Monitor) of tumor sample (archival or recent) must be 
available for biomarker evaluation at a central laboratory, as described in Section 1.1.1. 
In order to be randomized, subjects will be classified as PD-L1 positive, PD-L1 negative 
or PD-L1 unevaluable. Biopsy should be excisional, incisional or core needle. Fine 
beedle biopsies, drainage of pleural effusions with cytospins, or punch biopsies are not 
considered adequate for biomarker review and randomization. Biopsies of bone lesions 
that do not have a soft tissue component or decalcified bone tumor samples are also not 
acceptable
f)
All baseline laboratory requirements will be assessed and should be obtained within 
14 days prior to randomization. Screening laboratory values must meet the following 
criteria 
i)
WBCs 2000/µL
ii)
Neutrophils 1500/µL
iii)
Platelets 100 x 10³/µL
iv)
Hemoglobin 9.0 g/dL
v)
Serum creatinine of 1.5 X ULN or creatinine clearance ＞40 mL/minute
(using Cockcroft/Gault formula)
Female CrCl= (140- age in years) x weight in kg x 0.85
                           72 x serum creatinine in mg/ dL
Male CrCl= (140- age in years) x weight in kg x 1.00
                           72 x serum creatinine in mg/ dL
vi)
AST 1.5X ULN 
vii)
ALT 1.5X ULN 
viii)
Total bilirubin ULN
ix)
Alkaline phosphatase 2.5 X ULN
Revised Protocol No: 05
Date: 13-Dec-2017
41
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
g) Prior palliative radiotherapy to non-CNS lesions must have been completed at least 
2 weeks prior to randomization. Subjects with symptomatic tumor lesions at baseline that 
may require palliative radiotherapy within 4 weeks of randomization are strongly 
encouraged to receive palliative radiotherapy prior to randomization
h) Subject Re-enrollment: This study permits the re-enrollment of a subject that has
discontinued the study as a pre-treatment failure (ie, subject has not been randomized / 
has not been treated). If re-enrolled, the subject must be re-consented
3. Age and Reproductive Status
a) Males and Females, 18 years of age
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within
24 hours prior to the start of study drug.
c) Women must not be breastfeeding.
d) WOCBP must agree to follow instructions for method(s) of contraception for the duration 
of treatment plus 5 half-lives of Nivolumab plus 30 days (duration of ovulatory cycle) for 
a total of 23 weeks post-treatment completion (for subjects in Arm A). 
WOCBP must also agree to follow instructions for method(s) of contraception for the 
duration of treatment with Docetaxel plus 5-half lives of Docetaxel plus 30 days (duration 
of ovulatory cycle) for a total of 33 days post treatment completion or a duration 
specified by the local labels of the chemotherapy drugs received, whichever is longer (for 
subjects treated in Arm B)
e) Males who are sexually active with WOCBP must agree to follow instructions for 
method(s) of contraception for the duration of treatment with Nivolumab plus 5 half-lives 
of the Nivolumab plus 90 days (duration of sperm turnover) for a total of 31 weeks post-
treatment completion. 
Men who are sexually active with WOCBP must agree to follow instructions for 
method(s) of contraception for the duration of treatment with Docetaxel plus 5 half-lives 
of Docetaxel plus 90 days (duration of sperm turnover) for a total of 90 days post 
treatment completion or a duration specified by the local labels of the chemotherapy 
drugs received, whichever is longer (for subjects treated in Arm B
f)
Azoospermic males and WOCBP who are continuously not heterosexually active are 
exempt from contraceptive requirements.  However they must still undergo pregnancy 
testing as described in this section.
Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on 
the importance of pregnancy prevention and the implications of an unexpected pregnancy. 
Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on 
the use of highly effective methods of contraception. Highly effective methods of contraception 
have a failure rate of < 1% when used consistently and correctly.
At a minimum, subjects must agree to the use of two methods of contraception, with one method 
being highly effective and the other method being either highly effective or less effective as 
listed below
Revised Protocol No: 05
Date: 13-Dec-2017
42
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
HIGHLY EFFECTIVE METHODS OF CONTRACEPTION

Hormonal methods of contraception including combined oral contraceptive pills, vaginal 
ring, injectables, implants and intrauterine devices (IUDs) such as Mirenaby WOCBP 
subject or male subject’s WOCBP partner. Female partners of male subjects participating in 
the study may use hormone based contraceptives as one of the acceptable methods of 
contraception since they will not be receiving study drug 

IUDs, such as ParaGard

Tubal ligation

Vasectomy.

Complete Abstinence*
*Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an 
acceptable form of contraception for all study drugs. Female subjects must continue to have 
pregnancy tests. Acceptable alternate methods of highly effective contraception must be 
discussed in the event that the subject chooses to forego complete abstinence
LESS EFFECTIVE METHODS OF OF CONTRACEPTION

Male condoms with spermicide

Diaphragm with spermicide

Cervical cap with spermicide

Vaginal sponge

Male Condom without spermicide 

Progestin only pills by WOCBP subject or male subject’s WOCBP partner 

Female Condom*.
* A male and female condom must not be used together
UNACCEPTABLE METHODS OF CONTRACEPTION

Periodic abstinence (calendar, symptothermal, post-ovulation methods)

Withdrawal (coitus interruptus)

Spermicide only

Lactation amenorrhea method (LAM).
3.3.1.1
Inclusion Criteria for Entering the Nivolumab Crossover Extension 
Phase-Subjects Previously Randomized to Docetaxel
4. Signed Written Informed Consent
a) Subjects must have signed and dated an IRB/IEC approved written informed consent 
form for the nivolumab crossover extension phase in accordance with regulatory and 
institutional guidelines. This must be obtained before the performance of any nivolumab 
crossover extension protocol-related procedures that are not part of normal subject care.
b) Subjects must be willing and able to comply with scheduled visits, treatment schedule, 
laboratory tests and other requirements of the nivolumab crossover extension phase.
5. Target population
a) Patients previously randomized to Docetaxel Treatment Arm B on the CA209078 study.
Revised Protocol No: 05
Date: 13-Dec-2017
43
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
b) Prior systemic anti-cancer therapy, including docetaxel must have been completed at least 
3 weeks prior to first dose of nivolumab administration. Prior radiotherapy must have 
been completed at least 2 weeks prior to first dose of nivolumab administration.
c) All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must 
have resolved to grade 1 or baseline before administration of first dose of nivolumab .
d) Subjects with asymptomatic brain metastases are eligible. Subjects with symptomatic 
CNS metastases are eligible if CNS metastases are treated and subjects are neurologically 
returned to baseline (except for residual signs or symptoms related to the CNS treatment) 
for at least 2 weeks prior to first dose of nivolumab administration. In addition, subjects 
must be either off corticosteroids, or on a stable or decreasing dose of 10 mg daily 
prednisone (or equivalent). 
e) Laboratory values must meet the following criteria and should be obtained within 14 days 
prior to first dose of nivolumab:
i)
WBC 2000/µL
ii) Neutrophils 1500/µL
iii) Platelets 100x103/µL
iv) Hemoglobin 9.0 g/dL
v) Serum creatinine 1.5 x ULN or creatinine clearance
(CrCl) > 40 mL/min (using the Cockcroft/Gault formula):
Female CrCl = (140 - age in years) x weight in kg x 0.85
                          72 x serum creatinine in mg/dL
Male CrCl = (140 - age in years) x weight in kg x 1.00
                         72 x serum creatinine in mg/dL
vi)
AST/ALT 3.0 x ULN 
vii)Total Bilirubin 1.5 x ULN (except subjects with Gilbert Syndrome, who can have 
total bilirubin < 3`.0 mg/dL).
f)
ECOG performance status 0-1 
6.
Age and Reproductive Status
See Section 3.3.1 3) Age and Reproductive Status
3.3.2
Exclusion Criteria
1. Target Disease Exceptions
a) Subjects with carcinomatous meningitis.
b) Subjects with active CNS metastases are excluded. Subjects are eligible if CNS
metastases are adequately treated and subjects are neurologically returned to baseline 
(except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks 
prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable 
or decreasing dose of 10 mg daily prednisone (or equivalent).
Revised Protocol No: 05
Date: 13-Dec-2017
44
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
c) Subjects with EGFR mutation regardless of mutation type are excluded. Non squamous 
subjects with unknown EGFR mutation status must be tested for EGFR mutation (use of 
PCR based test is strongly encouraged). If the EGFR mutation is positive, subject is 
excluded.
d) Subjects with known ALK translocation are excluded.
2. Medical History and Concurrent Diseases
a) Subjects with an active, known or suspected autoimmune disease are excluded. Subjects 
with type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, skin 
disorder (such as vitiligo, psoriasis or alopecia) not requiring systemic treatment, or 
conditions not expected to recur in the absence of an external trigger are permitted to 
enroll. 
b) Subjects with a condition requiring systemic treatment with either corticosteroids 
(> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 
14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid 
doses > 10 mg daily prednisone equivalent, are permitted in the absence of active 
autoimmune disease.
c) Prior therapy with anti-tumor vaccines or other immuno-stimulatory antitumor agents.
d) Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 
antibody (including ipilimumab or any other antibody or drug specifically targeting 
T-cell co-stimulation or checkpoint pathways).
e) Not applicable
f)
Prior treatment with docetaxel.
g) Subjects with interstitial lung disease that is symptomatic or may interfere with the 
detection or management of suspected drug-related pulmonary toxicity.
h) Other active malignancy requiring concurrent intervention. 
i)
Subjects with previous malignancies (except non-melanoma skin cancers, and the 
following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, 
melanoma, or breast) are excluded unless a complete remission was achieved at least 
2 years prior to study entry AND no additional therapy is required or anticipated to be 
required during the study period.
j)
All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must 
have resolved to Grade 1 National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI CTCAE version 4.0) or baseline before administration of study 
drug.
k) Subjects must have recovered from the effects of major surgery or significant traumatic 
injury at least 14 days prior to randomization.
l)
Active Tuberculosis (TB) infection based on chest X-ray, sputum tests, and clinical
examination. Patients with a history of active TB infection within last 1 year are excluded 
even if it was treated; Patients with a history of active TB infection greater than 1 year 
Revised Protocol No: 05
Date: 13-Dec-2017
45
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
ago are eligible if there is no evidence of active TB in current status in the investigator’s 
opinion.
m) Subjects with a history of screen failure to any anti-PD-1 or anti-PD-L1 antibody clinical 
trial due to PD-L1 negative status.
n) EGFR wild-type subjects who received EGFR inhibitor as prior systemic anti-cancer 
therapy are excluded. Subjects without ALK translocation who received ALK inhibitor as 
prior systemic anti-cancer therapy are exclude.
o) Known medical condition that, in the investigator’s opinion, would increase the risk 
associated with study participation or study drug administration or interfere with the 
interpretation of safety results
3. Physical and Laboratory Test Findings
a) Known history of testing positive for human immunodeficiency virus (HIV) or known 
acquired immunodeficiency syndrome (AIDS).
b) Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus antibody 
(HCV Ab) indicating acute or chronic infection.
c) Subjects with Grade 2 peripheral neuropathy
4. Allergies and Adverse Drug Reaction
a) History of severe hypersensitivity reactions to other monoclonal antibodies.
b) History of severe hypersensitivity reaction to prior paclitaxel.
c) History of allergy or intolerance (unacceptable adverse event) to study drug components 
or Polysorbate-80-containing infusions.
5. Other Exclusion Criteria
a) Prisoners or subjects who are involuntarily incarcerated.
b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness.
Eligibility criteria for this study have been carefully considered to ensure the safety of the study 
subjects and that the results of the study can be used. It is imperative that subjects fully meet all 
eligibility criteria.
3.3.2.1
Exclusion Criteria for Entering the Nivolumab Crossover Extension 
Phase-Subjects Previously Randomized to Docetaxel
6. Medical History and Concurrent Diseases
a) Subjects with active, known or suspected autoimmune disease. Subjects with type I 
diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders 
(such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions 
not expected to recur in the absence of an external trigger are permitted to enroll in 
nivolumab crossover extension phase
b) Subjects with a condition requiring systemic treatment with either corticosteroids 
(> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 
Revised Protocol No: 05
Date: 13-Dec-2017
46
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
14 days prior first dose of nivolumab administration. Corticosteroids with minimal 
systemic absorption (for example topical, inhalational, or as specified in Section 3.4.3), 
and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted 
in the absence of active autoimmune disease
c) Subjects must have recovered from the effects of major surgery or significant traumatic 
injury at least 14 days before the first dose of nivolumab administration 
d) Prior treatment with an anti-PD-1 or anti-PD-L1 therapy.
e) Subjects with carcinomatous meningitis
f)
Other active malignancy requiring concurrent intervention
g) Subjects with interstitial lung disease that is symptomatic or may interfere with the 
detection or management of suspected drug-related pulmonary toxicity
h) Any other serious or uncontrolled medical disorder, active infection, physical exam 
finding, laboratory finding, altered 
mental status, or psychiatric condition that, in the 
opinion of the investigator, would limit a subject’s ability to comply with the study 
requirements, substantially increase risk to the subject, or impact the interpretability of 
study results
7. Physical and Laboratory Test Findings
a) Known history of testing positive for human immunodeficiency virus (HIV) or known 
acquired immunodeficiency syndrome (AIDS)
b) Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic 
infection
8. Allergies and Adverse Drug Reaction
a) History of severe hypersensitivity reactions to other monoclonal antibodies.
b) History of allergy or intolerance (unacceptable adverse event) to study drug components 
or Polysorbate-80-containing infusions
9. Other Exclusion Criteria
a) Any other serious or uncontrolled medical disorder, active infection, physical exam 
finding, laboratory finding, altered mental status, or psychiatric condition that, in the 
opinion of the investigator, would limit a subject’s ability to comply with the study 
requirements, substantially increase risk to the subject, or impact the interpretability of 
study results. 
b) Prisoners or subjects who are involuntarily incarcerated
c) Subjects who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness
Eligibility criteria for the Nivolumab Crossover Extension Phase have been carefully considered 
to ensure the safety of the study subjects and to ensure that the results of the study can be used. It 
is imperative that subjects fully meet all eligibility criteria.
3.3.3
Women of Childbearing Potential
A Women of childbearing potential (WOCBP) is defined as any female who has experienced 
menarche and who has not undergone surgical sterilization (hysterectomy or bilateral 
oophorectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in 
Revised Protocol No: 05
Date: 13-Dec-2017
47
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
a woman over age 45 years in the absence of other biological or physiological causes. In 
addition, females under the age of 55 years must have a serum follicle stimulating hormone, 
(FSH) level > 40mIU/mL to confirm menopause.
*Females treated with hormone replacement therapy, (HRT) are likely to have artificially 
suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the investigators should use their 
judgement in checking serum FSH levels. If the serum FSH level is >40 mIU/ml at any time
during the washout period, the woman can be considered postmenopausal:

1 week minimum for vaginal hormonal products (rings, creams, gels)

4 week minimum for transdermal products

8 week minimum for oral products
Other parenteral products may require washout periods as long as 6 months.
3.4
Concomitant Treatments
3.4.1
Prohibited and/or Restricted Treatments
Strong CYP3A4 inhibitors should be avoided for subjects in Arm B (docetaxel) during the study
(refer to docetaxel package insert for details). This includes (but is not limited to):
3.4.1.1
Strong CYP3A4 inhibitors

Ketoconazole

Itraconazole

Clarithromycin

Atazanavir

Indinavir

Nefazodone

Nelfinavir

Ritonavir

Saquinavir

Teithromycin

Voriconazole
The following medications are prohibited during the study (unless utilized to treat a drug related 
adverse event):

Immunosuppressive agents

Immunosuppressive doses of systemic corticosteroids (except as stated in this Section 3.4.3).

Any concurrent antineoplastic therapy (ie, chemotherapy, hormonal therapy, immunotherapy
(including but not limited to thymosin, interleukine-2), extensive, non-palliative radiation 
therapy, standard or investigational agents for treatment of NSCLC).
Revised Protocol No: 05
Date: 13-Dec-2017
48
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Except for the permitted procedures specified as palliative local therapies (Section 3.4.3.1), all 
other radiation therapy or surgery to any tumor lesion is not permitted during study treatment. 
Subjects who require such non-palliative procedures must be discontinued from study treatment
3.4.2
Other Restrictions and Precautions
Subjects randomized to Arm B (docetaxel) should refrain from excessive consumption of 
grapefruit, seville oranges, and products/juices made with these fruit. 
Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily 
prednisone equivalent) or other immunosuppressive medications within 14 days of 
randomization are excluded. Inhaled or topical steroids, and adrenal replacement steroid doses 
> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
3.4.3
Permitted Therapy
Subjects are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational 
corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses > 10 mg 
daily prednisone are permitted Physiologic replacement doses of systemic corticosteroids (eg, 
prednisone 10 mg/day) are permitted. A brief (less than 3 weeks) course of corticosteroids for 
prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, 
delayed-type hypersensitivity reaction caused by a contact allergen) is permitted.
Concomitant palliative and supportive care for disease related symptoms (including 
bisphosphonates) is allowed. RANK-L inhibitors are not allowed during study treatment. Prior 
palliative radiotherapy must have been completed at least 2 weeks prior to randomization.
3.4.3.1
Palliative local therapy
Palliative local therapy, including palliative radiation therapy- and palliative surgical resection,
to symptomatic non-target bone lesions, skin lesions, or CNS lesions is permitted prior to 
discontinuation of study treatment for subjects who do not have evidence of overall clinical or 
radiographic progression per RECIST 1.1. Palliative local therapy to lesions causing hemoptysis 
may also be permitted prior to discontinuation of study treatment in subjects who do not have 
evidence of overall clinical or radiographic progression per RECIST 1.1, provided that the 
lesions undergoing palliative local therapy are not the only sites of measurable disease and the 
case is discussed with and approved by the BMS Medical Monitor.
Subjects requiring palliative local therapy should be evaluated for objective evidence of disease 
progression prior to the initiation of such therapy, particularly if the most recent tumor 
assessment was more than 4 weeks prior to the start of local therapy. If progression per 
RECIST 1.1 is identified on any tumor assessments prior to the initiation of palliative local 
therapy, then subjects in Arm A (Nivolumab) must either discontinue nivolumab or they must 
meet criteria to continue nivolumab treatment beyond progression (Section 4.5.4) in order to 
resume nivolumab after palliative local therapy. Subjects in Arm B (Docetaxel) who are found to 
have progression per RECIST 1.1 on any tumor assessments prior to the initiation of palliative 
local therapy must discontinue chemotherapy.
Revised Protocol No: 05
Date: 13-Dec-2017
49
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
The potential for overlapping toxicities with radiotherapy and nivolumab currently is not known; 
however, anecdotal data suggests that it is tolerable. As concurrent radiotherapy and nivolumab 
have not been formally evaluated, in cases where palliative radiotherapy is required for a tumor 
lesion, then nivolumab should be withheld for at least 1 week before, during, and 1 week after 
radiation. Subjects should be closely monitored for any potential toxicity during and after 
receiving radiotherapy, and AEs should resolve to Grade 1 prior to resuming nivolumab
3.5
Discontinuation of Subjects Following any Treatment with Study Drug
Subjects MUST discontinue investigational product (and non-investigational product at the 
discretion of the investigator) for any of the following reasons:

Subject’s request to stop study treatment

Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in the 
opinion of the investigator, indicates that continued participation in the study is not in the 
best interest of the subject

Termination of the study by Bristol-Myers Squibb (BMS)

Loss of ability to freely provide consent through imprisonment or involuntarily incarceration 
for treatment of either a psychiatric or physical (eg, infectious disease) illness

Additional protocol-specific reasons for discontinuation (See Section 4.5.5).
In the case of pregnancy, the investigator must immediately notify the BMS Medical 
Monitor/designee of this event. In most cases, the study drug will be permanently discontinued in 
an appropriate manner. If the investigator determines a possible favorable benefit/risk ratio that 
warrants continuation of study drug, a discussion between the investigator and the BMS Medical 
Monitor/designee must occur.
All subjects who discontinue study drug should comply with protocol specified follow-up 
procedures as outlined in Section 5. The only exception to this requirement is when a subject 
withdraws consent for all study procedures including post-treatment study follow-up or loses the 
ability to consent freely (ie, is imprisoned or involuntarily incarcerated for the treatment of either 
a psychiatric or physical illness).
If study drug is discontinued prior to the subject’s completion of the study, the reason for the 
discontinuation must be documented in the subject’s medical records and entered on the 
appropriate case report form (CRF) page.
3.6
Post Study Drug Study Follow up
In this study overall survival is a key endpoint of the study. Post study follow-up is of critical 
importance and is essential to preserving subject safety and the integrity of the study. Subjects 
who discontinue study drug must continue to be followed for collection of outcome and/or 
survival follow-up data as required and in line with Section 5 until death or the conclusion of the 
study.
Follow-Up Visit 1 to occur 35 days from the last dose (7 days) or coinciding with the date of 
discontinuation of study drug (7 days) if the date of discontinuation is greater than 42 days 
Revised Protocol No: 05
Date: 13-Dec-2017
50
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
from the last dose. Follow-Up Visit 2 to occur 80 days from Follow-Up Visit 1 (7 days). 
Survival Follow-Up Visits to occur approximately every 3 months from Follow-Up Visit 2. 
Survival Follow-up visits may be performed by phone contact or office visit.
BMS may request that survival data be collected on all randomized subjects outside of the 
protocol defined window (Table 5.1-4). At the time of this request, each subject will be contacted 
to determine their survival status unless the subject has withdrawn consent for all contact.
3.6.1
Withdrawal of Consent
Subjects who request to discontinue study drug will remain in the study and must continue to be 
followed for protocol specified follow-up procedures. The only exception to this is when 
a subject specifically withdraws consent for any further contact with him/her or persons 
previously authorized by subject to provide this information. Subjects should notify the 
investigator of the decision to withdraw consent from future follow-up in writing, whenever 
possible. The withdrawal of consent should be explained in detail in the medical records by the 
investigator, as to whether the withdrawal is from further treatment with study drug only or also 
from study procedures and/or post treatment study follow-up, and entered on the appropriate 
CRF page. In the event that vital status (whether the subject is alive or dead) is being measured, 
publicly available information should be used to determine vital status only as appropriately 
directed in accordance with local law.
3.6.2
Lost to Follow-Up
All reasonable efforts must be made to locate subjects to determine and report their ongoing 
status. This includes follow-up with persons authorized by the subject as noted above. Lost to 
follow-up is defined by the inability to reach the subject after a minimum of three documented 
phone calls, faxes, or emails as well as lack of response by subject to one registered mail letter. 
All attempts should be documented in the subject’s medical records. If it is determined that the 
subject has died, the site will use permissible local methods to obtain the date and cause of death.
If investigator’s use of third-party representative to assist in the follow-up portion of the study 
has been included in the subject’s informed consent, then the investigator may use a 
Sponsor-retained third-party representative to assist site staff with obtaining subject’s contact 
information or other public vital status data necessary to complete the follow-up portion of the 
study. The site staff and representative will consult publicly available sources, such as public 
health registries and databases, in order to obtain updated contact information. If after all 
attempts, the subject remains lost to follow-up, then the last known alive date as determined by 
the investigator should be reported and documented in the subject’s medical records.
4
STUDY DRUG
Study drug includes both Investigational [Medicinal] Product (IP/IMP) and Non-investigational 
[Medicinal] Product (Non-IP/Non-IMP) and can consist of the following:
Revised Protocol No: 05
Date: 13-Dec-2017
51
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 4-1:
Study Drug for CA209078
Product Description / 
Class and Dosage Form 
Potency
IP/Non-IMP
Blinded or Open 
Label
Packaging/Appearance
Storage Conditions
(per label)
Nivolumab
Solution for Injection
100 mg (10 mg/mL)
IP
Open Label
10 mL vial/
5 vials per carton
Clear to opalescent, 
colorless to pale yellow 
liquid. May contain 
particles.
2° to 8°C. Protect from 
light and freezing.
Docetaxel 
Concentrate for 
solution for infusion
160 mg (20 mg/ mL)a
IP
Open Label
8 mL vial/ 1 vial per 
carton
Pale yellow to brownish 
yellow solution
Do not store above 
25°C. Store in original 
package and Protect 
from light.
Docetaxel 
Concentrate for 
solution for infusion
20 mg (40 mg/ mL)
IP
Open Label
2 vials per carton
(1 vial of 20mg/0.5mL 
concentrate for solution 
+ 1 vial of solvent)
Clear viscous, yellow to 
brown-yellow solution
Do not store above 
25°C. Store in original 
package and Protect 
from light.
Dexamethasone Tablets
4 mga
Non-IP
N/A
Wallet (blister) card of
20 tablets 
Scored tablets
Store at 15° - 25° C.
**Medications used to treat nivolumab-related infusion reactions are (eg diphenhydramine, acetaminophen/paracetamol, corticosterioids) considered NIMPs 
(noninvestigational products) and will not be provided by the sponsor. These will be obtained by the investigational sites as marketed product, which should 
be stored in accordance to the package insert or summary of product characteristics (SmPC). For further details related to these medications and nivolumab-
related infusion reactions, please see Section 4.5.6.
a For sites/countries in which investigative site staff will procure locally marketed product, the potency/packaging size may differ based on the locally available 
product
Revised Protocol No: 05
Date: 13-Dec-2017
52
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
4.1
Investigational Product
An investigational product, also known as investigational medicinal product in some regions, is 
defined a pharmaceutical form of an active substance or placebo being tested or used as a 
reference in a clinical study, including products already with a marketing authorization but used 
or assembled (formulated or packaged) differently than the authorized form, or used for an 
unauthorized indication, or when used to gain further information about the authorized form.
The investigational product should be stored in a secure area according to local regulations. It is 
the responsibility of the investigator to ensure that investigational product is only dispensed to 
study subjects. The investigational product must be dispensed only from official study sites by 
authorized personnel according to local regulations.
In this protocol, investigational product(s) is/are: 

Nivolumab

Docetaxel
Docetaxel will be provided by BMS as listed in Table 4-1 for certain countries and may be 
procured by the investigative sites in other countries as local commercial product, where allowed 
by local regulations. The sites will also procure IV bags, diluents, and micron in-line filters 
(ie, 0.2/ 1.2 micron; see current Nivolumab Investigator Brochure for required filter details).
4.2
Non-investigational Product
Other medications used as support or escape medication for preventative, diagnostic, or 
therapeutic reasons, as components of the standard of care for a given diagnosis, may be
considered as non-investigational products. 
In this protocol, non-investigational product(s) is/are: Dexamethasone (for 3 days in the 
docetaxel arm only as premedication), and any medications used to treat nivolumab related 
infusion reactions (see Section 4.5.6).
4.3
Storage and Dispensing
The product storage manager should ensure that the study drug is stored in accordance with the 
environmental conditions (temperature, light, and humidity) as determined by BMS. If concerns 
regarding the quality or appearance of the study drug arise, the study drug should not be 
dispensed and contact BMS immediately.
Investigational product documentation (whether supplied by BMS or not) must be maintained 
that includes all processes required to ensure drug is accurately administered. This includes 
documentation of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets).
For non-investigational product, if marketed product is utilized, it should be stored in accordance 
with the package insert, summary of product characteristics (SmPC), or similar.
Revised Protocol No: 05
Date: 13-Dec-2017
53
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Nivolumab vials must be stored in the refrigerator at 2 - 8°C, protected from light and freezing. 
If stored in a glass front refrigerator, vials should be stored in the carton. 
Docetaxel and dexamethasone should be stored according to the market product package insert 
or clinical label. 
Recommended safety measures for preparation and handling of nivolumab include laboratory 
coats and gloves. 
After Nivolumab has been prepared for administration, the total storage time (combination of 
refrigeration and room temperature) is not to exceed 24 hours. For details on prepared drug 
storage and use time under room temperature/light and refrigeration, please refer to the current 
Nivolumab Investigator Brochure.22
Care must be taken to assure sterility of the prepared solution as the product does not contain any 
anti-microbial preservative or bacteriostatic agent. No incompatibilities between nivolumab and 
polyolefin bags have been observed.
Nivolumab is to be administered as a 60 minute IV infusion. It is not to be administered as an IV 
push or bolus injection. At the end of the infusion, flush the line with a sufficient quantity of 
normal saline (per institutional standard of care).
Details regarding the mixing and concentrations of the dose (preparation) and administration will 
be found in the pharmacy reference sheet and/or the current Investigator brochure for 
nivolumab.22
For sites utilizing the docetaxel 160 mg, 20 mg vials provided by Bristol-Myers Squibb, the 
preparation instructions found within the current SmPC (or equivalent document) should be 
followed.92
For sites utilizing locally-sourced docetaxel,
please follow storage and administration 
instructions on the package insert or SmPC.89,92
4.4
Method of Assigning Subject Identification
After the subject’s eligibility is established and informed consent has been obtained, the subject 
will be enrolled and a number will be assigned through an interactive voice response system 
(IVRS). Specific instructions and procedures for using IVRS will be provided to the 
investigational site in a separate document/ manual.
The investigator (or designee) will register the subject for enrollment by following the 
enrollment procedures established by BMS. The following information is required for 
enrollment:

Date of informed consent

Date of birth

Gender at birth.
Once enrolled in IVRS, enrolled subjects that have signed informed consent and met all 
eligibility criteria will be ready to be randomized through the IVRS, upon confirmation of receipt 
Revised Protocol No: 05
Date: 13-Dec-2017
54
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
of required tissue sample by the central lab. The following information is required for subject 
randomization:

Subject number

Date of birth

Gender at birth

Date of informed consent

Histology (squamous vs non-squamous) : Subjects with mixed histology should be classified 
according to the predominant histology. Subjects with adenosquamous histology should be 
classified as non-squamous histology

ECOG Performance status (0 vs 1)

PDL-1 Status
Subjects meeting all eligibility criteria and randomized onto the study will be assigned in a 
2:1 ratio into one of the two treatment arms, and stratified by the following factors: histology 
(squamous vs non-squamous)/ PD-L1 Status (positive vs negative/ unevaluable)/ ECOG 
Performance status (0 vs 1). The randomization will be carried out via permuted blocks within 
each stratum.
Amendment 05 Update: IVRS will be amended to allow all subjects previously randomized to 
Arm B (docetaxel treatment) to receive treatment with nivolumab. The IVRS will assign the 
nivolumab treatment for all subjects eligible for the Nivolumab Crossover Extension Phase. 
Procedural information will be provided in a separate document.
Subjects currently randomized to Arm B (docetaxel treatment) may continue docetaxel treatment 
previously through the IVRS, as long as subjects continue to derive benefit from docetaxel in the 
judgment of the investigator.
4.4.1
Treatment Arms
Arm A: Nivolumab and Nivolumab Crossover Extension Phase
No premedications are recommended for initiation of dosing.
Arm B: Docetaxel
Dexamethasone 8 mg PO BID (or institutional equivalent) on the day before, day of, and day 
after chemotherapy. Please use the institutional standard for dexamethasone dosing.
4.5
Selection and Timing of Dose for Each Subject
Nivolumab
Subjects randomized to Arm A (the experimental arm) and enrolled in Nivolumab Crossover 
Extension Phase will receive treatment with nivolumab as a 60 minute IV infusion, on Day 1 of a 
treatment cycle every 2 weeks. Dosing calculations should be based on the body weight assessed 
at the start of each cycle as per Table 5.1-2 or Table 5.1-6 for Nivolumab Crossover Extension 
Phase. If the subject’s weight on the day of dosing differs by > 10% from the weight used to 
Revised Protocol No: 05
Date: 13-Dec-2017
55
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
calculate the prior dose, the dose must be recalculated. All doses should be rounded to the 
nearest milligram. There will be no dose escalations or reductions of nivolumab allowed. 
Subjects may be dosed no less than 12 days from the previous dose and no more than 3 days 
from the scheduled dose. There are no premedications recommended for nivolumab on the first 
cycle. If an acute infusion reaction is noted, subjects should be managed according to 
Section 4.5.6.
Docetaxel
Subjects randomized to Arm B (the control arm) will receive treatment with docetaxel as a 
60 minute IV infusion on Day 1 of a treatment cycle every 3 weeks. Dosing calculations should 
be based upon the body surface area calculation assessed as per Table 5.1-3. If the subject’s 
weight on the day of dosing differs by > 10% from the weight used to calculate the prior dose, 
the dose must be recalculated. Dose modifications for toxicity will be performed according to 
Section 4.5.2.2. Subjects may be dosed no less than 19 days from the previous dose and no more 
than 3 days from the scheduled dose.
On both arms and Nivolumab Crossover Extension Phase, treatment may be delayed for up to a 
maximum of 6 weeks from the last dose (see Section 4.5.3). 
Subjects will be monitored continuously for AEs while on study. Treatment modifications 
(eg, dose delay, reduction, or discontinuation) will be based on specific laboratory and adverse 
event criteria.
4.5.1
Dose Delay Criteria
Tumor assessments for all subjects should continue as per protocol even if dosing is delayed.
4.5.1.1
Nivolumab Dose Delay Criteria
Nivolumab administration should be delayed for the following:

Grade 2 non-skin, drug-related adverse event, with the exception of fatigue

Grade 2 drug-related creatinine, AST, ALT and/or Total Bilirubin abnormalities

Grade 3 skin, drug-related adverse event

Grade 3 drug-related laboratory abnormality, with the following exceptions: 

Grade 3 lymphopenia or asymptomatic amylse or lipase does not require dose delay

Grade 3 AST, ALT, Total Bilirubin will require dose discontinuation (see 4.5.5.1)

Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants delaying the dose of study medication.
Subjects who require delay of nivolumab should be re-evaluated weekly or more frequently if 
clinically indicated and resume nivolumab dosing when re-treatment crietria are met.
Revised Protocol No: 05
Date: 13-Dec-2017
56
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
4.5.1.2
Docetaxel Dose Delay Criteria
Docetaxel administration should be delayed for the following:

Any Grade 2 non-skin, drug-related adverse event, with the following exceptions:

Grade 2 drug-related fatigue or laboratory abnormalities do not require a treatment delay

Any Grade 3 skin, drug-related adverse event

Any Grade 3 drug-related laboratory abnormality, with the following exceptions for 
lymphopenia, neutrophil count, AST, ALT, or total bilirubin:

Grade 3 lymphopenia does not require dose delay

Should not be given if neutrophil counts are < 1500 cells/mm3

Should not be given if total bilirubin > upper limit of normal (ULN), or if AST and/or 
ALT > 1.5xULN concomitant with alkaline phosphatase > 2.5x ULN

Any AE, laboratory abnormality or inter-current illness which, in the judgment of the 
investigator, warrants delaying the dose of study medication.
Subsequent dose reductions may be required as per Section 4.5.2.2.
Subjects receiving docetaxel may receive growth factors (including G-CSF and erythropoietin) at 
the discretion of the investigator.
4.5.2
Dose Reductions
4.5.2.1
Nivolumab Dose Reductions
There will be no dose reduction for nivolumab.
4.5.2.2
Docetaxel Dose Reductions
Dose reductions of docetaxel may be required,87 and will be performed according to Table 
4.5.2.2-1.
Table 4.5.2.2-1:
Dose Reductions of Docetaxel
Dose Level
Docetaxel
Starting dose
75 mg/m²
First dose reduction
55 mg/m²
Second dose reduction
37.5 mg/m²
Third dose reduction
Discontinue docetaxel
Doses of docetaxel will be modified for subjects who experience any of the following conditions 
during docetaxel treatment:

Febrile neutropenia (body temperature 38.5 C and neutrophils < 1,000 cell/mm3)

Neutrophils < 500 cell/mm³ for more than one week despite growth factor support

Severe or cumulative cutaneous reactions
Revised Protocol No: 05
Date: 13-Dec-2017
57
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab

Other Grade 3/4 non-hematological toxicities.
Subjects should have treatment delayed according to Sections 4.5.1.2 and 4.5.2.2, and then 
resumed at one dose level reduction (55 mg/m2). Should these AEs occur after the first dose 
reduction, then a second dose reduction to 37.5 mg/m2 is permitted. If a third dose reduction is 
required, then the subject should discontinue docetaxel treatment and enter the follow-up phase.
Subjects who develop Grade 3 peripheral neuropathy, or who otherwise meet criteria specified 
in Section 4.5.5.2, should discontinue docetaxel treatment and enter the follow-up phase.
4.5.3
Criteria to Resume Dosing
4.5.3.1
Criteria to Resume Treatment with Nivolumab
Subjects may resume treatment with nivolumab when the drug-related AE(s) resolve(s) to 
Grade 1 or baseline, with the following exceptions:

Subjects may resume treatment in the presence of Grade 2 fatigue

Subjects who have not experienced a Grade 3 drug-related skin AE may resume treatment in
the presence of Grade 2 skin toxicity

For subjects with Grade 2 AST, ALT and/or Total Bilirubin Abnormalities, dosing may 
resume when laboratory values return to baseline and management with corticosteroids, if 
needed, is complete.

Subjects with combined Grade 2 AST/ALT AND
total bilirubin values meeting 
discontinuation parameters (Section 4.5.5.1) should have treatment permanently discontinued

Drug-related pulmonary toxicity, diarrhea or colitis must have resolved to baseline before 
treatment is resumed. Subjects with persistent Grade 1 pneumonitis after completion of a 
steroid taper over at least 1 month may be eligible for retreatment if discussed with and 
approved by BMS Medical Monitor.

Subjects with drug-related endocrinopathies adequately controlled with only physiologic 
hormone replacement may resume treatment after consultation with the BMS Medical 
Monitor.
Adrenal insufficiency requires discontinuation of control with hormone 
replacement.

If treatment is delayed > 6 weeks, the subject must be permanently discontinued from study 
therapy, except as specified in Section 4.5.5.1.
4.5.3.2
Criteria to Resume Treatment with Docetaxel
Subjects may resume treatment with docetaxel when the drug-related AE(s) resolve(s) to 
Grade 1 or baseline, with the following exceptions:

Subjects may resume treatment in the presence of Grade 2 fatigue 

Subjects who have not experienced a Grade 3 drug-related skin AE may resume treatment in 
the presence of Grade 2 skin toxicity 

Subjects with decreased neutrophil counts, or with elevations in total bilirubin, AST or ALT 
must meet criteria for resuming treatment according to the boxed warning contained within 
the docetaxel Prescribing Information
Revised Protocol No: 05
Date: 13-Dec-2017
58
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab

Subjects with combined Grade 2 AST/ALT AND
total bilirubin values meeting 
discontinuation parameters (Section 4.5.5.2) should have treatment permanently discontinued
If treatment is delayed > 6 weeks, the subject must be permanently discontinued from study 
therapy, except as specified in Section 4.5.5.2.
When resuming docetaxel treatment, please follow the dose reduction recommendations noted in 
Section 4.5.2.2.
4.5.4
Treatment Beyond Disease Progression
As described in Section 1.4.3.3, accumulating evidence indicates a minority of subjects treated 
with immunotherapy may derive clinical benefit despite initial evidence of PD.
Subjects treated with docetaxel (Arm B) will not be permitted to continue their treatment beyond 
initial RECIST 1.1 defined PD. 
Subjects treated with nivolumab (Arm A and Nivolumab Crossover Extension Phase) will be 
permitted to continue treatment beyond initial RECIST 1.1 defined PD as long as they meet the 
following criteria: 
1. Investigator-assessed clinical benefit, and do not have rapid disease progression
2. Tolerance of study drug
3. Stable performance status
4. Treatment beyond progression will not delay an imminent intervention to prevent serious 
complications of disease progression (eg, CNS metastases)
5. Subject provides written informed consent prior to receiving additional nivolumab treatment, 
using an ICF describing any reasonably foreseeable risks or discomforts, or other alternative 
treatment options.
The decision to continue treatment beyond initial progression should be discussed with the BMS 
medical Monitor and documented in the study records. 
A radiographic assessment/ scan should be performed within 6 weeks (7 days) of original PD 
to determine whether there has been a decrease in the tumor size, or continued PD. The 
assessment of clinical benefit should be balanced by clinical judgment as to whether the subject 
is clinically deteriorating and unlikely to receive any benefit from continued treatment with 
nivolumab.
If the investigator feels that the nivolumab subject continues to achieve clinical benefit by 
continuing treatment, the subject should remain on the trial and continue to receive monitoring 
according to the Time and Events Schedule on Table 5.1-2 or Table 5.1-6 for Nivolumab 
Crossover Extension Phase.
For the subjects who continue nivolumab study therapy beyond progression, further progression 
is defined as an additional 10% increase in tumor burden volume from time of initial PD. This 
includes an increase in the sum of all target lesions and/ or the development of new measurable 
lesions. 
Revised Protocol No: 05
Date: 13-Dec-2017
59
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
New lesions are considered measureable at the time of initial progression if the longest diameter 
is at least 10 mm (except for pathological lymph nodes which must have a short axis of at least 
15 mm). Any new lesion considered non-measureable at the time of initial progression may 
become measureable and therefore included in the tumor burden volume if the longest diameter 
increases to at least 10 mm (except for pathological lymph nodes which must have a short axis of 
at least 15 mm). 
For subjects in both treatment arms and the Nivolumab Crossover Extension Phase, global 
deterioration of health status requiring discontinuation of treatment without objective evidence of 
disease progression at that time should be reported as « symptomatic » deterioration. Every effort 
should be made to document objective progression (ie, radiographic confirmation) even after 
discontinuation from study treatment. 
4.5.5
Treatment Discontinuation Criteria
Tumor assessments for all subjects should continue as specified in Section 5.4.1 even if dosing is 
discontinued.
4.5.5.1
Nivolumab Dose Discontinuation
Nivolumab treatment should be permanently discontinued for the following:

Grade 2 drug-related uveitis, eye pain or blurred vision that does not respond to topical 
therapy and does not improve to Grade 1 severity within the re-treatment period OR requires 
systemic treatment 

Grade 3 non-skin, drug-related adverse event lasting > 7 days or recurs, with the following 
exceptions for laboratory abnormalities, drug related uveitis, pneumonitis, bronchospasm, 
hypersensitivity reactions, infusion related reactions and endocrinopathies: 

Grade 3 drug-related uveitis, pneumonitis, bronchospasm, hypersensitivity reaction, or 
infusion reaction of any duration require discontinuation

Grade 3 drug-related endocrinopathies adequately controlled with only physiologic 
hormone replacement do not require discontinuation. Adrenal insufficiency requires 
discontinuation regardless of control with hormone replacement

Grade 3 drug-related laboratory abnormalities do not require treatment discontinuation 
except:
Grade 3 drug-related thrombocytopenia > 7 days or associated with bleeding requires 
discontinuation
Grade 3 drug-related AST, ALT or Total Bilirubin requires discontinuation*
Concurrent AST or ALT > 3 x ULN and total bilirubin > 2x ULN
* In most cases of Grade 3 AST or ALT elevation, study drug(s) will be permanently 
discontinued. If the investigator determines a possible favorable benefit/risk ratio that 
warrants continuation of study drug(s), a discussion between the investigator and the 
BMS Medical Monitor/designee must occur

Grade 4 drug-related adverse event or laboratory abnormality (including but not limited to 
creatinine, AST, ALT or total bilirubin), except for the following events which do not require 
discontinuation:
Revised Protocol No: 05
Date: 13-Dec-2017
60
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab

Grade 4 neutropenia 7 days

Grade 4 lymphopenia or leukopenia or asymptomatic amylse or lipase

Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 
72 hours of their onset

Grade 4 drug-related endocrinopathy adverse events, such as hyper- or hypothyroidism, 
or glucose intolerance, which resolve or are adequately controlled with physiologic 
hormone replacement (corticosteroids, thyroid hormones) or glucose-controlling agents, 
respectively, may not require discontinuation after discussion with and approval from the 
BMS Medical Monitor.

Creatinine > 6x ULN

Any event that leads to delay in dosing lasting > 6 weeks from the previous dose requires 
discontinuation, with the following exceptions:

Dosing delays to allow for prolonged steroid tapers to manage drug-related adverse 
events are allowed. 

Dosing delays lasting > 6 weeks from the previous dose that occur for non-drug-related 
reasons may be allowed if approved by the BMS medical monitor. 
Prior to re-initiating treatment in a subject with a dosing delay lasting > 6 weeks, the BMS 
medical monitor must be consulted. Tumor assessments should continue as per protocol even if 
dosing is delayed. Periodic study visits to assess safety and laboratory studies should also 
continue every 6 weeks or more frequently if clinically indicated during such dosing delays.

Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the Investigator, presents a substantial clinical risk to the subject with continued nivolumab 
dosing.
Revised Protocol No: 05
Date: 13-Dec-2017
61
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
4.5.5.2
Docetaxel Dose Discontinuation
Docetaxel treatment should be permanently discontinued for the following:

Any Grade 3 peripheral neuropathy

Any Grade 3 non-skin drug-related adverse event lasting > 7 days, with the following 
exceptions for laboratory abnormalities:

Grade 3 drug-related laboratory abnormalities do not require treatment discontinuation 
except: 
Grade 3 drug-related thrombocytopenia associated with bleeding requires 
discontinuation
Any drug-related liver function test (LFT) abnormality that meets the following 
criteria require discontinuation: 

AST or ALT > 5~10x ULN for > 2 weeks

AST or ALT > 10x ULN

Total bilirubin > 5x ULN

Concurrent AST or ALT > 3x ULN and total bilirubin > 2x ULN

Any Grade 4 drug-related adverse event or laboratory abnormality, except for the following 
events which do not require discontinuation:

Grade 4 neutropenia

Grade 4 lymphopenia or leukopenia

Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 
72 hours of their onset

Any dosing delay lasting > 6 weeks with the following exceptions:

Dosing delay > 6 weeks that occur for non-drug-related reasons may be allowed if 
approved by the BMS medical monitor. Prior to re-initiating treatment in a subject with a 
dosing delay lasting > 6 weeks, the BMS medical monitor must be consulted. Tumor 
assessments should continue as per protocol even if dosing is delayed.

Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the Investigator, presents a substantial clinical risk to the subject with continued docetaxel 
dosing.
4.5.6
Treatment of Nivolumab-Related Infusion Reactions
Since nivolumab contains only human immunoglobulin protein sequences, it is unlikely to be 
immunogenic and induce infusion or hypersensitivity reactions. However, if such a reaction were 
to occur, it might manifest with fever, chills, rigors, headache, rash, pruritus, arthalgias, 
hypotension, hypertension, bronchospasm, or other allergic-like reactions. All Grade 3 or 4 
infusion reactions should be reported within 24 hours to the study medical monitor and reported 
as an SAE if it meets the criteria. Infusion reactions should be graded according to NCI CTCAE 
(Version 4.0) guidelines.
Treatment recommendations are provided below and may be modified based on local treatment 
standards and guidelines, as appropriate:
Revised Protocol No: 05
Date: 13-Dec-2017
62
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
For Grade 1 symptoms: (Mild reaction; infusion interruption not indicated; intervention 
not indicated).

Remain at bedside and monitor subject until recovery from symptoms. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg 
(or equivalent) and/or acetaminophen/paracetamol 325 to 1000 mg at least 30 minutes before 
additional nivolumab administrations.
For Grade 2 symptoms: (Moderate reaction requires therapy or infusion interruption but 
responds promptly to symptomatic treatment [eg, antihistamines, non-steroidal 
anti-inflammatory 
drugs, 
narcotics, 
corticosteroids, 
bronchodilators, 
IV 
fluids]; 
prophylactic medications indicated for 24 hours).

Stop the nivolumab infusion, begin an IV infusion of normal saline, and treat the subject with 
diphenhydramine 50 mg IV (or equivalent) and/or acetaminophen/paracetamol 325 to 
1000 mg; remain at bedside and monitor subject until resolution of symptoms. Corticosteroid 
and/or bronchodilator therapy may also be administered as appropriate. If the infusion is 
interrupted, then restart the infusion at 50% of the original infusion rate when symptoms 
resolve; if no further complications ensue after 30 minutes, the rate may be increased to 
100% of the original infusion rate. Monitor subject closely. If symptoms recur, then no 
further nivolumab will be administered at that visit.

For future infusions, the following prophylactic premedications are recommended: 
diphenhydramine 50 mg (or equivalent) and/or acetaminophen/paracetamol 325 to 1000 mg 
should be administered at least 30 minutes before nivolumab infusions. If necessary, 
corticosteroids (up to 25 mg of SoluCortef or equivalent) may be used.
For Grade 3 or 4 symptoms: (Severe reaction, Grade 3: prolonged [ie, not rapidly 
responsive to symptomatic medication and/or brief interruption of infusion]; recurrence of 
symptoms following initial improvement; hospitalization indicated for other clinical 
sequelae [eg, renal impairment, pulmonary infiltrates]. Grade 4: Life-threatening; pressor 
or ventilatory support indicated).

Immediately discontinue infusion of nivolumab. Begin an IV infusion of normal saline and 
treat the subject as follows: Recommend bronchodilators, epinephrine 0.2 to 1 mg of a 
1:1000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution 
injected slowly for IV administration, and/or diphenhydramine 50 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Subject should be monitored until 
the Investigator is comfortable that the symptoms will not recur. Nivolumab will be 
permanently discontinued. Investigators should follow their institutional guidelines for the 
treatment of anaphylaxis. Remain at bedside and monitor subject until recovery of the 
symptoms.
In case of late-occurring hypersensitivity symptoms (eg, appearance of a localized or generalized 
pruritus within 1 week after treatment), symptomatic treatment may be given (eg, oral 
antihistamine or corticosteroids).
Revised Protocol No: 05
Date: 13-Dec-2017
63
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
4.5.7
Management Algorithms for Immuno-Oncology Agents
Immuno-oncology (I-O) agents are associated with adverse events that can differ in severity and 
duration than adverse events caused by other therapeutic classes. Nivolumab is considered 
immuno-oncology agents in this protocol. Early recognition and management of adverse events 
associated with immuno-oncology agents may mitigate severe toxicity. Management algorithms 
have been developed to assist investigators in assessing and managing the following groups of 
adverse events: gastrointestinal, renal, pulmonary, pancreatitis, hepatic, endocrinopathies, skin 
and neurological. The management algorithms can be found in the Nivolumab investigator 
brochure and Appendix 3 of this protocol.
4.6
Blinding/Unblinding
Not applicable.
An open-label (rather than blinded) study design was selected because the management of 
similar AEs will differ between treatment arms, given the different mechanisms of action of 
docetaxel and nivolumab. Different dose modification rules (no dose reductions for nivolumab 
vs allowance for dose reductions for docetaxel) and different drug-drug interaction profiles add 
complexity to any blinding strategy. 
Subjects have potentially different AEs, as nivolumab has shown immune-related events while 
docetaxel has an adverse event profile that consists primarily of hematologic events. Although 
both drugs have been noted to cause pulmonary AEs, these events are treated differently. With 
docetaxel, pulmonary AEs are mainly due to neutropenic fever and pneumonia, requiring 
broad-spectrum antibiotics and growth factors. With nivolumab, pulmonary AEs are immune 
related and are treated with systemic steroids. If this trial is blinded, the management of AEs 
would potentially be delayed or detrimental to the subject.
4.7
Treatment Compliance
Treatment compliance will be monitored by drug accountability as well as the subject’s medical 
record and eCRF.
4.8
Destruction of Study Drug
For this study, study drugs (those supplied by BMS or sourced by the investigator) such as 
partially used study drug containers, vials and syringes may be destroyed on site. 
Any unused study drugs can only be destroyed after being inspected and reconciled by the 
responsible Study Monitor unless study drug containers must be immediately destroyed as 
required for safety, or to meet local regulations (eg, cytotoxics or biologics). 
On-site destruction is allowed provided the following minimal standards are met:

On-site disposal practices must not expose humans to risks from the drug.

On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
Revised Protocol No: 05
Date: 13-Dec-2017
64
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab

Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s SOPs and a copy provided to BMS upon request.

Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal 
vendor must be documented.

Accountability and disposal records are complete, up-to-date, and available for the Monitor 
to review throughout the clinical trial period.
If conditions for destruction cannot be met the responsible Study Monitor will make 
arrangements for return of study drug.
It is the investigator’s responsibility to arrange for disposal of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept.
4.9
Return of Study Drug
If study drug will not be destroyed upon completion or termination of the study, all unused 
and/or partially used study drug that was supplied by BMS must be returned to BMS. The return 
of study drug will be arranged by the responsible Study Monitor. 
It is the investigator’s responsibility to arrange for disposal of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept. 
Revised Protocol No: 05
Date: 13-Dec-2017
65
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
5
STUDY ASSESSMENTS AND PROCEDURES
5.1
Flow Chart/Time and Events Schedule 
Table 5.1-1:
Screening Assessments and Procedures (CA209078) For ARMS A and B
Procedure
Screening
Visit
Notes
Eligibility Assessments
Informed Consent
X
Inclusion/Exclusion Criteria
X
Assessed prior to randomization.
Medical History
X
Review Prior Cancer treatment
X
Safety Assessments
Vital Signs and oxygen saturation
X

Temperature, BP, HR, RR, O2 saturation by pulse oximetry at rest.

Obtain vital signs at screening visit and within 72 hours prior to first dose.
Physical examination and physical 
measurements (including Performance 
Status)
X
Includes Height and Weight, and ECOG status within 28 days prior to first dose
Laboratory Tests
X
Labs performed locally within 14 days prior to randomization:

CBC with differential

Serum chemistry (BUN or serum urea level, serum creatinine, sodium, 
potassium, calcium, magnesium, phosphate, chloride, glucose, amylase and 
lipase)

AST, ALT, total bilirubin, alkaline phosphatase, albumin, LDH, 

TSH, free T3, free T4, 

HepB/C (HBV sAg, HCV Ab) within 28 days prior to randomization

HIV testing only if no known history for testing result (per local requirement)
Pregnancy Test
X
Performed within 24 hours prior to first dose (serum or urine for WOCBP only).
Revised Protocol No: 05
Date: 13-Dec-2017
66
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-1:
Screening Assessments and Procedures (CA209078) For ARMS A and B
Procedure
Screening
Visit
Notes
ECG (12-Lead)
X
Assessment of Signs and Symptoms
X
After obtaining Informed Consent, assess all signs and symptoms within 14 days of
first dose.
Concomitant Medication collection
X
Within 14 days prior to first dose.
Efficacy Assessments
Radiographic Tumor Assessment 
(Chest, abdomen, pelvis, brain)
X

Should be performed within 28 days prior to randomization.

CT/MRI of brain (with contrast) should be performed to rule out brain 
metastases. (Brain MRI is preferred) 

Additional sites of known or suspected disease (including CNS) should be 
imaged at the screening visit and at subsequent on-study assessments.
Biomarker Assessments
Archived Tumor Tissue or Recent 
Tumor Biopsy (for IHC)
X
May be archival or recent sample. 1 formalin-fixed paraffin embedded tumor tissue
block, or minimum of 10 FFPE unstained slides are needed. 
Submission of fewer than 10 unstained slides may be acceptable under certain 
circumstances and must be approved by BMS Medical Monitor
PD-L1 result will be assessed prior to randomization and will be used as 
stratification factor (PD-L1 positive vs PD-L1 negative/unevaluable)
EGFR Mutation Status
X
To be available prior to randomization for non squamous subjects. Historical results 
is acceptable. EGFR mutant subjects are excluded. 
IVRS / CLINICAL DRUG
SUPPLIES
IVRS
X
For subject number assignment at the time informed consent is obtained.
Revised Protocol No: 05
Date: 13-Dec-2017
67
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-2:
On-Study Assessments ARM A (NIVOLUMAB)
Procedure
Cycle 1 
Day 1
Each cycle
(every 2 weeks) 
on Day 1 (3
days)
Every other cycle
(every 4 weeks)
on Day 1
(5 days)
Every 3 cycles
(6 weeks 
5 days)
Notes
(add note on cycles)
Safety Assessments
Vital Signs and oxygen saturation
X
X
Temperature, BP, HR, RR, O2 saturation by pulse 
oximetry at rest (also monitor amount of
supplemental oxygen if applicable) within 3 
calendar days prior to dosing and at any time a 
subject has any new or worsening respiratory 
symptoms..
Physical examination and 
physical measurements 
(including Performance Status)
X
X
Includes Weight and ECOG status.
Adverse Events (AE) and Serious
Adverse Event (SAE) 
Assessment
--------------------------------Continuously----------------------------------
Assessed using NCI CTCAE v. 4.0.
Laboratory Tests
X
X
Within 3 calendar days prior to dosing and 
include: CBC with differential, BUN or serum 
urea level, serum creatinine, sodium, potassium, 
calcium, magnesium, phosphate, chloride, 
amylase, lipase, glucose, AST, ALT, total 
bilirubin, alkaline phosphatase, albumin,  LDH
Note: Cycle 1 Day 1  labs do not need to be 
repeated if they were performed within 14 days 
prior to 1st dose
Thyroid Function Testing
X
X
TSH (reflex to free T3 and free T4 if abnormal
result).
Note: Cycle 1 Day 1  labs do not need to be 
repeated if they were performed within 14 days 
prior to 1st dose
Pregnancy Test
X
X
Serum or urine (for WOCBP only) test to be
performed within 24 hours prior to first dose and 
every 4 weeks ( 1 week) regardless of dosing 
schedule.
Revised Protocol No: 05
Date: 13-Dec-2017
68
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-2:
On-Study Assessments ARM A (NIVOLUMAB)
Procedure
Cycle 1 
Day 1
Each cycle
(every 2 weeks) 
on Day 1 (3
days)
Every other cycle
(every 4 weeks)
on Day 1
(5 days)
Every 3 cycles
(6 weeks 
5 days)
Notes
(add note on cycles)
Review of Concomitant
Medications
continuously
Review at every visit.
Efficacy assessments
Radiographic Tumor Assessment

FIRST tumor assessment should first be performed at 6 weeks (7 days) from randomization date. SUBSEQUENT 
tumor assessments should occur every 6 weeks (7 days) up to first 12 months, then every 12 weeks (+-- 14 days) 
until disease progression (or discontinuation of study medication for subjects treated beyond radiographic 
progression).

Subjects with a history of brain metastasis should have surveillance MRI every 6 weeks, or sooner if clinically 
indicated.

Assessments should include chest, pelvis and abdomen (with contrast) as well as any area that is being monitored. 

Follow RECIST 1.1 criteria
Biomarker
Serum (for soluble factors and
miRNA Analyses)
X
X

Must be obtained any time after 
randomization (prior to dosing) at Cycle 1 
Day 1, then every 6 weeks.

If dose is delayed, serum samples are not 
taken and are delayed until dose is resumed
Whole Blood (for SNP testing)
X
Can be obtained on Day -3 to Day 1 prior to
dosing.
Pharmacokinetic and
Immunogenicity Assessments
(nivolumab Treatment Arm
ONLY)
---------- Throughout study ----------
For detailed sample timing, see Table 5.5-1 in this 
section.
Amendment 05 Update: As of Amendment 05,
PK/immunogenicity will not be collected.
Revised Protocol No: 05
Date: 13-Dec-2017
69
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-2:
On-Study Assessments ARM A (NIVOLUMAB)
Procedure
Cycle 1 
Day 1
Each cycle
(every 2 weeks) 
on Day 1 (3
days)
Every other cycle
(every 4 weeks)
on Day 1
(5 days)
Every 3 cycles
(6 weeks 
5 days)
Notes
(add note on cycles)
Outcome Research assessments
Patient reported outcomes (PRO)
Assessment
X
X

For Cycle 1Day 1- performed after 
randomization PRIOR to first dose (day -3 to 
+1).

For on study visits: Assessments (LCSS 
and EQ-5D) will be performed PRIOR to 
any study procedures and treatment.

Assessments will be performed at every 
other cycle on Day 1 (+/- 5 days) for the first 
6 months on study, then every 6 weeks 
thereafter for the remainder of the study.
Health Care Resource Utilization
X

Except Cycle 1 (Day 1)
Clinical Drug Supplies
Nivolumab (3mg/kg)
X
X

Cycle 1 Day 1 dose must be administered 
within 3 business days of randomization

Record Study Drug Infusion start and stop
times.
Note: Continues until disease progression, 
discontinuation due to unacceptable toxicity, 
withdrawal of consent or study closure
Revised Protocol No: 05
Date: 13-Dec-2017
70
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-3:
On-Study Assessments ARM B (DOCETAXEL)
Procedure
Cycle 
1
Day1
Each cycle
(every 3 weeks) 
on Day 1 (3
days)
Every 2 cycles
(6 weeks 
5 day)
Notes
(add note on cycles)
Safety Assessments
Vital Signs and oxygen saturation
X
X
Temperature, BP, HR, RR, O2 saturation by pulse oximetry at rest (also 
monitor amount of supplemental oxygen if applicable) within 3 
calendar days prior to dosing and at any time a subject has any new or
worsening respiratory symptoms..
Physical examination and physical 
measurements (including
Performance Status)
X
X
Includes Weight (calculated BSA) and ECOG status.
Adverse Events (AE) and Serious
Adverse Event (SAE)Assessment
----------Continuously----------
Assessed using NCI CTCAE v. 4.0.
Laboratory Tests
X
X
Within 3 calendar days prior to dosing and include: CBC with 
differential, BUN or serum urea level, serum creatinine, sodium, 
potassium, calcium, magnesium, phosphate, chloride, amylase, lipase, 
glucose, AST, ALT, total bilirubin, alkaline phosphatase, albumin,  
LDH
Note: Cycle 1 Day 1  labs do not need to be repeated if they were 
performed within 14 days prior to 1st dose
Thyroid Function Testing
X
X
TSH (reflex to free T3 and free T4 if abnormal result)
Note: Cycle 1 Day 1  labs do not need to be repeated if they were 
performed within 14 days prior to 1st dose
Pregnancy Test
X
X
Serum or urine (for WOCBP only) test to be performed within 24 hours 
prior to first dose and every 4 weeks (1 week) regardless of dosing 
schedule. 
Review of Concomitant 
Medications
Continuously
Review at every visit
Revised Protocol No: 05
Date: 13-Dec-2017
71
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-3:
On-Study Assessments ARM B (DOCETAXEL)
Procedure
Cycle 
1
Day1
Each cycle
(every 3 weeks) 
on Day 1 (3
days)
Every 2 cycles
(6 weeks 
5 day)
Notes
(add note on cycles)
Efficacy Assessment
Radiographic Tumor Assessment

FIRST tumor assessment should first be performed at 6 weeks (7 days) from randomization date. 
SUBSEQUENT tumor assessments should occur every 6 weeks (7 days) up to first 12 months, then every 12 
weeks until disease progression.

Subjects with a history of brain metastasis should have surveillance MRI every 6 weeks, or sooner if clinically 
indicated.

Assessments should include chest, pelvis and abdomen (with contrast) as well as any area that is being monitored. 

Follow RECIST 1.1 criteria
Biomarker
Serum (for soluble factors and 
miRNA Analyses)
X
X

Must be obtained any time after randomization (prior to dosing) at 
Cycle 1 Day 1, then every 6 weeks.

If dose is delayed, serum samples are not taken and are delayed 
until dose is resumed
Whole Blood (for SNP testing) 
X
Can be obtained on Day -3 to Day 1 prior to dosing
Outcome Research assessments
Patient reported outcomes (PRO)
Assessment
X
X

For Cycle 1 Day 1- performed after randomization PRIOR to first 
dose (day -3 to +1).

For on-study visits: Assessments (LCSS and EQ-5D) will be 
performed PRIOR to any study procedures and treatment.

Assessments will be performed at every cycle on Day 1 (5 days) 
for the first 6 months on study, then every 6 weeks thereafter for 
the remainder of the study.
Health Care utilization
X

Except Cycle 1 Day 1
Revised Protocol No: 05
Date: 13-Dec-2017
72
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-3:
On-Study Assessments ARM B (DOCETAXEL)
Procedure
Cycle 
1
Day1
Each cycle
(every 3 weeks) 
on Day 1 (3
days)
Every 2 cycles
(6 weeks 
5 day)
Notes
(add note on cycles)
Clinical Drug Supply
Docetaxel (75mg/m2)
X
X

Cycle 1 Day 1 dose must be administered within 3 business days 
of randomization

Record Study Drug Infusion start and stop times.

Dexamethasone 8mg PO BID (or institutional equivalent) on the 
day before, day of, and day after chemotherapy. Please use the
institutional standard for dexamethasone dosing.
Note: continues until disease progression, discontinuation due to 
unacceptable toxicity, withdrawal of consent or study closure
Revised Protocol No: 05
Date: 13-Dec-2017
73
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-4:
Follow-up and Survival Procedures (CA209078) For ARM A and B
Procedure
Follow-up Visits 1 
(X01) and 2 (X02)a
Further Follow-up 
Phase (beyond X02)b
Notes
Radiographic Tumor 
Assessment

For subjects who discontinue study treatment for reasons other than PD, follow up scans should be performed every 6 
weeks (± 7 days) up to the first 12 months, then every 12 weeks (± 14 days) until PD, withdrawal of consent, lost 
to follow-up or death.

Radiographic assessments for subjects who have not experienced PD must be obtained every 6 weeks (±7 days), and
not delayed until X01 or X02.
Outcome Research Assessments
Patient reported outcomes (PRO)
Assessment
X
EQ5-D Only
Both the LCSS and EQ-5D will be given in FU Visits 1 & 2. In 
Survival Visits, the EQ-5D will be collected every 3 months for the 
first year of the Survival Phase, then every 6 months thereafter
Healthcare resource utilization
X
Safety assessment
Adverse Events (AE) and Serious
Adverse Event (SAE)Assessment
X
X*
* beyond 100 days from the last dose of study therapy, subjects will 
be followed for ongoing drug related adverse events until resolved, 
return to baseline or deemed irreversible, or until lost to follow-up, 
withdrawal of study consent, or start of subsequent anti cancer 
therapy
Laboratory Tests
X

At First follow-up visit (X01) only

CBC with differential.

Serum chemistry (BUN or serum urea level, serum creatinine, 
albumin, sodium, potassium, calcium, magnesium, phosphate, 
chloride, and glucose ), LDH.

AST, ALT, total bilirubin, alkaline phosphatase, amylase, lipase.

TSH (reflex to free T3 and free T4 if abnormal result)
Note: Repeat at Visit 2 only of study drug toxicity persists
Pregnancy test
X
Review of Concomitant 
Medications
X
Revised Protocol No: 05
Date: 13-Dec-2017
74
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-4:
Follow-up and Survival Procedures (CA209078) For ARM A and B
Procedure
Follow-up Visits 1 
(X01) and 2 (X02)a
Further Follow-up 
Phase (beyond X02)b
Notes
Collection of Survival Status 
Information
X
X
Every 3 months (+/- 14 days) in Survival visits until death, lost to
follow-up, or withdrawal of study consent. May be performed by 
phone contact or office visit to update survival information and assess 
subsequent anti-cancer therapy
a Follow up visit 1 to occur 35 days from the last dose (7 days). Follow up visit 2 to occur 80 days (7 days) from Follow-up visit 1
b First Survival visit to occur 3 months (14 days) from Follow-up visit 2
Revised Protocol No: 05
Date: 13-Dec-2017
75
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-5:
Screening Assessments and Procedures (CA209078) For Subjects Previously Randomized to Docetaxel 
Entering Nivolumab Crossover Extension Phase
Procedure
Screening
Visit
Notes 
Eligibility Assessments
Informed Consent
X
Inclusion/Exclusion Criteria
X
Assessed prior to calling IVRS and registering subject for crossover extension phase
Medical History
X
Safety Assessments
Vital Signs and Oxygen saturation
X
Temperature, BP, HR, RR, O2 saturation by pulse oximetry at rest (also monitor amount of supplemental 
oxygen, if applicable). Obtain vital signs w/in 72 hrs of first dose of nivolumab
Physical Measurements (including 
Performance Status)
X
Includes Height and Weight, and ECOG status within 28 days prior to first dose of nivolumab Focused 
physical exam may be performed at screening, if clinically indicated
Laboratory Tests
X
Labs performed locally within 14 days prior to first dose of Nivolumab (unless otherwise specified):
CBC with differential, Serum chemistry (BUN or serum urea level, serum creatinine, sodium, potassium, 
calcium, magnesium, phosphate, chloride, and glucose), amylase, lipase, AST, ALT, total bilirubin, 
alkaline phosphatase, albumin, LDH, TSH, free T3, free T4 
Pregnancy Test 
X
Performed within 24 hours prior to first dose of nivolumab (serum or urine for WOCBP only)
ECG (12-Lead)
X
Assessment of signs and symptoms
X
After obtaining Informed Consent, assess all signs and symptoms within 14 days prior to first dose of 
nivolumab
Concomitant Medication collection
X
Within 14 days prior to first dose of nivolumab
Efficacy Assessments
Radiographic Tumor Assessment 
(Chest, abdomen, pelvis, brain) 
X
Should be performed within 28 days prior to first dose of nivolumab. CT/MRI of brain (with contrast, 
unless contraindicated) is required in subjects with a known history of brain metastases (brain MRI is 
preferred). Additional sites of known or suspected disease (including CNS) should be imaged prior to first 
dose of nivolumab and at subsequent study assessments.
Revised Protocol No: 05
Date: 13-Dec-2017
76
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-6:
On-Study Assessments (CA209078) For Subjects Previously Randomized to Docetaxel Entering 
Nivolumab Crossover Extension Phase
Procedure
F1D1
Each cycle
on Day 1
(3 days)
Every 3 cycles
on Day 1  
(3 days)
Every 6 cycles
on Day 1
(3 days)
Notes
3mg/kg dosing cycle = 2 Weeks
Safety Assessments
Vital Signs and Oxygen 
saturation
X
X
Within 72 hours prior to dosing: temperature, BP, HR, RR, O2 
saturation by pulse oximetry (also monitor amount of supplemental 
oxygen if applicable) prior to dosing and at any time a subject has any 
new or worsening respiratory symptoms
Adverse Events (AE) and 
Serious Adverse Event (SAE) 
Assessment
-------------------continuously--------------
Assessed using NCI CTCAE v. 4.0
Physical examination and 
physical measurements 
(including Performance Status)
X
X
Includes Weight and ECOG status
Complete blood counts(CBCs)
(Results obtained prior to 
dosing on infusion days)
X
X
Screening labs performed within 7 days of F1D1 visit do not need to 
be repeated unless clinically indicated.
For F2D1 and beyond, to be performed within 72 hours prior to 
dosing, tests include WBC count with differential, ANC, lymphocyte 
count, hemoglobin, hematocrit, and platelet count
Serum Chemistry Tests
(Results obtained prior to 
dosing on infusion days)
X
X
Screening labs performed within 7 days of F1D1 visit do not need to 
be repeated unless clinically indicated.
For F2D1 and beyond, to be performed within 72 hours prior to 
dosing, tests include: Serum chemistry (BUN or serum urea level, 
serum creatinine, sodium, potassium, calcium, magnesium, phosphate, 
chloride, and glucose), LDH
Liver Function Testing
(Results obtained prior to 
dosing on infusion days)
X
X
Screening labs performed within 7 days of F1D1 visit do not need to 
be repeated unless clinically indicated.
For F2D1 and beyond, to be performed within 72 hours prior to 
dosing, tests include: aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), total bilirubin, alkaline phosphatase, albumin
Revised Protocol No: 05
Date: 13-Dec-2017
77
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-6:
On-Study Assessments (CA209078) For Subjects Previously Randomized to Docetaxel Entering 
Nivolumab Crossover Extension Phase
Procedure
F1D1
Each cycle
on Day 1
(3 days)
Every 3 cycles
on Day 1  
(3 days)
Every 6 cycles
on Day 1
(3 days)
Notes
3mg/kg dosing cycle = 2 Weeks
Thyroid Function Testing
X
X 
See Note
.
Screening labs performed within 7 days of F1D1 visit do not need to 
be repeated unless clinically indicated.
TSH (reflex to free T3 and free T4 if abnormal TSH result)
Review of Concomitant 
Medications
X
X
Review at every visit
Pregnancy Test
X 
See note
Serum or urine (for WOCBP only) test to be performed every 4 weeks 
or more frequently as per local standards for subjects receiving 
nivolumab 3mg/kg every 2 weeks.
Efficacy Assessments
Radiographic Tumor 
Assessment
X
Tumor assessments are conducted  every 6 weeks (7 days), from 
first dose for the first year on treatment, then every 12 weeks after the 
first year on treatment, until documented disease progression (Or 
discontinuation of study therapy in subjects receiving BMS-936558 
(nivolumab) beyond progression).
Assessments should include chest, pelvis, and abdomen (with contrast, 
unless contraindicated) as well as any area that is being monitored. 
Follow RECIST 1.1 criteria. 
Subjects with a history of brain metastasis should have surveillance 
CT/MRI approximately every 6 weeks, or sooner if clinically 
indicated. (MRI is preferred)
Patient reported outcomes 
(PRO) Assessment
X
X**
For F1D1: performed PRIOR to first dose of nivolumab (day -3 to 
+1).
For on study visits: EQ-5D will be performed PRIOR to any study 
procedures and treatment.
**Assessment will be performed on Day 1 of every 6th cycle (every 
12 weeks) for the first 12 months, then every 6 months thereafter for 
the on Day1 remainder of the treatment period, as permitted by local 
Revised Protocol No: 05
Date: 13-Dec-2017
78
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-6:
On-Study Assessments (CA209078) For Subjects Previously Randomized to Docetaxel Entering 
Nivolumab Crossover Extension Phase
Procedure
F1D1
Each cycle
on Day 1
(3 days)
Every 3 cycles
on Day 1  
(3 days)
Every 6 cycles
on Day 1
(3 days)
Notes
3mg/kg dosing cycle = 2 Weeks
law.
Health Resource Utilization
X
Except cycle 1. To include: concomitant medication collection.
Clinical Drug Supplies
BMS-936558- nivolumab *
X
X
First dose must be administered within 3 business days of enrollment 
in Nivolumab Crossover Extension Phase
Record Study Drug Infusion start and stop times. 
* Subjects may be dosed no less than 12 days from previous dose
Revised Protocol No: 05
Date: 13-Dec-2017
79
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-7:
Follow-up and Survival Procedures (CA209078) For Subjects Previously Randomized to Docetaxel 
Entering Nivolumab Crossover Extension Phase
Procedure
Initial Follow-Up Phase
(100 days from date of last study treatment)
Follow-up Visits 1 (XX01) and 2 (XX02) 
XX01 to occur approximately 35 days (7 days) 
after last dose or coinciding with the date of 
discontinuation (7 days) if date of discontinuation 
is greater than 42 days after last dose
XX02 to occur approximately 80 days (7 days) 
after XX01.
Further 
Follow-up 
Phase
(beyond XX02)
Notes
Radiographic Tumor 
Assessment
X*
X
For subjects who discontinue study treatment 
for reasons other than PD, follow up scans 
should be performed according to the on-study 
assessment schedule until PD, withdrawal of 
consent, death, lost to follow-up, 
*Radiographic assessments for subjects who 
have not experienced PD must be obtained 
according to the on-study assessment schedule, 
and not delayed until XX01 or XX02.
Patient reported outcomes 
Assessment (PRO)
X
X
EQ-5D only
Beyond 100 days from the last dose of study 
therapy, the EQ-5D will be administered every 
6 months thereafter, as permitted by local law.
Safety Assessments
Adverse Events (AE) and 
Serious Adverse Event (SAE) 
Assessment
X
X*
*Beyond 100 days from the last dose of study 
therapy, subjects will be followed for ongoing 
drug-related adverse events until resolved, 
return to baseline or deemed irreversible, or 
until lost to follow-up, withdrawal of study 
consent, 
Revised Protocol No: 05
Date: 13-Dec-2017
80
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Table 5.1-7:
Follow-up and Survival Procedures (CA209078) For Subjects Previously Randomized to Docetaxel 
Entering Nivolumab Crossover Extension Phase
Procedure
Initial Follow-Up Phase
(100 days from date of last study treatment)
Follow-up Visits 1 (XX01) and 2 (XX02) 
XX01 to occur approximately 35 days (7 days) 
after last dose or coinciding with the date of 
discontinuation (7 days) if date of discontinuation 
is greater than 42 days after last dose
XX02 to occur approximately 80 days (7 days) 
after XX01.
Further 
Follow-up 
Phase
(beyond XX02)
Notes
Laboratory Tests
X
CBC with differential, Serum chemistry (BUN 
or serum urea level, serum creatinine, albumin, 
sodium, potassium, calcium, magnesium, 
phosphate, chloride), AST, ALT, total 
bilirubin, alkaline phosphatase, glucose, LDH, 
TSH (reflex to free T3 and free T4 if abnormal 
result)
Note: Repeat at Visit 2 only of study drug 
toxicity persists
Pregnancy Testing
X
Review of Concomitant 
Medications
X
Collection of Survival 
Information
X
X
Every 3 months (±14 days) until death, lost to 
follow-up, or withdrawal of study consent. May 
be performed by phone contact or office visit to 
update survival information and assess 
subsequent anti-cancer therapy.
Revised Protocol No: 05
Date: 13-Dec-2017
81
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
5.1.1
Retesting During Screening
Retesting of laboratory parameters and/or other assessments within any single Screening will be 
permitted (in addition to any parameters that require a confirmatory value).
Any new result will override the previous result (ie, the most current result prior to 
Randomization) and is the value by which study inclusion will be assessed, as it represents the 
subject’s most current, clinical state.
Laboratory parameters and/or assessments are included in Table 5.1-1 and Screening Procedural 
Outline may be repeated in an effort to find all possible well-qualified subjects.  Consultation 
with the Medical Monitor may be needed to identify whether repeat testing of any particular 
parameter is clinically relevant.
5.2
Study Materials
The following materials will be provided at study start:

NCI CTCAE version 4.0

Nivolumab Investigational Brochure

Pharmacy Binder

Laboratory manuals for collection and handling of blood (including PKs, biomarker and 
immunogenicity) and tissue specimens

Site manual for operation of interactive voice response system (randomization)

Serious Adverse Event (or eSAE) case report forms

Pregnancy Surveillance Forms

RECIST 1.1 Pocket guide

Lung Cancer Symptom Score and EuroQol Group’s EQ-5D questionnaires.
5.3
Safety Assessments
Screening Assessments
Screening assessments and procedures must be completed within 28 days prior to randomization, 
in accordance with Table 5.1-1.

A complete medical history and concomitant medications, including review of prior systemic 
treatment received for NSCLC

Assessment of pre-treatment signs and symptoms

Patient reported outcomes Assessments (PRO): Lung Cancer Symptom Scale (LCSS) and 
EuroQol Group’s EQ-5D

Vital signs including temperature, blood pressure, heart rate, respiratory rate, oxygen 
saturation by pulse oximetry at rest (also monitor amount of supplemental oxygen if 
applicable) within 3 calendar days prior to first dose.

Physical examination and physical measurements including height, and weight (and 
calculated BSA for subjects randomized to treatment Arm B) and ECOG performance status 
(see Appendix 1).
Revised Protocol No: 05
Date: 13-Dec-2017
82
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab

Laboratory tests include: 

Blood for complete blood count (CBC) with differential, including neutrophil and 
lymphocyte count 

Serum chemistry tests (BUN or serum urea level, serum creatinine, sodium, potassium, 
calcium, magnesium, phosphate, chloride, glucose, amylase, lipase and LDH)

AST, ALT, total bilirubin, alkaline phosphatase, albumin

TSH, free T3 and free T4

Hepatitis B virus surface antigen (HBV sAg) and Hepatitis C virus antibody (HCV Ab)

HIV testing, if applicable

A pregnancy test for WOCBP will be collected within 24 hours prior to first dose.
All subjects are required to have a 12-lead ECG performed during Screening. If clinically 
indicated, additional ECGs may be obtained during the study.
Amendment 05 Update: No retesting for HBV, HCV, or HIV is required during the Nivolumab 
Crossover Extension Phase. For subjects moving in to the Nivolumab Crossover Extension 
Phase, please refer to Table 5.1-5 for the schedule of screening assessments.
On-Study Safety Assessments and Procedures
The following assessments will be monitored according to the frequency for each treatment Arm 
starting on Cycle 1 Day 1 and will continue at the specified frequency until discontinuation from 
the study. (See Table 5.1-2 and Table 5.1-3 for frequency of testing by treatment arm).

Patient reported outcomes Assessments (PRO): Lung Symptom Cancer Scale (LCSS) and 
EuroQol Group’s EQ-5D. (For subjects treated in the Nivolumab Crossover Extension Phase, 
ONLY the EQ-5D assessment will be completed according to Table 5.1-6. The LCSS will 
not be completed in the Nivolumab Crossover Extension Phase.)

Vital signs including temperature, blood pressure, heart rate, respiratory rate, oxygen 
saturation by pulse oximetry at rest should be obtained within 3 calendar days prior to each 
dosing and at any time the subject has any new or worsening respiratory symptoms. (Also 
monitor amount of supplemental oxygen if applicable). If a subject shows changes in oxygen 
saturation or supplemental oxygen requirement, or other pulmonary-related signs (hypoxia, 
fever) or symptoms (eg. dyspnea, cough) consistent with possible pulmonary adverse events, 
the subject should be immediately evaluated to rule out pulmonary toxicity, according to the 
suspected pulmonary toxicity management algorithm contained within the Investigator’s 
Brochure.

AEs and SAEs continuously throughout the study

Physical examination and physical measurements including weight (and calculated BSA for 
subjects randomized to treatment Arm B) and ECOG performance status (see Appendix 1)

Laboratory tests within 3 calendar days prior to the dosing, to include: 

CBCs with differential, including WBC, lymphocyte count, ANC, hemoglobin, 
hematocrit, platelet, BUN or serum urea level, serum creatinine, sodium, potassium, 
calcium, magnesium, phosphate, chloride, glucose, LDH, amylase and lipase

Liver function tests including AST, ALT, total bilirubin, alkaline phosphatase, albumin

Thyroid function testing includes TSH (reflex to free T3 and free T4 if abnormal result)
Revised Protocol No: 05
Date: 13-Dec-2017
83
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab

A pregnancy test for WOCBP will be performed every 4 weeks on study regardless of dosing 
schedule.
Concomitant medications taken throughout the study duration should be recorded within the 
eCRF. 
Blood samples will also be collected for pharmacokinetics and immunogenicity as noted in Table 
5.5-1 (for subjects randomized to the nivolumab treatment Arm A only), and for SNP testing as 
noted in Table 5.1-2 or Table 5.1-3. (For subjects treated in the Nivolumab Crossover Extension 
phase, NO pharmacokinetics and immunogenicity samples will be collected in the extension 
phase.)
Additionally, serum samples (for soluble factors and miRNA analyses) will be obtained from all 
randomized subjects prior to first dose of study drug and every 6 weeks during the treatment 
period as shown on Table 5.1-2 or Table 5.1-3. (For subjects treated in the Nivolumab Crossover 
Extension phase, NO serum samples will be collected in the extension phase.)
For subjects who discontinue study treatment due to toxicity, please follow the procedures for 
the last scheduled visit on study treatment (prior to discontinuation of study therapy and 
follow-up visits) from either Table 5.1-2 or Table 5.1-3 (and Table 5.5-1 Pharmacokinetic and 
Immunogenicity Sample Collection Nivolumab Arm).
Some of the assessments referred to in this section may not be captured as data in the eCRF.
They are intended to be used as safety monitoring by the treating physician. Additional testing or
assessments may be performed as clinically necessary or where required by institutional or local
regulations.
Amendment 05 Update: Laboratory tests of amylase and lipase are not required for subjects
who enroll in the Nivolumab Crossover Extension Phase. 
For subjects ernolled in the Nivolumab Crossover Extension Phase, please refer to Table 5.1-6
for the complete schedule of required assessments.
Follow-up and Survival Procedures
Subjects will be monitored for safety according to Table 5.1-4. Subjects will have two follow-up 
visits for safety. Safety assessments will include: review of concomitant medications, laboratory 
measurements (CBC, serum chemistry, liver function and thyroid function), and assessment of 
AEs and SAEs.
Beyond 100 days from the last dose of study treatment, subjects will be followed for ongoing 
drug related adverse events until resolved, return to baseline or deemed irreversible, or until lost 
to follow-up, withdrawal of consent, or start of subsequent anti-cancer therapy.
Both the LCSS and EQ-5D will be given in FU Visits 1 & 2. In Survival Visits, the EQ-5D will 
be collected every 3 months for the first year of the Survival Phase, then every 6 months 
thereafter
Revised Protocol No: 05
Date: 13-Dec-2017
84
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Beyond the second follow-up visit, subjects should be followed for survival assessment every
3 months until death, lost to follow-up, or withdrawal of consent. The survival assessments may 
be performed by phone contact or an office visit.
Amendment 05 Update: For subjects treated in the Nivolumab Crossover Extension phase of 
the study, please refer to Table 5.1-7 for the complete schedule of required Follow-up and 
Survival phase assessments.
5.3.1
Imaging Assessment for the Study
Any incidental findings of potential clinical relevance that are not directly associated with the 
objectives of the protocol should be evaluated and handled by the Study Investigator as per 
standard medical/clinical judgment.
5.4
Efficacy Assessments
5.4.1
Primary Efficacy Assessment
This study has primary endpoint of OS (see Section 8.3 for definition of OS). Every effort will 
be made to collect survival data on all subjects including subjects who progressed and 
discontinue study treatment, withdrawn from treatment for any reason, who are eligible to 
participate in the study and who have not withdrawn consent for survival data collection. 
Survival will be followed either by direct contact (office visits) or via telephone contact, 
according to Table 5.1-4 until death, withdrawal of study consent, or lost to follow-up. 
If the death of a subject is not reported, all dates in this study representing a date of subject 
contact will be used in determination of the subject’s last known date alive.
5.4.2
Secondary Efficacy Assessments
For secondary efficacy analyses (ORR, PFS, and clinical efficacy in terms of OS, ORR, and PFS 
in different subgroups, including squamous and non-squamous NSCLC subgroups, PD-L1 
positive and PD-L1 negative protein expression subgroups, and Chinese and non-Chinese 
subgroups), subjects will be monitored by radiographic assessment using RECIST 1.1.93 High 
resolution CT with PO/IV contrast or contrast-enhanced MRI are the preferred imaging 
modalities for assessing radiographic tumor response. If a subject has a known allergy to contrast 
material, please use local prophylaxis standards to obtain the assessment with contrast if at all 
possible, or use the alternate modality. In cases where contrast is strictly contraindicated, a 
non-contrast scan will suffice. 
Screening assessments should be performed within 28 days of randomization (as shown in Table 
5.1-1) and include chest, abdomen, and pelvis, brain (to rule out brain metastasis) and all known 
or suspected sites of disease. Subsequent assessments (for frequency, refer to Table 5.1-2 or 
Table 5.1-3) should include chest, abdomen, pelvis and all known or suspected sites of disease 
using the same imaging method and technique. Subjects with a history of brain metastasis should 
have surveillance MRI approximately every 6 weeks from first scan or sooner if clinically 
indicated. 
Revised Protocol No: 05
Date: 13-Dec-2017
85
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
If more than one method is used at screening, then the most accurate method according to 
RECIST 1.1 should be used when recording data, and should again be used for all subsequent 
assessments. Bone scan, PET scan, or ultrasound is not adequate for assessment of RECIST 
response. In selected circumstances where such modalities are the sole modality used to assess 
certain non-target organs, those non-target organs may be evaluated less frequently. For 
example, bone scans may need to be repeated only when complete response (CR) is identified in 
target disease or when progression in bone is suspected. 
First radiographic tumor assessment will be conducted at Week 6 (7 days) from randomization 
date and then every 6 weeks from Week 6 (7 days) up to first 12 months, then every 12 weeks 
(14 daysuntil disease progression (or until discontinuation of study therapy in patients 
receiving nivolumab beyond progression), lost to follow-up, withdrawal of study consent or 
death. Tumor assessments for all subjects should continue as per protocol even if dosing is 
interrupted. Tumor measurements should be made by the same investigator or radiologist for 
each assessment whenever possible. Changes in tumor measurements and tumor responses to 
guide ongoing study treatment decisions will be assessed by the investigator using RECIST 1.1 
(see Appendix 2 for details of RECIST 1.1).88
Subjects achieving a timepoint response of CR or PR will require confirmation of BOR 
determination as per RECIST 1.1 at their next scheduled tumor assessment in the first year and at 
least 4 weeks apart in the second half of the year. In the case of SD, measurements must have 
met the SD criteria at least once after study entry at a minimum interval of 6 weeks (7 days).
 
 
 
 
 
 
 
 
Revised Protocol No: 05
Date: 13-Dec-2017
86
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No: 05
Date: 13-Dec-2017
87
7.0
Approved
930067687
7.0
v






Clinical Protocol
CA209078
BMS-936558
nivolumab
 
 
 
 
 
 
5.8.3
Healthcare Resource Utilization
Healthcare resource utilization data associated with hospitalizations and non-protocol specified 
medical visits related to either study therapy or disease will be collected for all randomized 
subjects. The healthcare resource utilization will be assessed during the study according to 
treatment arm assignments below: 

Treatment arm A (nivolumab): Day 1 of each cycle (every 2 weeks) except Cycle 1 and at 
the first 2 follow-up visits after discontinuation of study treatment. 

Treatment arm B (docetaxel): Day 1 of each cycle (every 3 weeks) except Cycle 1 and at the 
first 2 follow-up visits after discontinuation of study treatment.
5.9
Results of Central Assessments
Not applicable.
6
ADVERSE EVENTS
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation subject administered study drug and that 
does not necessarily have a causal relationship with this treatment. An AE can therefore be any 
unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of study drug, whether or not considered related to the study 
drug.
The causal relationship to study drug is determined by a physician and should be used to assess 
all adverse events (AE). The casual relationship can be one of the following:
Related: There is a reasonable causal relationship between study drug administration and 
the AE.
Not related: There is not a reasonable causal relationship between study drug 
administration and the AE.
The term "reasonable causal relationship" means there is evidence to suggest a causal 
relationship. 
Adverse events can be spontaneously reported or elicited during open-ended questioning, 
examination, or evaluation of a subject. (In order to prevent reporting bias, subjects should not be 
questioned regarding the specific occurrence of one or more AEs.)
Revised Protocol No: 05
Date: 13-Dec-2017
90
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
6.1
Serious Adverse Events
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: 

results in death

is life-threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused death if it 
were more severe)

requires inpatient hospitalization or causes prolongation of existing hospitalization 
(see NOTE below)

results in persistent or significant disability/incapacity

is a congenital anomaly/birth defect 

is an important medical event (defined as a medical event(s) that may not be immediately 
life-threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above.) 
Examples of such events include, but are not limited to, intensive treatment in an emergency 
room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not 
result in hospitalization.) Potential drug induced liver injury (DILI) is also considered an 
important medical event. (See Section 6.6 for the definition of potential DILI.)
Suspected transmission of an infectious agent (e.g., pathogenic or nonpathogenic) via the study 
drug is an SAE.
Although pregnancy, overdose, cancer, and potential drug induced liver injury (DILI) are not 
always serious by regulatory definition, these events must be handled as SAEs. (See 
Section 6.1.1 for reporting pregnancies).
Any component of a study endpoint that is considered related to study therapy (eg, death is an 
endpoint, if death occurred due to anaphylaxis, anaphylaxis must be reported) should be reported 
as SAE (see Section 6.1.1 for reporting details).
NOTE: 
The following hospitalizations are not considered SAEs in BMS clinical studies: 

a visit to the emergency room or other hospital department < 24 hours, that does not 
result in admission (unless considered an important medical or life-threatening event)

elective surgery, planned prior to signing consent

admissions as per protocol for a planned medical/surgical procedure

routine health assessment requiring admission for baseline/trending of health status 
(eg, routine colonoscopy)

medical/surgical admission other than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases

admission encountered for another life circumstance that carries no bearing on health 
status and requires no medical/surgical intervention (eg, lack of housing, economic 
inadequacy, caregiver respite, family circumstances, administrative reason).

Admission for administration of anticancer therapy in the absence of any other SAEs 
(applies to oncology protocols)
Revised Protocol No: 05
Date: 13-Dec-2017
91
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
6.1.1
Serious Adverse Event Collection and Reporting
Sections 5.6.1 and 5.6.2 in the Investigator Brochure (IB) represent the Reference Safety 
Information to determine expectedness of serious adverse events for expedited reporting. 
Following the subject’s written consent to participate in the study, all SAEs, whether related or 
not related to study drug, must be collected, including those thought to be associated with 
protocol-specified procedures. All SAEs must be collected that occur during the screening period 
and within 100 days of discontinuation of dosing. Subjects, who are randomized and never 
treated with study drug, must have SAEs collected for 30 days from the date of randomization. If 
applicable, SAEs must be collected that relate to any later protocol-specified procedure (eg, a 
follow-up skin biopsy). 
The investigator should report any SAE that occurs after these time periods and that is believed 
to be related to study drug or protocol-specified procedure. 
An SAE report should be completed for any event where doubt exists regarding its seriousness. 
If the investigator believes that an SAE is not related to study drug, but is potentially related to 
the conditions of the study (such as withdrawal of previous therapy or a complication of a study 
procedure), the relationship should be specified in the narrative section of the SAE Report Form.
SAEs, whether related or not related to study drug, and pregnancies must be reported to BMS 
(or designee) within 24 hours of awareness of the event. SAEs must be recorded on the SAE 
Report Form; pregnancies on a Pregnancy Surveillance Form (electronic or paper forms). The 
preferred method for SAE data reporting collection is through the eCRF.  The paper 
SAE/pregnancy surveillance forms are only intended as a back-up option when the eCRF system 
is not functioning.  In this case, the paper forms are to be transmitted via email or confirmed 
facsimile (fax) transmission to:
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.
For studies capturing SAEs through electronic data capture (EDC), electronic submission is the 
required method for reporting. The paper forms should be used and submitted immediately, only 
in the event the electronic system is unavailable for transmission. When paper forms are used, 
the original paper forms are to remain on site.
SAE Telephone Contact (required for SAE and pregnancy reporting): Refer to Contact
Information list.
If only limited information is initially available, follow-up reports are required. (Note: Follow-up 
SAE reports should include the same investigator term(s) initially reported.) 
If an ongoing SAE changes in its intensity or relationship to study drug or if new information 
becomes available, a follow-up SAE report should be sent within 24 hours to the BMS
(or designee) using the same procedure used for transmitting the initial SAE report.
All SAEs should be followed to resolution or stabilization.
Revised Protocol No: 05
Date: 13-Dec-2017
92
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
6.2
Nonserious Adverse Events
A nonserious adverse event is an AE not classified as serious.
6.2.1
Nonserious Adverse Event Collection and Reporting
The collection of nonserious AE information should begin at initiation of study drug. Nonserious 
AE information should also be collected from the start of a placebo lead-in period or other 
observational period intended to establish a baseline status for the subjects.
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see Section 6.1.1). Follow-up is also required for nonserious AEs that cause 
interruption or discontinuation of study drug and for those present at the end of study treatment 
as appropriate. All identified nonserious AEs must be recorded and described on the nonserious 
AE page of the CRF (paper or electronic). 
Every adverse event must be assessed by the investigator with regard to whether it is considered 
immune-mediated. For events which are potentially immune-mediated, additional information 
will be collected on the subject’s case report form
Completion of supplemental CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported/identified during the course of the study.
6.3
Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the nonserious AE CRF 
page or SAE Report Form (paper or electronic) as appropriate:

Any laboratory test result that is clinically significant or meets the definition of an SAE 

Any laboratory test result abnormality that required the subject to have study drug 
discontinued or interrupted

Any laboratory test result abnormality that required the subject to receive specific corrective 
therapy.
It is expected that wherever possible, the clinical rather than laboratory term would be used by 
the reporting investigator (eg, anemia versus low hemoglobin value).
6.4
Pregnancy
If, following initiation of the study drug, it is subsequently discovered that a study subject is 
pregnant or may have been pregnant at the time of study drug exposure, including during at least 
5 half lives after product administration. investigator must immediately notify the BMS Medical 
Monitor/designee of this event and complete and forward a Pregnancy Surveillance Form to 
BMS Designee within 24 hours of awareness of the event and in accordance with SAE reporting 
procedures described in Section 6.1.1.
In most cases, the study drug will be permanently discontinued in an appropriate manner (eg, 
dose tapering if necessary for subject safety).
Revised Protocol No: 05
Date: 13-Dec-2017
93
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
In the rare event that the benefit of continuing study drug is thought to outweigh the risk, after 
consultation with BMS, the pregnant subject may continue study drug after a thorough 
discussion of benefits and risk with the subject 
Protocol-required procedures for study discontinuation and follow-up must be performed on the 
subject unless contraindicated by pregnancy (eg, x-ray studies). Other appropriate pregnancy 
follow-up procedures should be considered if indicated.
The investigator must immediately notify the BMS (or designee) Medical Monitor of this event 
and complete and forward a Pregnancy Surveillance Form to BMS (or designee) within 24 hours 
and in accordance with SAE reporting procedures described in Section 6.1.1. 
Follow-up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome and, where applicable, offspring information must be reported on the Pregnancy 
Surveillance Form.
Any pregnancy that occurs in a female partner of a male study participant should be reported to 
BMS. Information on this pregnancy will be collected on the Pregnancy Surveillance Form.
6.5
Overdose
An overdose is defined as the accidental or intentional administration of any dose of a product 
that is considered both excessive and medically important. All occurrences of overdose must be 
reported as an SAE (see Section 6.1.1 for reporting details.).
6.6
Potential Drug Induced Liver Injury (DILI)
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, 
meeting the defined criteria, must be reported as SAEs (see Section 6.1.1 for reporting details).
Potential drug induced liver injury is defined as: 
1) AT (ALT or AST) elevation > 3 times upper limit of normal (ULN)
AND 
2) Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase),
AND 
3) No other immediately apparent possible causes of AT elevation and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic. 
6.7
Other Safety Considerations
Any 
significant 
worsening 
noted 
during 
interim 
or 
final 
physical 
examinations, 
electrocardiogram, x-ray filming, any other potential safety assessment required or not required 
by protocol should also be recorded as a nonserious or serious AE, as appropriate, and reported 
accordingly.
Revised Protocol No: 05
Date: 13-Dec-2017
94
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
For recommendations regarding suspected pulmonary toxicity, diarrhea and colitis, suspected 
hepatotoxicity (including asymptomatic LFT elevations), or suspected endocrinopathy, please 
see the Evaluation and Management Guidelines found in the Investigator Brochure.22
6.7.1
Adverse Events of Interest
Definition of Immune-mediated Adverse Events
Immune-mediated Adverse Events (IMAEs) are specific events (that include pneumonitis, 
diarrhea/colitis, hepatitis, nephritis/renal dysfunction, rash, and endocrine (adrenal insufficiency, 
hypothyroidism/thyroiditis, hyperthyroidism, diabetes mellitus, and hypophysitis) for which 
subjects received immunosuppressive medication for treatment of the event, with the exception 
of endocrine events (hypothyroidism/thyroiditis, hyperthyroidism, hypophysitis, diabetes 
mellitus, adrenal insufficiency), which are included regardless of treatment since these events are 
often managed without immunosuppression.
IMAEs include events, regardless of causality, occurring within 100 days of the last dose. 
IMAEs are limited to subjects who received immunosuppressive medication for treatment of the 
event, with the exception of endocrine events (hypothyroidism/thyroiditis, hyperthyroidism, 
hypophysitis, diabetes mellitus, adrenal insufficiency), which are included regardless of 
treatment since these events are often managed without immunosuppression.
Table 6.7.1-1 below provides a summary of the IMAEs category and their respective PTs.
Table 6.7.1-1:
Preferred Terms Included in Analysis of IMAEs to Support 
Warnings and Precautions
IMAE Category
PTs included under IMAE Category
Pneumonitis
Pneumonitis, Interstitial lung disease
Diarrhea/Colitis
Diarrhea, Colitis, Enterocolitis
Hepatitis
Hepatotoxicity, Hepatitis, Hepatitis acute, Autoimmune 
hepatitis, AST increased, ALT increased, Bilirubin 
increased, ALP increased
Adrenal insufficiency
Adrenal insufficiency
Hypothyroidism/Thyroiditis
Hypothyroidism, Thyroiditis
Thyroiditis acute (collapsed with thyroiditis for 
frequency), Autoimmune thyroiditis (collapsed with 
thyroiditis for frequency)
Hyperthyroidism
Hyperthyroidism
Hypophysitis
Hypophysitis
Diabetes mellitus
Diabetes mellitus, Diabetic ketoacidosis
Nephritis and renal dysfunction
Nephritis, Nephritis allergic, Tubulointerstitial 
nephritis, Acute renal failure, Renal failure, Increased 
creatinine
Rash
Rash, Rash maculopapular
Revised Protocol No: 05
Date: 13-Dec-2017
95
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
7
DATA MONITORING COMMITTEE AND OTHER EXTERNAL 
COMMITTEES
A DMC will be established to provide oversight of safety and efficacy considerations in protocol 
CA209078, and to provide advice to the Sponsor regarding actions the committee deems 
necessary for the continuing protection of subjects enrolled in the trial. The DMC will be 
charged with assessing such actions in light of an acceptable benefit/risk profile for nivolumab. 
The DMC will act in an advisory capacity to BMS and will monitor subject safety and evaluate 
the available efficacy data for the study. Efficacy will also be reviewed by the DMC - as part of 
the benefit-to-risk assessment and for the formal analyses of TTF and OS.
The DMC will be advisory to the clinical study leadership team. The clinical study leadership 
team will have responsibility for overall conduct of the study including managing the 
communication of study data. The group will be responsible for promptly reviewing the DMC 
recommendations, for providing guidance regarding the continuation or termination of the study, 
and for determining whether amendments to the protocol or changes in study conduct are 
required.
After meeting, the DMC will notify the clinical study leadership group that it has met and will 
provide recommendations about the study by telephone or email. Detailed procedures to deliver 
and address the DMC recommendations are described in the BMS Standard Operating 
Procedure, which specifies the establishment and operation of clinical trial DMCs. Any 
recommendation by the DMC regarding study modification will be submitted to the clinical 
study leadership team within pre-specified business days of the DMC meeting.
The oncology therapeutic area of BMS has primary responsibility for design and conduct of the 
study. Details of DMC responsibilities and procedures will be specified in the DMC charter.
8
STATISTICAL CONSIDERATIONS
8.1
Sample Size Determination
The sample size is calculated in order to compare the overall survival (OS) between subjects 
randomized to receive nivolumab and subjects randomized to receive docetaxel. Approximately 
500 subjects will be randomized (Intent-To-Treat (ITT) population) to the nivolumab and 
docetaxel arms in a 2:1 ratio. At least 382 deaths will be required for the final analysis of OS. 
A formal OS interim analysis will be conducted when at least 291 deaths (76% information 
fraction) have been observed. 
Simulations were run in R to calculate the power of the (weighted) log-rank test.
A mixed population was generated as follows: 500 subjects were randomly assigned to 3 cohorts 
with 40% squamous (SQ) subjects, 30% non-squamous (NSQ) PD-L1 positive subjects and 30% 
non-squamous (NSQ) PD-L1 negative subjects. 
Heterogeneity of treatment effects among histology and PD-L1 status subgroups was considered 
for the calculation of overall power and number of events at interim and final analyses of OS.
Revised Protocol No: 05
Date: 13-Dec-2017
96
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
1. For docetaxel, median Overall Survival (mOS) is assumed to be 10 months for SQ and 
12 months for NSQ, as per Asian data.94,95,96,97,98,99 Exponential distributions of OS times 
are assumed.
2. For SQ subjects from nivolumab arm, a hazard ratio of 0.6 (mOS nivolumab vs docetaxel:
16.7 vs 10 months) and exponential distribution of OS times are assumed. Assumption on 
treatment effect is based on results from the Phase 3 Study CA209017 (HR: 0.59; 95% CI: 
0.44 - 0.79). 
3. For NSQ subjects from nivolumab arm, non proportional hazard models are assumed based 
on results from the Phase 3 study CA209057. Piecewise exponential models are used to 
model survival function. For the NSQ PD-L1 positive subjects, a 4-month delay effect 
(exponential distribution with mOS of 12 months) followed by an exponential distribution 
with mOS of 24 months was used in the model, providing an overall mOS of 20 months. For 
the NSQ PD-L1 negative subjects, the piecewise exponential model was as followed: for the 
first 2 months, survival function is assumed to follow an exponential distribution with mOS
of 5 months; after Month 2, an exponential distribution with mOS of OS 18 months, 
providing an overall mOS of 12.8 months.
Overall survival (OS) in all comers was compared between nivolumab and docetaxel, using a 
two-sided log-rank test with a significance level of 5%. Fleming-Harrington (FH) weighted 
log-rank test was also used as it is known to be more efficient for testing survival difference 
when a delay effect is present. The power of both the log-rank and FH weighted log-rank tests, 
using G (rho = 0, gamma = 1) weights in the terminology of Fleming and Harrington was 
assessed. To control the overall Type I error rate under a two-sided 5%, significance levels of 
0.020 and 0.044 were used at the interim and final analyses to decide if the study could be
stopped for efficacy. These significance levels were calculated using the Lan-DeMets error 
spending function by East (version 6). Hazard ratios (HR) were estimated using Cox proportional 
hazards model with treatment arm as the only covariate in the model.
At both IA OS and FA OS, a consistency check will be performed first followed by superiority 
test (hierarchical testing). Consistency was defined if the observed HR for OS maintains at least 
50% of the risk reduction of death in the global studies. The probability that the observe HR is 
not greater than the consistency HR threshold was calculated at both the interim and final 
analyses i.e. the probability that the simulated HR the consistency HR among all simulated 
trials.
The impact of crossover effect was assessed. Power and hazard ratios were calculated assuming 
0%, 5%, 10%, 15% and 20% crossover rates in the control arm. For subjects in the control arm 
who were identified as crossover, their survival time were simulated based on the OS distribution 
of the treatment arm according to their histology and PD-L1 status.
All results were generated by 5000 simulations. Accrual information used in the simulations had 
the same pattern as the actual data at time of the protocol amendment (500 subjects were accrued 
in 11 months). Simulation results are displayed in Table 8.1-1.
In absence of cross over, IA OS (291 deaths) and FA OS (382 deaths) occurred approximately at 
24 months (13 months of minimum follow-up) and 37 months (26 months of minimum 
Revised Protocol No: 05
Date: 13-Dec-2017
97
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
follow-up) respectively. Using the log-rank test, cumulative power was 73% and 96% and 
average HR was 0.70 and 0.67 at the interim and final analyses, respectively. Power reached 
86% and 98% accordingly with the weighted log-rank test. Probability of Technical Success 
(PTS) for consistency check at the interim analysis was 95% (ie. the probability that the observed 
HR 0.850). At the final analysis, probability of technical success for consistency check was 
98% (ie, probability that the observed HR 0.835 was 98%). PTS of the log-rank test decreases 
when cross-over is present. PTS of the weighted log-rank test decreases as well but less than the 
conventional log-rank test. PTS for consistency check remains above 90% for crossover rates up 
to 20%.
Table 8.1-1:
Simulations Results
No 
Crossover
5% 
Crossover
10% 
Crossover
15% 
Crossover
20% 
Crossover
Events at IA/FA
291/382
291/382
291/382
291/382
291/382
Timing for IA/FA 
(months)
24/37
24/38
24/38
24/38
24/38
Expected HRs at IA/FA
0.70/0.67
0.71/0.69
0.73/0.71
0.74/0.72
0.75/0.73
Consistency HR 
thresholds at IA/FA 
(maintaining 50% of risk 
reduction)
0.850/0.835
0.855/0.845
0.865/0.855
0.870/0.860
0.875/0.865
PTS for log-rank test at 
IA/FA
73%/96%
69%/94%
63%/90%
59%/86%
53%/82%
PTS for weighted log-
rank test at IA/FA
86%/98%
82%/97%
77%/94%
72%/91%
67%/88%
PTS for consistency 
check
95%/98%
93%/98%
93%/97%
91%/96%
90%/94%
After the first ~380 randomized subjects have been followed for at least 8 months 
(approx. 16 months after study initiation), TTF is to be compared across treatment groups using a 
weighted log-rank test.100,101 With one-sided type 1 error of 0.025, the power for the weighted 
log-rank test of TTF was ~95% per simulations using data observed in global pivotal studies 
(CheckMate 057 and 017), and, adjusted for the proportion of SQ and NSQ in this study. 
Expected HR for TTF was 0.7.
8.2
Populations for Analyses

Enrolled subjects: All subjects who signed an informed consent form and were registered 
into the IVRS

Randomized subjects: All enrolled subjects who were randomized to any treatment arm in 
the study. This is the primary dataset for analyses of efficacy and baseline characteristics

TTF population: All randomized subjects with at least 8 months of follow-up at the time of 
TTF analysis. This dataset will be used for all ITT analyses at the TTF interim analysis.
Subject’s follow-up time is defined here as the time between randomization date and 
Revised Protocol No: 05
Date: 13-Dec-2017
98
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
database cutoff date regardless of subject disposition (ie, intent-to-treat population). The 
clinical database cutoff date will occur when the first approximately 380 randomized subjects 
will have at least 8-month of follow-up.

Treated subjects: All randomized subjects who received at least one dose of nivolumab or 
docetaxel. This is the primary dataset for analyses of dosing and safety

Treated subjects among TTF population: This is the primary dataset safety and exposure 
analyses on the treated subjects among TTF population

PK subjects: All subjects
treated with Nivolumab
who had
available serum 
time-concentration data 

Immunogenicity subjects: All subjects treated with Nivolumab who had available ADA data 

Biomarker subjects: All randomized subjects who had available biomarker data.
8.3
Endpoints
8.3.1
Primary Endpoint(s)

Consistency in OS benefit is defined as maintaining 50% of the risk reduction of death from 
CheckMate 057 and CheckMate 017 after adjusting for the patient distribution and the use of 
anti-PD-1/PD-L1 agents in the docetaxel arm. 

The primary endpoint of this study is OS. It is defined as the time from randomization to the 
date of death. A subject who has not died will be censored at last known date alive. 
OS will be followed continuously while subjects are on the study treatment and every 3 months 
via in-person or phone contact after subjects go off the study treatment. 
8.3.2
Secondary Endpoint(s)
The secondary efficacy endpoints in this study include ORR, progression free survival (PFS), 
time to treatment failure (TTF) and disease-related symptom deterioration by Week 12/ Week 24 
as measured by LCSS. Detailed definitions of these endpoints are described below:
8.3.2.1
Objective Response Rate
The ORR is defined as the number of subjects whose BOR of CR or partial response (PR)
divided by the number of randomized subjects. BOR is defined as the best response designation, 
as determined by the investigators, recorded between the date of randomization and the date of 
objectively documented progression per RECIST 1.1 or the date of subsequent anticancer 
therapy (excluding on-treatment palliative radiotherapy of CNS, skin or bone non-target lesions), 
whichever occurs first. For subjects without documented progression or subsequent anti-cancer 
therapy, all available response designations will contribute to the BOR determination. For 
subjects who continue nivolumab beyond progression, the BOR should be determined based on 
response designations recorded up to the time of the initial RECIST 1.1-defined progression.
Tumor assessments will be assessed every 6 weeks from the first on-study radiographic 
assessment (at Week 6) until disease progression (or until discontinuation of study therapy in 
patients receiving nivolumab beyond progression), lost to follow-up, withdrawal of study 
consent or death.
Revised Protocol No: 05
Date: 13-Dec-2017
99
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
8.3.2.2
Progression Free Survival
PFS is defined as the time from randomization to the date of the first documented tumor 
progression as determined by investigators per RECIST 1.1, or death due to any cause. Clinical 
deterioration in the absence of unequivocal evidence of progression (per RECIST 1.1) is not 
considered progression for purposes of determining PFS. Subjects who die without a reported 
prior progression will be considered to have progressed on the date of their death. Subjects who 
did not have disease progression or die will be censored on the date of their last evaluable tumor 
assessment. Subjects who did not have any on study tumor assessments and did not die will be 
censored at the randomization date. Subjects who started any subsequent anti-cancer therapy
(including on-treatment palliative RT of non-target bone lesions, skin lesions or CNS lesions)
without a prior reported progression will be censored at the last evaluable tumor assessment prior 
to or on initiation of the subsequent anti-cancer therapy. 
8.3.2.3
Time to Treatment Failure
Time to Treatment Failure (TTF) is defined as the minimum of the time from randomization to 
the following dates:

disease progression date (RECIST 1.1 or Clinical)

death date

last dose date if subject discontinued from treatment for any reasons other than ‘maximum 
clinical benefit’ or ‘administrative reasons by sponsor’102.
TTF is considered as event at the randomization date for subjects who were randomized but not 
treated. Clinical progression date is considered for time to treatment failure only when treatment 
is discontinued due to clinical disease progression. For nivolumab subjects treated beyond 
RECIST 1.1 progression, the event will be at RECIST 1.1 progression date. TTF is censored at 
the last dose date for subjects who discontinued treatment (without RECIST 1.1 progression) due 
to maximum clinical benefit or administrative reason by sponsor. TTF is censored at the last dose 
date for subjects who continued on treatment without progression or death. 
TTF will be analyzed at the interim analysis of TTF only
8.3.2.4
Rate of Disease-related Symptom Deterioration
Disease-Related Symptom deterioration Rate by Week 12 and by Week 24 is defined as the 
proportion of randomized subjects who had 10 points or more increase from baseline in Average 
Symptom Burden Index (ASBI) score at anytime between randomization and Week 12/Week 24 
respectively. 
The LCSS is a measure of disease-related symptoms and quality of life suited to use in patients 
suffering from lung cancer. It includes six items measuring loss of appetite, fatigue, coughing, 
shortness of breath, hemoptysis, and pain. Three additional items measure overall symptom 
burden, disease-related functional limitations, and quality of life. The questionnaire uses a 
24-hour recall period, and responses for each item are captured using a 100-mm visual analog 
scale (VAS). Scores for individual items ranging from 0 (no symptomatology or highest quality 
Revised Protocol No: 05
Date: 13-Dec-2017
100
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
of life) to 100 (worst symptomatology or quality of life) are derived by dividing the length of the 
line drawn from the lowest possible response to the patient’s response by the length of the VAS 
and multiplying the resulting quotient by 100. An average symptom burden index (ASBI) score 
can be derived as the average of scores for the six symptom-related items with a clinically 
meaningful change in ASBI score being defined as 10 points. Accordingly, a meaningful 
deterioration in symptoms as measured by the ASBI is reflected in a mean post-baseline score 
change 10 points.103,104,105
The LCSS questionnaire is completed on Day 1 of the scheduled cycle for the first 6 months on 
study treatment, then every 6 weeks Table 5.1-2, Table 5.1-3, and Table 5.1-4 (for Follow-up 
visits) for frequency of assessments on study for each treatment arm. 
8.3.2.5
Rates of Treatment Related Selected AEs and SAEs 
The secondary safety endpoint is the rate of treatment related selected AEs and SAEs. Toxicities 
will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No: 05
Date: 13-Dec-2017
101
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
8.4
Analyses
8.4.1
Demographics and Baseline Characteristics
Demographics and baseline laboratory results will be summarized by treatment arm as 
randomized using descriptive statistics for all randomized subjects.
8.4.2
Efficacy Analyses
8.4.2.1
Methods of Primary Endpoint
OS is the primary endpoint of this study. 
At both the interim OS analysis and final OS analysis, a 2-step hierarchical testing will be 
performed. First, a check for consistency with global data in HR for OS will be performed. This 
is to mitigate loss of power due to confounding effects of cross-over (subjects receiving anti 
PD-1/PD-L1 agents in the comparator arm). 
If consistency in OS with global data is demonstrated, superiority for OS will be tested. The 
distribution of OS in two randomized arms will be compared at the interim and final analyses via 
a two-sided (adjusted for the interim) weighted, log-rank test stratified by the stratification 
factors used for randomization as determined per IVRS, ie, histology (squamous vs
non-squamous)/ PD-L1 Status (positive vs negative/unevaluable)/ ECOG Performance status 
(0 vs 1). The weighted log-rank test will use G (rho = 0, gamma = 1) weights, in the terminology 
of Fleming and Harrington100,101
The unweighted hazard ratio (HR) and the corresponding 100x (1- alpha)% confidence interval 
(CI) (adjusted for the interim) will be estimated in a stratified Cox proportional hazards model 
using randomized arm as a single covariate with the same stratification factors mentioned above. 
The OS curves for each randomized arm will be estimated using the Kaplan-Meier (KM) 
product-limit method. Two-sided, 95% confidence intervals for median OS will be computed by 
Brookmeyer and Crowley method, based on a log-log transformed CI for the survivor function 
S(t).106,107 Survival rates at 6, 12, and 18 months will also be estimated using KM estimates on 
the OS curve for each randomized arm. Associated two-sided 95% CIs will be calculated using 
the Greenwood formula.
 
 
 
Revised Protocol No: 05
Date: 13-Dec-2017
102
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.4.3
Safety Analyses 
The safety analysis will be performed in all treated subjects. The rate of treatment related 
selected AEs and SAEs in each treatment arm will be summarized. Descriptive statistics of 
safety will be presented using National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0 by treatment arm. All treatment emergent AEs, 
drug-related AEs, SAEs and drug-related SAEs will be tabulated using worst grade per NCI 
CTCAE v 4.0 criteria by system organ class and preferred term. On-study lab parameters 
including hematology, chemistry, liver function, thyroid function and renal function will be 
summarized using worst grade per NCI CTCAE v 4.0 criteria.
Revised Protocol No: 05
Date: 13-Dec-2017
103
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Frequency, management and resolution of IMAEs will be analyzed. A tabular summary and 
comparative analysis between treatment arms of the incidence of overall IMAEs (by preferred 
term) and serious IMAEs will be performed. A descriptive analysis of IMAEs including time-
toonset, severity, duration, action taken with the study drug, dosing delays of the study drug, 
corticosteroid details, re-challenge information and outcome of the AE are individually 
characterized: 

pneumonitis IMAEs 

diarrhea/colitis IMAEs 

hepatitis IMAEs 

nephritis and renal dysfunction IMAEs

rash IMAEs 

endocrine IMAEs by subcategories including adrenal insufficiency, hypophysitis, 
hypothyroidism/thyroiditis, hyperthyroidism, and diabetes
8.4.4
Pharmacokinetic Analyses
The concentration vs time data obtained in this study will be combined with data from other 
studies in the clinical development program to develop a population PK model. This model will 
be used to evaluate the effects of intrinsic and extrinsic covariates on the PK of nivolumab and to 
determine measures of individual exposure (such as steady-state peak, trough, and time-averaged 
concentration). Model determined exposures will be used for exposure-response analyses. 
Results of population PK and exposure-response analyses will be reported separately.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No: 05
Date: 13-Dec-2017
104
7.0
Approved
930067687
7.0
v




Clinical Protocol
CA209078
BMS-936558
nivolumab
 
8.5
Interim Analyses
One interim analysis of OS is planned after 291 OS events have been observed (76% of the total 
number of OS events at the final analysis). This formal comparison of OS will allow for early 
stopping for superiority. Lan-DeMets α spending function with O’Brien and Fleming type of 
boundary will be used. The stopping boundary will depend on the actual number of OS events at 
the time of the interim analysis. However, if the analysis were performed exactly at 291 OS 
events, the boundary for declaring superiority would be p-value < 0.020. The boundary for 
declaring superiority for the final analysis after 382 OS events would be p-value < 0.044. An 
independent statistician external to BMS will perform the analysis. In addition to the formal 
planned interim analysis for OS, the DMC will have access to periodic unblinded interim reports 
of efficacy and safety to allow a risk/benefit assessment. Details will be included in the DMC 
charter. 
A Time to Treatment Failure (TTF) interim analysis is planned after the first ~380 randomized 
subjects have been followed for at least 8 months (projected to occur approx. 16 months after 
study initiation). The DMC will review the safety and efficacy data from the TTF interim 
analysis. There is no alpha spending nor penalty for TTF analysis: this interim analysis is 
considered as a bridging strategy. If TTF is statistically significant at 1-sided 0.025 level, safety 
and ORR will be described (no formal comparison) using the TTF population. Regardless of 
whether TTF is positive or negative, study will continue to the planned OS interim/final analysis.
At the TTF analysis, the distribution of TTF will be compared in the two randomized arms via a 
1-sided, unstratified weighted log-rank test. The one-sided weighted log-rank p-value will be 
reported using G (rho = 0, gamma = 1) weights, in the terminology of Harrington and 
Fleming.103,111 The FH method (with rho = 0 and gamma = 1) leads to a loss of power when
treatment effect is not delayed but has higher power when a delay of more than 2 months is 
observed, which is expected for TTF, based on data from global studies CheckMate 017 and 057.
TTF will also be compared using a regular log rank test.
The hazard ratio (HR) and the corresponding 1-sided 97.5% CI upper bound will be estimated in 
an unstratified Cox proportional hazards model using randomized arm as a single covariate. The 
TTF curves for each treatment group will be estimated using the Kaplan-Meier (KM) 
product-limit method. Two-sided, 95% confidence intervals for median TTF will be constructed 
based on a log-log transformed CI for the survivor function S(t). 
As sensitivity analysis, TTF will be analyzed using the primary definition but censoring TTF for 
discontinuation due to due to patient preference (subject withdrew consent, subject lost to follow 
up) or physician withdrawal (subject no longer meets study criteria, administrative reason by 
sponsor). 
At the TTF analysis, ORR will be analyzed descriptively using the TTF population. In addition, 
analyses will be repeated using the Chinese subjects among the TTF population, and efficacy 
Revised Protocol No: 05
Date: 13-Dec-2017
106
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
will also be assessed by histology. BOR will be summarized by response category and treatment 
group and ORR will be computed with the exact 95% CI using Clopper-Pearson method. TTR 
and DOR will be evaluated for responders (i.e. subjects with confirmed CR or PR) of the TTF 
population. Study conduct and study population will be summarized on the TTF population. 
Exposure and safety (including death summary) will be summarized on the treated subjects 
among TTF population.
9
STUDY MANAGEMENT
9.1
Compliance
9.1.1
Compliance with the Protocol and Protocol Revisions
The study shall be conducted as described in this approved protocol. All revisions to the protocol 
must be discussed with, and be prepared by, BMS. The investigator should not implement any 
deviation or change to the protocol without prior review and documented approval/favorable 
opinion from the IRB/IEC of an amendment, except where necessary to eliminate an immediate 
hazard(s) to study subjects. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior 
to obtaining IRB/IEC approval/favorable opinion, as soon as possible the deviation or change 
will be submitted to:

IRB/IEC for review and approval/favorable opinion

BMS

Regulatory Authority(ies), if required by local regulations
Documentation of approval signed by the chairperson or designee of the IRB(s)/IEC(s) must be 
sent to BMS.
If an amendment substantially alters the study design or increases the potential risk to the 
subject: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review and 
approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study if they are affected by the amendment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
9.1.2
Monitoring
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site they will review study records and directly compare 
them with source documents, discuss the conduct of the study with the investigator, and verify 
that the facilities remain acceptable. 
Revised Protocol No: 05
Date: 13-Dec-2017
107
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
In addition, the study may be evaluated by BMS internal auditors and government inspectors 
who must be allowed access to CRFs, source documents, other study files, and study facilities. 
BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of any inspections scheduled by regulatory 
authorities, and promptly forward copies of inspection reports to BMS. 
9.1.2.1
Source Documentation
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data are hand-written on paper or 
entered electronically. If source data are created (first entered), modified, maintained, archived, 
retrieved, or transmitted electronically via computerized systems (and/or any other kind of 
electronic devices) as part of regulated clinical trial activities, such systems must be compliant 
with all applicable laws and regulations governing use of electronic records and/or electronic 
signatures. Such systems may include, but are not limited to, electronic medical/health records 
(EMRs/EHRs), adverse event tracking/reporting, protocol required assessments, and/or drug 
accountability records).
When paper records from such systems are used in place of electronic format to perform 
regulated activities, such paper records should be certified copies. A certified copy consists of a 
copy of original information that has been verified, as indicated by a dated signature, as an exact 
copy having all of the same attributes and information as the original. 
9.1.3
Investigational Site Training
Bristol-Myers Squibb will provide quality investigational staff training prior to study initiation. 
Training topics will include but are not limited to: GCP, AE reporting, study details and 
procedure, electronic CRFs, study documentation, informed consent, and enrollment of WOCBP.
9.2
Records
9.2.1
Records Retention
The investigator must retain all study records and source documents for the maximum period 
required by applicable regulations and guidelines, or institution procedures, or for the period 
specified by BMS, whichever is longer. The investigator must contact BMS prior to destroying 
any records associated with the study.
BMS will notify the investigator when the study records are no longer needed.
If the investigator withdraws from the study (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, IRB). Notice of such 
transfer will be given in writing to BMS.
9.2.2
Study Drug Records 
It is the responsibility of the investigator to ensure that a current disposition record of study drug 
(inventoried and dispensed) is maintained at the study site to include investigational product and 
Revised Protocol No: 05
Date: 13-Dec-2017
108
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
the following non-investigational product(s) Dexamethasone. Records or logs must comply with 
applicable regulations and guidelines and should include:

amount received and placed in storage area

amount currently in storage area

label identification number or batch number 

amount dispensed to and returned by each subject, including unique subject identifiers

amount transferred to another area/site for dispensing or storage

nonstudy disposition (e.g., lost, wasted) 

amount destroyed at study site, if applicable

amount returned to BMS

retain samples for bioavailability/bioequivalence, if applicable 

dates and initials of person responsible for Investigational Product dispensing/accountability, 
as per the Delegation of Authority Form.
Note: For study drug sourced by site, and not supplied by BMS or its vendors, the investigator or 
designee accepts responsibility for documenting traceability and study drug integrity in 
accordance with requirements applicable under law and the SOPs/standards of the sourcing 
pharmacy.
BMS will provide forms to facilitate inventory control if the investigational site does not have an 
established system that meets these requirements.
9.2.3
Case Report Forms
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the BMS electronic data capture tool, electronic CRFs will be prepared for all 
data collection fields except for fields specific to SAEs and pregnancy, which will be reported on 
the paper or electronic SAE form and Pregnancy Surveillance form, respectively. Spaces may be 
left blank only in those circumstances permitted by study-specific CRF completion guidelines 
provided by BMS. 
The confidentiality of records that could identify subjects must be protected, respecting the 
privacy and confidentiality rules in accordance with the applicable regulatory requirement(s).
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF, including any paper or electronic SAE/pregnancy CRFs, must be promptly 
reviewed, signed, and dated by the investigator or qualified physician who is a subinvestigator
and who is delegated this task on the Delegation of Authority Form .For electronic CRFs, review 
Revised Protocol No: 05
Date: 13-Dec-2017
109
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
and approval/signature is completed electronically through the BMS electronic data capture tool. 
The investigator must retain a copy of the CRFs including records of the changes and 
corrections.
Each individual electronically signing electronic CRFs must meet BMS training requirements 
and must only access the BMS electronic data capture tool using the unique user account 
provided by BMS. User accounts are not to be shared or reassigned to other individuals.
9.3
Clinical Study Report and Publications
A Signatory Investigator must be selected to sign the clinical study report. 
For this protocol, the Signatory Investigator will be selected considering the following criteria:

External Principal Investigator designated at protocol development

National Coordinating Investigator 

Study Steering Committee chair or their designee

Subject recruitment (eg, among the top quartile of enrollers)

Involvement in trial design

Regional representation (eg, among top quartile of enrollers from a specified region or 
country)

Other criteria (as determined by the study team)
The data collected during this study are confidential and proprietary to BMS. Any publications 
or abstracts arising from this study must adhere to the publication requirements set forth in the 
clinical trial agreement (CTA) governing [Study site or Investigator] participation in the study. 
These requirements include, but are not limited to, submitting proposed publications to BMS at 
the earliest practicable time prior to submission or presentation and otherwise within the time 
period set forth in the CTA.
Revised Protocol No: 05
Date: 13-Dec-2017
110
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
10
GLOSSARY OF TERMS
Term
Definition
Adverse Reaction
An adverse event that is considered by either the investigator 
or BMS as related to the investigational product
Unexpected Adverse Reaction
An adverse reaction, the nature or severity of which is not 
consistent with the applicable product information 
(eg, Investigator Brochure for an unapproved investigational 
product)
Serious Adverse Event
Serious adverse event defined as any untoward medical 
occurrence that at any dose: results in death; is life 
threatening (defined as an event in which the subject was at 
risk of death at the time of the event; it does not refer to an 
event which hypothetically might have caused death if it 
were more severe), requires inpatient hospitalization or 
causes prolongation of existing hospitalization; results in 
persistent or significant disability/incapacity, is a congenital 
anomaly/birth defect; is an important medical event (defined 
as a medical event(s) that may not be immediately life 
threatening or result in death or hospitalization but, based 
upon appropriate medical and scientific judgment, may 
jeopardize the subject or may require intervention 
[eg, medical, surgical] to prevent one of the other serious 
outcomes listed in the definition above). Examples of such 
events include, but are not limited to, intensive treatment in 
an emergency room or at home for allergic bronchospasm; 
blood dyscrasias or convulsions that do not result in 
hospitalization.). For reporting purposes only, BMS also 
considers the occurrence of pregnancy, overdose (regardless 
of association with an AE), and cancer as important medical 
events.
Revised Protocol No: 05
Date: 13-Dec-2017
111
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
11
LIST OF ABBREVIATIONS
ADA
Anti-drug antibody
AE
Adverse event
AEOSIs
Adverse Events of Special Interests
AIDS
Acquired Immunodeficiency Syndrome
ALK
Anaplastic lymphoma kinase (CD246)
ALT
Alanine Aminotransferase
APC
Antigen-presenting cells
ASEAN
Association of Southeast Asian Nations
ASR
Age-Standardized Rate
AST
Aspartate Aminotransferase
Bcl- xL
B-cell lymphoma-extra large
BID
Twice per day
B7-DC
Human B7 –dendritic cell
B7-H1
Human B7 homolog 1
BMS
Bristol-Myers Squibb
BOR
Best overall response
BSC
Best supportive care
BTLA
B-and T-cell attenuator
CD28
Cluster of differentiation 28
CD273
Cluster of differentiation 273
CD274
Cluster of differentiation 274
C57BL/6
C57 black 6 breed mouse
CI
Confidence interval
CMH
Cochran-Mantel Haenszel
CMV
Cytomegalovirus
CNS
Central nervous system
COX2
Cyclooxygenase-2
CR
Complete response
CRF
Case report form
CT
Computed tomography
CTA
Clinical trial agreement 
CTCAE
Common Terminology Criteria for Adverse Events
CTL
Cytotoxic T-Lymphocyte
CTLA-4
Cytotoxic T lymphocyte-associated antigen 4
CYP
Cytochrome P450
D
Day
DCF
Data clarification form
DILI
Drug induced liver injury
DLT
Dose-limiting toxicity
DMC
Data monitoring committee
Revised Protocol No: 05
Date: 13-Dec-2017
112
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
DOOR
Duration of objective response
ECL
Electrochemilumeminescent
ECOG
Eastern Cooperative Oncology Group
eCRF
Electronic case report form
EDC
Electronic data capture
EGFR
Epidermal growth factor receptor
EI
Equivalence interval 
ELISA
Enzyme-Linked Immunosorbent Assay Test
EOI
End-of-infusion
ESOI
Events of special interest
EU
European Union
FFPE
Formalin Fixed, Paraffin-Embedded
FLIP
caspase-8 (FLICE)-like inhibitory protein
FSH
Follicle stimulating hormone 
FU
Follow up
GCP
Good clinical practices
GMP
Good manufacturing practices
HBV sAg
Hepatitis B virus surface antigen
HCV Ab
Hepatitis C virus antibody
HCG
Human Chorionic Gonadotropin
HIPAA
Health Information Portability and Accountability Act
HIV
Human Immunodeficiency Virus 
HLA
Human leukocyte antigen
HR
Hazard ratio
HTA
Health authority
IB
Investigator Brochure
ICF
Informed consent form
ICH
International Conference on Harmonisation
ICOS
Inducible T-cell co-stimulator (CD278)
IDO
Inducible co-stimulator
IFN
Interferon
IFNGR1
Interferon Gamma-receptor-1
IFN-γ
Interferon Gamma
IgG4
Immunoglobulin G4
IHC
Immunohistochemistry
IL
Interleukin
IMP
Investigational medical product
ITIM
Immunoreceptor tyrosine inhibitory motif
ITSM
Immunoreceptor tyrosine-based switch motif
IRB/IEC
Institutional review board/independent ethics committee
IV
Intravenous
Revised Protocol No: 05
Date: 13-Dec-2017
113
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
IVRS
Interactive voice response system
KM
Kaplan-Meier curve
LCCS
Lung Cancer Symptom Scale
LFT
Liver function test
LMP
Low-molecular-mass protein
mAb
Monoclonal antibody
mCRPC
Metastatic castration-resistant prostate cancer
MedDRA
Medical Dictionary for Regulatory Activities
MEL
Metastatic melanoma
mg
Milligram
mL
Milliliter 
MLR
Mixed Lymphocyte Reaction
MRI
Magnetic resonance imaging
MTD
Maximum-tolerated dose
M²
Square meter
NCI
National Cancer Institute
NIMP
Non-investigational medical product
NK
Natural killer
NSAIDs
Non-steroidal anti-inflammatory drugs 
NSCLC
Non-small-cell lung cancer
NOS
Not otherwise specified
NOS2
Nitric oxide synthase 2
ORR
Objective response rate
OS
Overall survival
PBMC
Peripheral blood mononuclear cell
PD
Progressive disease
PD-1
Programmed death-1
PD-L1
Programmed cell death ligand 1
PD-L2
Programmed cell death ligand 2
PFS
Progression-free survival
PGE2
Prostaglandin E2
PK
Pharmacokinetics
PO
By mouth
P19
Serine-protease inhibitor
PPK
Population pharmacokinetic
PR
Partial response
PRO
Subject reported outcomes
PSA
Prostate-specific antigen
PVG
Pharmacovigilance
q
Every
PRO
Patient reported outcomes
Revised Protocol No: 05
Date: 13-Dec-2017
114
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
RAG
Recombination activating gene
RCC
Renal cell carcinoma
RECIST
Response Evaluation Criteria in Solid Tumors
RNA
Ribonucleic acid
RT
Radiation therapy
SAE
Serious adverse event
SD
Stable disease
SLD
Sum of longest diameters 
SNP
Single nucleotide polymorphism
SOC
System/Organ/Class
SOP
Standard operating procedures
Src
Sarcoma
STAT
Signal Transducers and Activators of Transcription
TAP1
Transporter associate with antigen processing 1
TCR
T-cell receptor
TEAE
Treatment-emergent adverse event
TGF
Transforming growth factor
TIL
Tumor-infiltrating lymphocytes
TKI
Tyrosine kinase inhibitor
TNF
Tumor necrosis factor
TRAIL
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand 
Treatment
Tregs
Regulatory T cells
TTF
Time To Treatment failure
TTR
Time to objective response
ULN
Upper limit of normal
Vz
Volume of Distribution
WBC
White blood cell
WOCBP
Women of child bearing potential
Revised Protocol No: 05
Date: 13-Dec-2017
115
7.0
Approved
930067687
7.0
v






















Clinical Protocol
CA209078
BMS-936558
nivolumab
APPENDIX 2
RECIST 1.1 GUIDELINES
1
EVALUATION OF LESIONS
At baseline, tumor lesions/lymph nodes will be categorized measurable or non-measurable as 
follows:
1.1
Measurable
Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
1. 10 mm by CT scan (CT scan slice thickness no greater than 5 mm)
2. 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured 
with calipers should be recorded as non-measurable)
3. 20 mm by chest x-ray
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be 15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm).
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor. Pathological nodes which are defined as 
measurable and may be identified as target lesions must meet the criterion of a short axis of 
15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. The 
short axis of the node is the diameter normally used by radiologists to judge if a node is involved 
by solid tumor. Nodal size is normally reported as two dimensions in the plane in which the 
image is obtained (for CT scan this is almost always the axial plane; for MRI the plane of 
acquisition may be axial, saggital or coronal). The smaller of these measures is the short axis. 
For example, an abdominal node which is reported as being 20 mm x 30 mm has a short axis of 
20 mm and qualifies as a malignant, measurable node. In this example, 20 mm should be 
recorded as the node measurement. All other pathological nodes (those with short axis 10 mm 
but < 15 mm) should be considered non-target lesions. Nodes that have a short axis < 10 mm are 
considered non-pathological and should not be recorded or followed.
1.2
Non-Measurable
All other lesions are considered non-measurable, including small lesions (longest diameter 
< 10mm or pathological lymph nodes with 10 to < 15 mm short axis) as well as truly 
non-measurable lesions. Lesions considered truly non-measurable include: leptomeningeal 
disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic 
involvement of skin or lung, abdominal masses/abdominal organomegaly identified by physical 
exam that is not measurable by reproducible imaging techniques.
Revised Protocol No: 05
Date: 13-Dec-2017
126
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
2
BASELINE DOCUMENTATION OF ‘TARGET’ AND ‘NON-TARGET’
LESIONS
When more than one measurable lesion is present at baseline all lesions up to a maximum of five 
lesions total (and a maximum of two lesions per organ) representative of all involved organs 
should be identified as target lesions and will be recorded and measured at baseline (this means 
in instances where patients have only one or two organ sites involved a maximum of two and 
four lesions respectively will be recorded).
Target lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, but in addition should be those that lend themselves to 
reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does 
not lend itself to reproducible measurement in which circumstance the next largest lesion which 
can be measured reproducibly should be selected.
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted above, only the short axis is added into the sum. The baseline 
sum diameters will be used as reference to further characterize any objective tumor regression in 
the measurable dimension of the disease.
All other lesions (or sites of disease) including pathological lymph nodes should be identified as 
non-target lesions and should also be recorded at baseline. Measurements are not required and 
these lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal progression’ 
(more details to follow). In addition, it is possible to record multiple nontarget lesions involving 
the same organ as a single item on the case record form (eg, ‘multiple enlarged pelvic lymph 
nodes’ or ‘multiple liver metastases’).
3
RESPONSE CRITERIA
3.1
Evaluation of Target Lesions
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to < 10 mm.
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking 
as reference the baseline sum diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that 
is the smallest on study). In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of 
one or more new lesions is also considered progression).
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study.
Revised Protocol No: 05
Date: 13-Dec-2017
127
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
3.1.1
Special Notes on the Assessment of Target Lesions
3.1.1.1
Lymph nodes
Lymph nodes identified as target lesions should always have the actual short axis measurement 
recorded (measured in the same anatomical plane as the baseline examination), even if the nodes 
regress to below 10 mm on study. This means that when lymph nodes are included as target 
lesions, the ‘sum’ of lesions may not be zero even if complete response criteria are met, since a 
normal lymph node is defined as having a short axis of < 10 mm. Case report forms or other data 
collection methods may therefore be designed to have target nodal lesions recorded in a separate 
section where, in order to qualify for CR, each node must achieve a short axis < 10 mm. For PR, 
SD and PD, the actual short axis measurement of the nodes is to be included in the sum of target 
lesions.
3.1.1.2
Target lesions that become ‘too small to measure’
While on study, all lesions (nodal and non-nodal) recorded at baseline should have their actual 
measurements recorded at each subsequent evaluation, even when very small (eg, 2 mm). 
However, sometimes lesions or lymph nodes which are recorded as target lesions at baseline 
become so faint on CT scan that the radiologist may not feel comfortable assigning an exact 
measure and may report them as being ‘too small to measure’. When this occurs it is important 
that a value be recorded on the case report form. If it is the opinion of the radiologist that the 
lesion has likely disappeared, the measurement should be recorded as 0 mm. If the lesion is 
believed to be present and is faintly seen but too small to measure, a default value of 5 mm 
should be assigned (Note: It is less likely that this rule will be used for lymph nodes since they 
usually have a definable size when normal and are frequently surrounded by fat such as in the 
retroperitoneum; however, if a lymph node is believed to be present and is faintly seen but too 
small to measure, a default value of 5 mm should be assigned in this circumstance as well). This 
default value is derived from the 5 mm CT slice thickness (but should not be changed with 
varying CT slice thickness). The measurement of these lesions is potentially non-reproducible, 
therefore providing this default value will prevent false responses or progressions based upon 
measurement error. To reiterate, however, if the radiologist is able to provide an actual measure, 
that should be recorded, even if it is below 5 mm.
3.1.1.3
Lesions that split or coalesce on treatment
When non-nodal lesions ‘fragment’, the longest diameters of the fragmented portions should be 
added together to calculate the target lesion sum. Similarly, as lesions coalesce, a plane between 
them may be maintained that would aid in obtaining maximal diameter measurements of each 
individual lesion. If the lesions have truly coalesced such that they are no longer separable, the 
vector of the longest diameter in this instance should be the maximal longest diameter for the 
‘coalesced lesion’.
Revised Protocol No: 05
Date: 13-Dec-2017
128
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
3.2
Evaluation of Non-Target Lesions
This section provides the definitions of the criteria used to determine the tumor response for the 
group of non-target lesions. While some non-target lesions may actually be measurable, they 
need not be measured and instead should be assessed only qualitatively at the time points 
specified in the protocol.
Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor 
marker level. All lymph nodes must be non-pathological in size (< 10mm short 
axis). 
Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits.
Progressive Disease (PD): Unequivocal progression (see comments below) of existing non-
target lesions. (Note: the appearance of one or more new lesions is also considered 
progression).
3.2.1
Special Notes on Assessment of Progression of Non-Target Disease
The concept of progression of non-target disease requires additional explanation as follows:
3.2.1.1
When the patient also has measurable disease
In this setting, to achieve ‘unequivocal progression’ on the basis of the non-target disease, there 
must be an overall level of substantial worsening in non-target disease such that, even in 
presence of SD or PR in target disease, the overall tumor burden has increased sufficiently to 
merit discontinuation of therapy (see examples in Appendix 2 and further details below). A 
modest ‘increase’ in the size of one or more non-target lesions is usually not sufficient to qualify 
for unequivocal progression status. The designation of overall progression solely on the basis of 
change in non-target disease in the face of SD or PR of target disease will therefore be extremely 
rare.
3.2.1.2
When the patient has only non-measurable disease
This circumstance arises in some trials when it is not a criterion of study entry to have 
measurable disease. The same general concepts apply here as noted above, however, in this 
instance there is no measurable disease assessment to factor into the interpretation of an increase 
in non-measurable disease burden. Because worsening in non-target disease cannot be easily 
quantified (by definition: if all lesions are truly non-measurable) a useful test that can be applied 
when assessing patients for unequivocal progression is to consider if the increase in overall 
disease burden based on the change in non-measurable disease is comparable in magnitude to the 
increase that would be required to declare PD for measurable disease: ie, an increase in tumor 
burden representing an additional 73% increase in ‘volume’ (which is equivalent to a 20% 
increase diameter in a measurable lesion). Examples include an increase in a pleural effusion 
from ‘trace’ to ‘large’, an increase in lymphangitic disease from localized to widespread, or may 
be described in protocols as ‘sufficient to require a change in therapy’. If ‘unequivocal 
progression’ is seen, the patient should be considered to have had overall PD at that point. While 
Revised Protocol No: 05
Date: 13-Dec-2017
129
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
it would be ideal to have objective criteria to apply to non-measurable disease, the very nature of 
that disease makes it impossible to do so; therefore the increase must be substantial.
3.2.2
New Lesions
The appearance of new malignant lesions denotes disease progression; therefore, some 
comments on detection of new lesions are important. There are no specific criteria for the 
identification of new radiographic lesions; however, the finding of a new lesion should be 
unequivocal: ie, not attributable to differences in scanning technique, change in imaging 
modality or findings thought to represent something other than tumor (for example, some ‘new’ 
bone lesions may be simply healing or flare of pre-existing lesions). This is particularly
important when the patient’s baseline lesions show partial or complete response. For example, 
necrosis of a liver lesion may be reported on a CT scan report as a ‘new’ cystic lesion, which it is 
not.
A lesion identified on a follow-up study in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression. An example of this is 
the patient who has visceral disease at baseline and while on study has a CT or MRI brain 
ordered which reveals metastases. The patient’s brain metastases are considered to be evidence 
of PD even if he/she did not have brain imaging at baseline.
If a new lesion is equivocal, for example because of its small size, continued therapy and 
follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there 
is definitely a new lesion, then progression should be declared using the date of the initial scan. 
While FDG-PET response assessments need additional study, it is sometimes reasonable to 
incorporate the use of FDG-PET scanning to complement CT scanning in assessment of 
progression (particularly possible ‘new’ disease). New lesions on the basis of FDG-PET imaging 
can be identified according to the following algorithm:
1. Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD based 
on a new lesion.
2. No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive FDG-PET at 
follow-up corresponds to a new site of disease confirmed by CT, this is PD. If the positive 
FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up 
CT scans are needed to determine if there is truly progression occurring at that site (if so, the 
date of PD will be the date of the initial abnormal FDG-PET scan). If the positive FDG-PET 
at follow-up corresponds to a pre-existing site of disease on CT that is not progressing on the 
basis of the anatomic images, this is not PD.
3.3
Response Assessment
3.3.1
Evaluation of Best Overall Response
The best overall response is defined as the best response designation, as determined by the 
investigators, recorded between the date of randomization and the date of objectively 
documented progression per RECIST 1.1 or the date of subsequent anticancer therapy, 
Revised Protocol No: 05
Date: 13-Dec-2017
130
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
whichever occurs first. The patient’s best overall response assignment will depend on the 
findings of both target and non-target disease and will also take into consideration the 
appearance of new lesions. Furthermore, depending on the nature of the study and the protocol 
requirements, it may also require confirmatory measurement.
3.3.2
Time Point Response
It is assumed that at each protocol specified time point, a response assessment occurs. Table 
3.3.2A provides a summary of the overall response status calculation at each time point for 
patients who have measurable disease at baseline. When patients have non-measurable (therefore 
non-target) disease only, Table 3.3.2B is to be used.
Table 3.3.2A:
Time Point Response: Patients With Target (Non-Target) 
Disease
Target Lesions
Non-Target Lesions
New Lesions
Overall 
Response
CR
CR
No
CR
CR
Non-CR/non-PD
No
PR
CR
Not evaluated
No
PR
PR
Non-PD or not all 
evaluated
No
PR
SD
Non-PD or not all 
evaluated
No
SD
Not all evaluated
Non-PD
No
NE
PD
Any
Yes or No
PD
Any
PD
Yes or No
PD
Any
Any
Yes
PD
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease and 
NE = inevaluable
Table 3.3.2B:
Time Point Response: Patients with Non-target Disease Only
Non-Target Lesions
New Lesions
Overall Response
CR
No
CR
Non-CR/non-PD
No
Non-CR/non-PDa
Not all evaluated
No
NE
Unequivocal PD
Yes or No
PD
Any
Yes
PD
CR = complete response, PD = progressive disease and NE = inevaluable
Revised Protocol No: 05
Date: 13-Dec-2017
131
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
a Non-CR/non-PD is preferred over SD for non-target disease since SD is increasingly used as endpoint for 
assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised.
3.3.3
Best Overall Response 
Best response determination of complete or partial response requires confirmation: Complete or 
partial responses may be claimed only if the criteria for each are met at a subsequent time point 
of 4 weeks later. In this circumstance, the best overall response can be interpreted as in 
Table 3.3.3.
Special note on response assessment: When nodal disease is included in the sum of target 
lesions and the nodes decrease to ‘normal’ size (< 10 mm), they may still have a measurement 
reported on scans. This measurement should be recorded even though the nodes are normal in 
order not to overstate progression should it be based on increase in size of the nodes. As noted 
earlier, this means that patients with CR may not have a total sum of ‘zero’ on the case report 
form (CRF).
Table 3.3.3:
Best Overall Response (Confirmation of CR&PR Required)
Overall Response 
First Time Point
Overall Response
Subsequent Time Point
BEST Overall Response
CR
CR
CR
CR
PR
SD, PD OR PRa
CR
SD
SD provided minimum criteria for SD durationb met, 
otherwise, PD
CR
PD
SD provided minimum criteria for SD durationb met, 
otherwise, PD
CR
NE
SD provided minimum criteria for SD durationb met, 
otherwise, NE
PR
CR
PR
PR
PR
PR
PR
SD
SD
PR
PD
SD provided minimum criteria for SD durationb met, 
otherwise, PD
PR
NE
SD provided minimum criteria for SD duration bmet, 
otherwise, NE
NE
NE
NE
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and 
NE = inevaluable
a If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). 
Best response would depend on whether minimum duration for SD was met. However, sometimes ‘CR’ may be 
claimed when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not 
Revised Protocol No: 05
Date: 13-Dec-2017
132
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
CR at the first time point. Under these circumstances, the original CR should be changed to PR and the best 
response is PR.
b Minimum criteria for SD duration is 6 weeks.
3.3.4
Confirmation Scans
Verification of Response: To be assigned a status of CR or PR, changes in tumor measurements 
must be confirmed by consecutive repeat assessments that should be performed no less than 28 
days after the criteria for response are first met. For this study, the next scheduled tumor 
assessment can meet this requirement.
Verification of Progression: Progression of disease should be verified in cases where progression 
is equivocal. If repeat scans confirm PD, then progression should be declared using the date of 
the initial scan. If repeat scans do not confirm PD, then the subject is considered to not have 
progressive disease.
Revised Protocol No: 05
Date: 13-Dec-2017
133
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
APPENDIX 3
MANAGEMENT OF SAFETY ALGORITHMS FOR IMMUNO-
ONCOLOGY AGENTS
Revised Protocol No: 05
Date: 13-Dec-2017
134
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Revised Protocol No: 05
Date: 13-Dec-2017
135
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Revised Protocol No: 05
Date: 13-Dec-2017
136
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Revised Protocol No: 05
Date: 13-Dec-2017
137
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Revised Protocol No: 05
Date: 13-Dec-2017
138
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Revised Protocol No: 05
Date: 13-Dec-2017
139
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Revised Protocol No: 05
Date: 13-Dec-2017
140
7.0
Approved
930067687
7.0
v


Clinical Protocol
CA209078
BMS-936558
nivolumab
Revised Protocol No: 05
Date: 13-Dec-2017
141
7.0
Approved
930067687
7.0
v

SAP_001.pdf: 
Official Title of Study:  An Open-label Randomized Multinational Phase 3 Trial of Nivolumab Versus 
Docetaxel in Previously Treated Subjects With Advanced or Metastatic Non-small Cell Lung Cancer 
(CheckMate 078: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 078)   
 
NCT Number:  NCT02613507 
 
Document Date:  May 2, 2017 


STATISTICAL ANALYSIS PLAN
FOR CLINICAL STUDY REPORT
AN OPEN-LABEL RANDOMIZED MULTINATIONAL PHASE III TRIAL OF 
NIVOLUMAB VERSUS DOCETAXEL IN PREVIOUSLY TREATED SUBJECTS WITH 
ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
PROTOCOL CA209-078
VERSION # 2.1
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
2
TABLE OF CONTENTS
STATISTICAL ANALYSIS PLAN FOR CLINICAL STUDY REPORT ...................................1
TABLE OF CONTENTS............................................................................................................2
LIST OF TABLES......................................................................................................................6
LIST OF FIGURES ....................................................................................................................6
7
1.1
Research Hypothesis.................................................................................................7
1.2
Schedule of Analyses................................................................................................7
2
STUDY DESCRIPTION ..........................................................................................8
2.1
Study Design ............................................................................................................8
2.2
Treatment Assignment..............................................................................................9
2.3
Blinding and Unblinding.........................................................................................10
2.4
Protocol Amendments.............................................................................................10
2.5
Data Monitoring Committee ...................................................................................11
3
OBJECTIVES ........................................................................................................11
3.1
Primary...................................................................................................................11
3.2
Secondary...............................................................................................................12
4
ENDPOINTS..........................................................................................................12
4.1
Primary Endpoint....................................................................................................12
4.2
Secondary Endpoints ..............................................................................................13
4.2.1
Objective Response Rate.........................................................................................13
4.2.2
Progression Free Survival ......................................................................................13
4.2.3
Time to Treatment Failure......................................................................................14
4.2.4
Disease related Symptom Deterioration Rate by Week 12 and Week 24 ..................14
16
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
3
5
SAMPLE SIZE AND POWER...............................................................................16
6
STUDY PERIODS, TREATMENT REGIMENS AND POPULATIONS 
FOR ANALYSES ..................................................................................................18
6.1
Study Periods..........................................................................................................18
6.2
Treatment Regimens...............................................................................................18
6.3
Populations for Analyses ........................................................................................19
7
STATISTICAL ANALYSES..................................................................................19
7.1
General Methods ....................................................................................................19
7.2
Study Conduct........................................................................................................20
7.2.1
Accrual...................................................................................................................20
7.2.2
Relevant Protocol Deviations..................................................................................20
7.3
Study Population ....................................................................................................22
7.3.1
Subject Disposition.................................................................................................22
7.3.2
Demographics and Other Baseline Characteristics.................................................22
7.3.3
Medical History......................................................................................................23
7.3.4
Prior Therapy Agent...............................................................................................23
7.3.5
Baseline Examinations............................................................................................24
7.3.6
Discrepancies between IVRS and CRF Stratification Factors .................................24
7.4
Extent of Exposure .................................................................................................24
7.4.1
Administration of Study Therapy.............................................................................25
7.4.2
Modifications of Study Therapy ..............................................................................25
7.4.2.1
Dose Delays ...........................................................................................................25
7.4.2.2
Dose Reductions.....................................................................................................26
7.4.3
Concomitant Medications.......................................................................................27
7.5
Efficacy..................................................................................................................27
7.5.1
Overall Survival .....................................................................................................27
7.5.1.1
Primary Analysis ....................................................................................................27
7.5.1.2
OS Sensitivity Analyses...........................................................................................28
7.5.1.3
Consistency of Treatment Effect on OS in Subsets...................................................29
7.5.1.4
Multivariate Analysis..............................................................................................29
7.5.1.5
Subject Follow-up for OS........................................................................................30
7.5.1.6
Follow-up Therapy .................................................................................................30
7.5.1.7
Analysis of Survival by Tumor Response.................................................................30
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
4
7.5.1.8
OS Analysis at time of TTF analysis........................................................................31
7.5.2
Objective Response Rate.........................................................................................31
7.5.2.1
Primary Analysis of ORR........................................................................................31
7.5.2.2
Sensitivity Analyses of ORR....................................................................................31
7.5.2.3
Duration of Objective Response..............................................................................31
7.5.2.4
Time to Objective Response ....................................................................................31
7.5.2.5
ORR Analysis at time of TTF analysis.....................................................................32
7.5.3
Progression Free Survival ......................................................................................32
7.5.3.1
Primary Analysis of PFS.........................................................................................32
7.5.3.2
Sensitivity Analyses of PFS.....................................................................................32
7.5.3.3
PFS Analysis at time of TTF analysis......................................................................33
7.5.4
Hierarchy for Key Secondary Efficacy Endpoints ...................................................33
7.5.5
Other Efficacy Analyses..........................................................................................33
7.5.6
TTF Interim Analysis..............................................................................................34
7.5.6.1
Sensitivity Analyses.................................................................................................34
7.5.7
OS Interim Analysis................................................................................................34
7.6
Safety.....................................................................................................................35
7.6.1
Deaths ....................................................................................................................35
7.6.2
Serious Adverse Events...........................................................................................35
7.6.3
Adverse Events Leading to Discontinuation of Study Therapy.................................35
7.6.4
Adverse Events Leading to Dose Delay of Study Therapy........................................35
7.6.5
Adverse Events .......................................................................................................36
7.6.6
Adverse Events by Subgroups .................................................................................36
7.6.7
Multiple Events.......................................................................................................36
7.6.8
Adverse Events of Special Interest ..........................................................................36
7.6.9
Clinical Laboratory Evaluations.............................................................................36
7.6.9.1
Hematology ............................................................................................................36
7.6.9.2
Serum Chemistry ....................................................................................................36
7.6.10
Vital Signs and Pulse Oximetry...............................................................................36
7.6.11
Immunogenicity Analysis ........................................................................................36
7.6.12
Pregnancy ..............................................................................................................36
7.6.13
Clinical Safety Program (CSP)...............................................................................36
7.7
Pharmacokinetics....................................................................................................36
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
5
8
CONVENTIONS....................................................................................................40
9
CONTENT OF REPORTS .....................................................................................41
10
DOCUMENT HISTORY........................................................................................42
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
6
LIST OF TABLES
Table 2.4-1:
Protocol Amendments ............................................................................10
Table 4.2.2-1:
Censoring Scheme for Primary Definition of PFS...................................13
Table 5-1:
Simulations results .................................................................................18
Table 7.4.1-1:
Administration of Study Therapy: Definition of Parameters....................25
Table 7.4.2.2-1:
Calculated Dose Ranges and Related Dose Levels of Docetaxel .............26
Table 10-1:
Document History ..................................................................................42
LIST OF FIGURES
Figure 2.1-1:
Study Design............................................................................................9
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1
Research Hypothesis
The treatment effect of nivolumab is consistent between the study population and subjects from 
global pivotal trials (CheckMate 057 and CheckMate 017) and nivolumab increases overall 
survival (OS) as compared with docetaxel, in subjects with advanced or metastatic NSCLC who 
have failed prior platinum-based doublet chemotherapy.
1.2
Schedule of Analyses
OS is the primary endpoint for this study.
One formal interim analysis for superiority of the OS is planned when at least 291 deaths on all 
randomized subjects (76% of total deaths required for the final OS analysis) have been observed 
The interim analysis of OS will be monitored by an independent Data Monitoring Committee 
(DMC) and is expected to occur approximately 24 months after study initiation. Details are 
specified in the DMC charter.
The final analysis for OS is planned to be performed when at least 382 deaths are observed (approx 
37 months after study initiation). Additional details can be found in Section 7.5.6.
In addition to the OS interim and final analyses, a Time to Treatment Failure interim analysis (TTF 
IA) is added to support an early filing in China. TTF IA will occur when the first ~380 randomized 
subjects have been followed for at least 8 months (TTF population). The interim analysis of TTF 
will be reviewed by the DMC. ORR and safety (including death summary) will be analyzed 
descriptively for subjects from the TTF population. 
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
8
2
STUDY DESCRIPTION
2.1
Study Design
This is an open-label, randomized, Phase 3 study in adult (18 years old) male and female subjects 
with advanced or metastatic NSCLC after failure of prior platinum-doublet chemotherapy. 
Approximately 500 subjects, will be randomized to nivolumab vs. docetaxel in a 2:1 ratio. 
Subjects will undergo screening evaluations to determine eligibility within 28 days prior to 
randomization. (see Study Design and Duration schema in Figure 2.1-1 below). Randomization 
will be stratified and balanced according to the following factors: histology (squamous vs.
non-squamous)/PD-L1 Status (positive vs. negative/unevaluable)/ ECOG Performance status 
(0 vs. 1). Approximately 100 PD-L1 unevaluable subjects will be randomized.
Treatment should be initiated within 3 business days of randomization. Nivolumab or docetaxel
(depending on randomized treatment arm) will be administered as an IV infusion over 60 minutes 
on Treatment Day 1. A treatment cycle is defined as 2 weeks for nivolumab and 3 weeks for 
docetaxel.
Subjects will be evaluated for response according to the RECIST 1.1 criteria. The first on treatment 
radiographic assessment will be obtained in both treatment arms at Week 6 (7 days). The 
subsequent radiographic assessments will be conducted every 6 weeks (7 days) for the first 12 
months (Week 48), then every 12 weeks (14 days) until disease progression (or until 
discontinuation of study therapy in patients receiving nivolumab beyond progression), lost to 
follow-up, withdrawal of study consent. Any subject who develops an objective tumor response 
per RECIST 1.1 (Complete Response or Partial Response) is required to undergo confirmatory 
scans at the next scheduled tumor assessment in the first year, and at least 4 weeks apart in the 
second and following year.
Subjects treated on the nivolumab arm will be allowed to continue study therapy after initial 
investigator-assessed RECIST 1.1-defined progression if they are assessed by the investigator to 
be deriving clinical benefit and tolerating study drug. Such subjects should discontinue study 
therapy when further progression is documented. After treatment discontinuation, subjects will 
have two follow-up visits for safety within the first 100 days from the last dose of study therapy. 
Beyond 100 days subjects will be followed for ongoing drug-related adverse events until resolved, 
return to baseline or deemed irreversible, or until loss of follow-up, withdrawal of study consent. 
All subjects will be followed for overall survival every 3 months until death, lost to follow-up or 
withdrawal of study consent.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
9
Figure 2.1-1:
Study Design
2.2
Treatment Assignment
Subjects are enrolled using the Interactive Voice Response System (IVRS) to obtain a subject ID. 
Subjects who have signed informed consent and met all eligibility criteria will be ready to be 
randomized through the IVRS, upon confirmation of receipt of required tissue sample by the 
central lab. The following information is required for subject randomization:

Subject number

Date of birth

Gender at birth

Date of informed consent

Histology (squamous vs. non-squamous): 

Subjects with mixed histology should be classified according to the predominant histology.

Subjects with adenosquamous histology should be classified as non-squamous histology

ECOG Performance status (0 vs. 1)

PD-L1 Status
The IVRS will randomly assign the subject in a 2:1 ratio to either Arm A (nivolumab) or Arm B 
(docetaxel), stratified by the following factors: 

Histology (squamous vs. non-squamous)

PD-L1 Status (positive vs. negative/ unevaluable)

ECOG Performance status (0 vs. 1)
The randomization will be carried out via permuted blocks within each stratum.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
10
2.3
Blinding and Unblinding
Not applicable. This is an open-label study.
2.4
Protocol Amendments
This SAP incorporates following protocol amendments.
 
 
 
 
 
 
 
 
 
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
11
Table 2.4-1:
Protocol Amendments
 
 
 
2.5
Data Monitoring Committee
A data monitoring committee (DMC) will be instituted for this study. This committee will provide 
independent oversight of safety and efficacy considerations, study conduct and risk-benefit ratio. 
Following review, the DMC will recommend continuation, modification, or discontinuation of this 
study based on reported safety and efficacy data. A separate DMC charter describes the members 
and activities of this committee, as well as the proposed meeting schedule. Representatives of the 
Sponsor will serve only as coordinators of the committee, without having full member 
responsibilities or privileges. In addition, the Sponsor will independently review safety data in a 
blinded manner during the conduct of this trial to ensure that any safety issues are identified and 
addressed.
3
OBJECTIVES
3.1
Primary

To demonstrate that the OS benefit of nivolumab in the study population with advanced or 
metastatic NSCLC after failure of prior platinum-based chemotherapy is consistent with 
benefit observed in global studies CheckMate 057 and CheckMate 017

To compare the OS of nivolumab versus docetaxel in subjects with advanced or metastatic 
NSCLC after failure of prior platinum-based chemotherapy.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
12
3.2
Secondary

To compare the objective response rate (ORR) of nivolumab vs. docetaxel

To compare progression-free survival (PFS) of nivolumab vs. docetaxel

To compare the time to treatment failure (TTF) of nivolumab versus docetaxel

To evaluate clinical efficacy (OS, ORR, and PFS) in different subgroups, including
squamous and non-squamous NSCLC subgroups, PD-L1 positive and PD-L1 negative protein 
expression subgroups, and Chinese and non-Chinese subgroups.

To evaluate rates of treatment related selected AEs and SAEs in nivolumab and docetaxel
arms.

To evaluate the proportion of subjects exhibiting disease-related symptom deterioration by
12 weeks and 24 weeks, as measured by LCSS, in nivolumab and docetaxel arms.
4
ENDPOINTS
4.1
Primary Endpoint
OS is defined as the time from randomization to the date of death. A subject who has not died will 
be censored at last known date alive.
Consistency in OS benefit is defined as maintaining 50% of the risk reduction of death from 
CheckMate 057 and CheckMate 017 after adjusting for the patient distribution and the use of anti-
PD-1/PD-L1 agents in the docetaxel arm. Method is described in detail in Section 5: Sample Size 
and Power
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
13
4.2
Secondary Endpoints
4.2.1
Objective Response Rate
Objective response rate (ORR) is defined as the number of subjects whose best objective response 
(BOR) is a confirmed CR or confirmed PR, as determined by the investigator, divided by the 
number of randomized subjects. BOR is defined as the best response designation, recorded 
between the date of randomization and the date of objectively documented progression per 
RECIST v1.1 or the date of subsequent anticancer therapy (excluding on-treatment palliative 
radiotherapy of CNS, skin or bone non-target lesions), whichever occurs first. For subjects without 
documented progression or subsequent anticancer therapy, all available response designations will 
contribute to the BOR determination. For subjects who continue treatment beyond progression, 
the BOR will be determined based on response designations recorded up to the time of the initial 
RECIST 1.1-defined progression.
4.2.2
Progression Free Survival
Progression-free survival (PFS) is defined as the time from randomization to the date of the first 
documented tumor progression as determined by the investigator using RECIST 1.1 criteria or 
death due to any cause. Clinical deterioration in the absence of unequivocal evidence of 
progression (per RECIST 1.1) is not considered progression for purposes of determining PFS. 
Subjects who die without a reported prior progression will be considered to have progressed on 
the date of their death. Subjects who did not progress or die will be censored on the date of their 
last evaluable tumor assessment. Subjects who did not have any on-study tumor assessments and 
did not die will be censored on the date they were randomized. Subjects who received any 
subsequent anti-cancer therapy (including on-treatment palliative RT of non-target bone lesions, 
skin lesions or CNS lesions) without a prior reported progression will be censored at the last 
evaluable tumor assessment prior to or on the date of initiation of the subsequent anti-cancer 
therapy.
Table 4.2.2-1:
Censoring Scheme for Primary Definition of PFS
Situation
Date of Progression or Censoring
Outcome
No baseline tumor assessments 
Randomization 
Censored
No on study tumor assessments and no 
death 
Randomization
Censored
New anticancer treatment started 
without a prior reported progression per 
RECIST 1.1  or death 
Date of last evaluable tumor assessment prior to 
or on the date of initiation of the subsequent 
anti-cancer therapy
Censored 
Progression per RECIST 1.1 
documented at scheduled or unscheduled 
visit and no new anticancer treatment 
started before
Date of the first documented tumor progression
Progressed
Subject progression free (per RECIST 
1.1)  and no new anticancer treatment 
started 
Date of last tumor assessment
Censored
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
14
Table 4.2.2-1:
Censoring Scheme for Primary Definition of PFS
Situation
Date of Progression or Censoring
Outcome
Death without prior progression per 
RECIST 1.1 and no new anticancer 
treatment started
Date of death
Progressed
4.2.3
Time to Treatment Failure
Time to Treatment Failure (TTF) is defined as the minimum of the time from randomization to the 
following dates:

disease progression date (RECIST or clinical)

death date

last dose date if subject discontinued from treatment for any reasons other than “maximum 
clinical benefit”, “administrative reasons by sponsor”. 
TTF is considered as event at the randomization date for subjects who were randomized but not 
treated. Clinical progression date is considered for time to treatment failure only when treatment 
is discontinued due to clinical disease progression. For nivolumab subjects treated beyond RECIST 
1.1 progression, the event will be at RECIST 1.1 progression date. TTF is censored at the last dose 
date for subjects who discontinued treatment (without RECIST 1.1 progression) due to maximum 
clinical benefit or administrative reason by sponsor. TTF is censored at the last dose date for 
subjects who continued on treatment without progression or death. TTF will be analyzed at the 
interim analysis of TTF only.
4.2.4
Disease related Symptom Deterioration Rate by Week 12 and Week 24
Disease-Related Symptom deterioration Rate by Week 12 and Week 24 is defined as the 
proportion of randomized subjects who had 10 points or more increase from baseline in Average 
Symptom Burden Index (ASBI) score at anytime between randomization and week 12 /week 24 
respectively. 
The LCSS is a measure of disease-related symptoms and quality of life suited to use in patients 
suffering from lung cancer. It includes six items measuring loss of appetite, fatigue, coughing, 
shortness of breath, hemoptysis, and pain. Three additional items measure overall symptom 
burden, disease-related functional limitations, and quality of life. The questionnaire uses a 24-hour 
recall period, and responses for each item are captured using a 100mm visual analog scale (VAS). 
Scores for individual items ranging from 0 (no symptomatology or highest quality of life) to 100 
(worst symptomatology or quality of life) are derived by dividing the length of the line drawn from 
the lowest possible response to the patient’s response by the length of the VAS and multiplying 
the resulting quotient by 100. An average symptom burden index (ASBI) score can be derived as 
the average of scores for the six symptom-related items with a clinically meaningful change in 
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
15
ASBI score being defined as 10 points. Accordingly, a meaningful deterioration in symptoms as 
measured by the ASBI is reflected in a mean post-baseline score change 10 points.
 
 
 
 
 
 
.
 
 
 
 
 
 
 
 
 
 
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
16
 
 
 
 
 
 
 
 
5
SAMPLE SIZE AND POWER
The sample size is calculated in order to compare the OS between subjects randomized to receive 
nivolumab and subjects randomized to receive docetaxel. Approximately 500 subjects will be 
randomized to the nivolumab and docetaxel arms in a 2:1 ratio. At least 382 deaths will be required 
for the final analysis of OS. A formal OS interim analysis will be conducted when at least 291
deaths (76% information fraction) have been observed. 
Simulations were run in R to calculate the power of the (weighted) log-rank test.
A mixed population was generated as follows: 500 subjects were randomly assigned to 3 cohorts 
with 40% squamous (SQ) subjects, 30% non-squamous (NSQ) PD-L1 positive subjects and 30% 
non-squamous (NSQ) PD-L1 negative subjects. 
Heterogeneity of treatment effects across histology (SQ vs. NSQ) and PD-L1 status subgroups was
considered with the assumptions as described below:

In the docetaxel treatment group, mOS was assumed to be 10 months for SQ and 
12 months for NSQ, as per Asian data.4,5,6,7,8,9 Exponential distributions of OS times were
assumed in both histologies.

For SQ subjects from nivolumab treatment group, a hazard ratio of 0.6 (mOS nivolumab vs. 
docetaxel: 16.7 vs. 10 months) and exponential distribution of OS times were assumed. 
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
17
Assumption on treatment effect was based on results from the Phase 3 study CA209017 
(HR: 0.59; 95% Condidence Interval (CI): 0.44 - 0.79). 

For NSQ subjects from nivolumab treatment group, non proportional hazard models was
assumed based on results from the Phase 3 study CA209057. Piecewise exponential models 
were used to model survival function. For the NSQ PD-L1 positive subjects, a 4-month delay 
effect (exponential distribution with mOS of 12 months) followed by an exponential 
distribution with mOS of 24 months was used in the model, providing an overall mOS of 
20 months. For the NSQ PD-L1 negative subjects, the piecewise exponential model was as 
followed: for the first 2 months, survival function was assumed to follow an exponential 
distribution with mOS of 5 months; after Month 2, an exponential distribution with mOS of 
OS 18 months, providing an overall mOS of 12.8 months.
Overall survival (OS) in all comers was compared between nivolumab and docetaxel, using a two-
sided log-rank test with a significance level of 5%. Fleming-Harrington (FH) weighted log-rank 
test was also used as as it is known to be more efficient for testing survival difference when a delay 
effect is present. The power of both the log-rank and FH weighted log-rank tests, using G (rho = 
0, gamma = 1) weights in the terminology of Fleming and Harrington was assessed. To control the 
overall Type I error rate under a two-sided 5%, significance levels of 0.020 and 0.044 were used 
at the interim and final analyses to decide if the study could be stopped for efficacy. These 
significance levels were calculated using the Lan-DeMets error spending function by East (version 
6). Hazard ratios (HR) were estimated using Cox proportional hazards model with treatment arm 
as the only covariate in the model.
At both IA OS and FA OS, a consistency check will be performed first followed by superiority 
test (hierarchical testing). Consistency was defined if the observed HR for OS maintains at least 
50% of the risk reduction of death in the global studies. The probability that the observe HR is not 
greater than the consistency HR threshold was calculated at both the interim and final analyses i.e. 
the probability that the simulated HR the consistency HR among all simulated trials.
The impact of crossover effect was considered. Power and hazard ratios were calculated assuming 
0%, 5%, 10%, 15% and 20% crossover rates in the control arm. For subjects in the control arm 
who were identified as crossover, their survival time were simulated based on the OS distribution 
of the treatment arm according to their histology and PD-L1 status
All results were generated by 5000 simulations. Accrual information used in the simulations had 
the same pattern as the actual data at time of the protocol amendment (500 subjects were accrued 
in 11 months).Simulation results are displayed in Table 5-1
In absence of cross over, IA OS (291 deaths) and FA OS (382 deaths) occurred approximately at 
24 months (13 months of minimum follow-up) and 37 months (26 months of minimum follow-up) 
respectively. Using the log-rank test, cumulative power was 73% and 96% and average HR was 
0.70 and 0.67 at the interim and final analyses, respectively. Power reached 86% and 98% 
accordingly with the weighted log-rank test. The Probability of Technical Success (PTS) for 
consistency check at the interim analysis was 95% (ie. the probability that the observed HR 
0.850). At the final analysis, probability of technical success for consistency check was 98% ( ie. 
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
18
probability that the observed HR 0.835 was 98%). PTS of the log-rank test decreases when cross-
over is present. PTS of the weighted log-rank test decreases as well but less than the conventional 
log-rank test. PTS for consistency check remains above 90% for crossover rates up to 20%.
Table 5-1:
Simulations results
No 
Crossover
5% 
Crossover
10% 
Crossover
15% 
Crossover
20% 
Crossover
Events at IA/FA
291/382
291/382
291/382
291/382
291/382
Timing for IA/FA 
(months)
24/37
24/38
24/38
24/38
24/38
Expected HRs at IA/FA
0.70/0.67
0.71/0.69
0.73/0.71
0.74/0.72
0.75/0.73
Consistency HR 
thresholds at IA/FA 
(maintaining 50% of risk 
reduction)
0.850/0.835
0.855/0.845
0.865/0.855
0.870/0.860
0.875/0.865
PTS for log-rank test at 
IA/FA
73%/96%
69%/94%
63%/90%
59%/86%
53%/82%
PTS for weighted log-
rank test at IA/FA
86%/98%
82%/97%
77%/94%
72%/91%
67%/88%
PTS for consistency 
check
95%/98%
93%/98%
93%/97%
91%/96%
90%/94%
After the first ~380 randomized subjects have been followed for at least 8 months 
(approx. 16 months after study initiation), TTF is to be compared across treatment groups using a 
weighted log-rank test10,11. With one-sided type 1 error of 0.025, the power for the weighted log-
rank test of TTF was ~95% per simulations using data observed in global pivotal studies 
(CheckMate 057 and 017), and , adjusted for the proportion of SQ and NSQ in this study. Expected 
HR for TTF was 0.7.
6
STUDY PERIODS, TREATMENT REGIMENS AND POPULATIONS FOR 
ANALYSES
6.1
Study Periods
See Core Safety SAP.
6.2
Treatment Regimens
The treatment group “as randomized” will be retrieved from the IVRS system

Arm A: Experimental arm (monotherapy) nivolumab

Arm B: Control arm docetaxel
The treatment group “as treated” will be the same as the arm randomized by IVRS. However, if 
a subject received the incorrect drug for the entire period of treatment, the subject’s treatment 
group will be defined as the incorrect drug the subject actually received.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
19
6.3
Populations for Analyses

All enrolled subjects: All subjects who signed an informed consent form and were registered 
into the IVRS. Analyses of the patients enrolled into the study but not randomized and the 
reason for not being randomized will be performed on the data set of all enrolled subjects.

All randomized subjects: All subjects who were randomized to any treatment group in the 
study. This is the primary dataset for analyses of demography, protocol deviations, baseline 
characteristics, efficacy, outcome research.

TTF population: All randomized subjects with at least 8 months of follow-up at clinical 
database cutoff date of TTF interim analysis (~380 subjects). This dataset will be used for all 
ITT analyses at the TTF IA. 

All treated subjects: All subjects who received at least one dose of nivolumab or docetaxel. 
This is the primary dataset for dosing and safety.

Treated subjects among TTF population: This is the primary dataset safety and exposure 
analyses on the treated subjects among TTF population.

All responders: randomized subjects with CR or PR

Response evaluable subjects: randomized subjects whose change in the sum of diameters of 
target lesions was assessed (ie.: target lesion measurements were made at baseline and at at 
least one on-study tumor assessment).

PK subjects: All subjects with available serum time-concentration data from randomized 
subjects dosed with nivolumab.

Immunogenicity subjects: See Core Safety SAP.

Biomarker subjects: All randomized subjects who had available biomarker data
7
STATISTICAL ANALYSES
7.1
General Methods
Unless otherwise noted, the bulleted titles in the following subsections describe tabulations of 
discrete variables, by the frequency and proportion of subjects falling into each category, grouped 
by treatment (with total). Percentages given in these tables will be rounded and, therefore, may not 
always sum to 100%. Continuous variables will be summarized by treatment group (with total) 
using the mean, standard deviation, median, minimum and maximum values.
Time to event distribution (i.e. time to treatment failure, progression free survival, overall survival 
and duration of response) will be estimated using Kaplan Meier techniques. 
Median survival time along with 95% CI will be constructed based on a log-log transformed CI 
for the survivor function S(t)12,13. Rates at fixed timepoints (e.g. OS at 6 months) will be derived 
from the Kaplan Meier estimate and corresponding confidence interval will be derived based on 
Greenwood formula14 for variance derivation and on log-log transformation applied on the 
survivor function S(t)15.
Unless otherwise specified, the stratified log-rank test will be performed to test the comparison 
between time to event distributions. Stratification factors will be prior use of histology (squamous 
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
20
vs. non-squamous)/ PD-L1 Status (positive vs. negative/unevaluable)/ ECOG Performance status 
(0 vs. 1), as entered into the IVRS.
Unless otherwise specified, the stratified hazard ratio between 2 treatment groups along with CI 
will be obtained by fitting a stratified Cox model with the treatment group variable as unique 
covariate. Stratification factors will be same as above.
The difference in rates between the two treatment arms along with their two-sided 95% CI will be 
estimated using the following Cochran-Mantel-Haenszel (CMH) method of weighting16, adjusting 
for the stratification factors:
^
2
^
2
(1
)
(1
)
1
1
~
,
iy
iy
ix
ix
i
i
i
i
ix
iy
i
i
i
i
i
p
p
p
p
w
w
n
n
N
w
w









































where 
^
ix
iy
p
p


is the rate difference of the ith stratum,
ix
iy
i
ix
iy
n n
w
n
n


, and 
ix
n and 
iy
n are the 
number of subjects randomized to treatments x and y, respectively, in the ith stratum.
Stratification factors will be the same as above. Associated odds-ratio will be derived.
The p-values from sensitivity analyses for efficacy endpoints are for descriptive purpose only and 
not adjusted for multiplicity.
7.2
Study Conduct
Unless otherwise specified, study conduct analyses at the TTF analysis timepoint will be 
performed using the TTF population. At the formal OS analysis timepoints, analyses will be 
conducted using the all randomized population.
7.2.1
Accrual
The accrual pattern will be summarized per country, investigational site and per month for all 
enrolled subjects. Randomization date, first dosing date, country, investigational site will be 
presented in a by subject listing of accrual.
7.2.2
Relevant Protocol Deviations
The relevant Protocol Deviations will be summarized, by treatment group and overall. The 
following programmable deviations from inclusion and exclusion criteria will be considered as 
relevant protocol deviations. Non-programmable relevant eligibility and on-treatment protocol 
deviations, as well as significant (both programmable and non-programmable) eligibility and on-
treatment protocol deviations will be reported through ClinSIGHT listings.
At Entrance:
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
21

Subjects who received first-line treatment but not with platinum doublet chemotherapy. 

Subjects who didn’t receive first-line treatment.

Subjects with known EGFR mutation or ALK rearrangement. 

Subjects who received prior treatment with docetaxel.

Subjects without measurable disease at baseline.

Subject with baseline ECOG PS > 1.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
22
On-study:

Subjects receiving concurrent anti-cancer therapy (defined as chemotherapy, hormonal 
immunotherapy, radiation therapy, standard or investigational agents for treatment of 
NSCLC). 

Subjects treated differently as randomized (subjects who received the wrong treatment, 
excluding the never treated).
A subject listing will also be produced.
7.3
Study Population
Unless otherwise specified, study population analyses at the formal TTF analysis timepoint will 
be performed on the TTF population . At the formal OS analysis timepoints, analyses will be 
performed on the all randomized population.
7.3.1
Subject Disposition
The total number of subjects enrolled (randomized or not randomized) will be presented along 
with the reason for not being randomized.
Number of subjects randomized will be presented along with reason for not being treated. 
Days from Randomization to first dose date (3, 4 - 5, 6-7, 8-14, 15 - 21, > 21 days) will be 
tabulated for all treated subjects.
Number of treated subjects by study treatment discontinuation status will be tabulated along with 
reason for treatment discontinuation.
The current status of follow-up for overall survival will be summarized for all randomized subjects. 
Subjects count by for time from date of last contact to last patient last visit will be presented using 
the following categories: 0, 1 - 30, 31 - 60, 61 - 90, 91 - 120, 121 - 150, > 150 days. Subjects who 
have died will categorized as having an event at day 0. For subjects with last known date alive 
after data cut-off date, they will have zero value for currentness of follow-up as well.
7.3.2
Demographics and Other Baseline Characteristics
The following baseline characteristics will be summarized by treatment arm as randomized. All 
baseline presentations identify subjects with missing measurements. Listings will also be provided.
Source is CRF.

Age (descriptive statistics).

Age category (< 65, 65 - < 75, 75, 65).

Gender (male/female)

Race (White/Black/Asian/Other )

Region (Asia vs. Europe).

Country (China (split by China Mainland/Hong Kong), Singapore, Russia) 
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
23

Baseline ECOG Performance Status 

Weight (Kg)..

Smoking Status (current/former smoker, never smoker, unknown)

Cell Type (Squamous cell carcinoma, Adenocarcinoma, Large cell carcinoma, Other-specify)

Time from Initial Disease Diagnosis to Randomization (< 1 year, 1-< 2 year, 2 - < 3 year, 
3 - < 4 year, 4 - < 5 year, 5 year).

Disease stage at study entry (stage IIIB, stage IV, recurrent)

EGFR mutation status, ALK translocation status, KRAS mutation status.

All lesions (Investigator Tumor Assessments at Baseline): sites of disease, number of disease 
sites per subject.

Target Lesions (Investigator Tumor Assessments at Baseline): Presence of target lesions, site 
of target lesion, sum of diameters of target lesions.

CNS metastases (yes/no).
7.3.3
Medical History
General medical history will be listed by subject and pretreatment events will be tabulated. 
7.3.4
Prior Therapy Agent
Prior anti-cancer therapy will be summarized as follows:

Number of lines of prior systemic cancer therapy received (1, 2, > 2)

Number of Subjects who received prior maintenance therapy

Prior systemic therapy regimen setting (number of subjects who received adjuvant therapy, 
neo-adjuvant therapy, number of subjects who received regimen with metastatic setting)

Prior systemic cancer therapy summary (by agent)

Best response to most recent prior systemic therapy regimen (CR/PR, SD, PD, Unknown or 
Not reported)

Time from completion of most recent prior systemic therapy regimen to randomization 
(< 3 months, 3 - 6 months, > 6 months)

Time from completion of prior adjuvant/neo adjuvant to randomization (< 6 months, 
6 months) 

Prior surgery related to cancer (yes, no, not reported)

Prior radiotherapy (yes, no, not reported)
Prior systemic therapy will be classified by therapeutic class and generic name.
Other Prior therapy:

Prior/current non-study medication classified by anatomic and therapeutic classes.
Agents and medication will be reported using the generic name. A listing by subject will also be 
provided.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
24
7.3.5
Baseline Examinations
Subjects with abnormal baseline physical examination will be tabulated by examination criteria 
and by treatment group.
7.3.6
Discrepancies between IVRS and CRF Stratification Factors
Summary tables (cross-tabulations) by treatment group for the following stratification factor will 
be provided to show any discrepancies between what was reported through IVRS vs. CRF data 
(baseline).

ECOG Performance Status: 0 vs. 1

Histology: Squamous , Non-Squamous
PD-L1status (Positive vs. Negative/unevaluable) and PD-L1 expression will be reported as entered 
into the IVRS.
Frequency of PD-L1 Status at baseline (Source: IVRS) will be summarized using 3 pre-specified 
PD-L1 expression cutoff values (1%, 5% and 10%). 

PD-L1 Positive: subjects with baseline PD-L1 expression x% cutoff value

PD-L1 Negative: subjects with baseline PD-L1 expression < x% cutoff value and 0% 

PD-L1 Unevaluable: subjects with no quantifiable PD-L1 expression at baseline. 
7.4
Extent of Exposure
Extent of exposure analyses will be performed by treatment group “as treated”. The primary 
population at theTTF analysis will be the Treated subjects among TTF population. The population 
at the formal OS analyses will be the all treated population. 
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
25
7.4.1
Administration of Study Therapy
The following parameters will be summarized (descriptive statistics) by treatment group:

Relative dose intensity (%) using the following categories: < 50%; 50 - < 70%; 70 - < 90%; 90 
- < 110%; 110%. 

Number of doses received (summary statistics).

Cumulative dose 
Duration of treatment will be presented by treatment group using a Kaplan-Meier curve whereby 
the last dose date will be the event date for those subjects who are off study therapy. Median 
duration of treatment and associated 95% CI will be provided. Subjects who are still on study 
therapy will be censored on their last dose date.
A by-subject listing of dosing of study medication (record of study medication, infusion details, 
dose change) and a listing of batch number will be also provided.
Below table summarizes the key parameters used to calculate dosing data.
Table 7.4.1-1:
Administration of Study Therapy: Definition of Parameters
Nivolumab
Docetaxel
Dosing schedule 
per protocol
3mg/kg every 2 weeks 
75mg/m² every 3 weeks 
Dose
Dose (mg/kg) is defined as total dose 
administered (mg)/most recent weight (kg). 
Dose administered in mg at each dosing date 
and weight are collected on the CRF.
Dose (mg/m²) is is defined as total dose 
administered (mg)/most recent BSA. Dose 
administered in mg at each dosing date and 
BSA (computed using recent weight and 
baseline height) are collected on the CRF.
Cumulative Dose
Cum dose (mg/kg) is sum of the doses 
(mg/kg) administered to a subject during the 
treatment period.
Cum dose (mg/m²) is sum of the doses 
(mg/m²) administered to a subject during the 
treatment period.
Relative dose 
intensity (%)
Cum dose (mg/kg) / [(Last dose date - Start 
dose date + 14) 3 / 14 ] 100]
Cum dose (mg/m²) / [(Last dose date - Start 
dose date + 21) 75 / 21 ] 100]
Duration of 
treatment  
Last dose date - Start dose date + 1
Last dose date - Start dose date + 1
7.4.2
Modifications of Study Therapy
7.4.2.1
Dose Delays
A dose will be considered as actually delayed if the delay is exceeding 3 days (i.e., greater than or 
equal to 4 days from scheduled dosing date) for both nivolumab and docetaxel. It is defined as 
(duration of previous cycle in days -14) for nivolumab (or -21 for docetaxel). Dose delays will be 
divided into following categories: on-time, 4 - 7 days, 8 - 14 days, 15 - 42, > 42 days. Reason for 
dose delay will be retrieved from CRF dosing pages.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
26
Each nivolumab or docetaxel infusion can be interrupted and/or the IV infusion rate can be 
reduced. This information will be retrieved from CRF dosing pages.
The following parameters will be summarized by treatment arm:

Number of dose delayed per subject, Length of Delay and Reason for Dose Delay.

Number of subject with at least one dose infusion interrupted along with reason for the 
interruptions and number of infusions interrupted per subject.
7.4.2.2
Dose Reductions
There will be no dose escalations or reductions of nivolumab allowed. Subjects may be dosed no 
less than 12 days from the previous dose.
Each nivolumab or docetaxel infusion can be interrupted and/or the IV infusion rate can be 
reduced. This information will be retrieved from CRF dosing pages.
Dose of Docetaxel may be modified for toxicity. Subjects may be dosed no less than 19 days from 
the previous dose. 
Dose levels of docetaxel are defined in the protocol as follows:

Dose level -1: 55mg/m².

Dose level -2: 37.5mg/m².
For any cycle (excluding Cycle 1), it will be defined as a dose reduction if the observed dose level 
(based on calculated administered dose) is below the dose level of the previously administered 
dose. Dose ranges for dose levels of docetaxel are defined in Table 7.4.2.2-1.
Table 7.4.2.2-1:
Calculated Dose Ranges and Related Dose Levels of Docetaxel
Dose Range (mg/m2)
Dose Level
65
Level 0
45 - < 65
Level -1
< 45
Level -2
The reason for dose reduction as reported by the investigator will be tabulated for all instances of 
dose reduction based on the Dose Change CRF page. A category ‘Unknown’ will be defined for 
all reductions with no reason reported by the investigator.
The following will be summarized by treatment group:

Number of subjects with at least one infusion with IV rate reduced along with the reason of 
the rate reduction.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
27
The following will be summarized for docetaxel subjects:

Number and percentage of subjects with at least one dose reduction and reason of the dose 
reduction, number and percentage of subjects with a dose reduction to dose level -1, number 
and percentage of subjects with a dose reduction to dose level -2.
7.4.3
Concomitant Medications
Concomitant medications, defined as medications other than study medications which are taken at 
any time on-treatment (i.e. on or after the first day of study therapy and within 100 days following 
the last dose of study therapy), will be coded using the WHO Drug Dictionary.
The following summary tables will be provided: 

Concomitant medications (subjects with any concomitant medication, subjects by medication 
class and generic term).
A by-subject listing will accompany the table.
7.5
Efficacy
Efficacy analyses at the TTF analysis timepoint will be performed on the TTF population. At the 
formal OS analysis timepoints, analyses will be performed on the all randomized population.
7.5.1
Overall Survival
7.5.1.1
Primary Analysis
OS is the primary endpoint of this study. 
At both the interim OS analysis and final OS analysis, a 2-step hierarchical testing will be 
performed. First, a check for consistency in HR for OS will be performed. This is to mitigate loss 
of power due to confounding effects of cross-over (subjects receiving anti PD-1/PD-L1 agents in 
the comparator arm). 
If consistency in OS with global data is demonstrated, superiority for OS will be tested. The 
distribution of OS will be compared in two randomized arms via a two-sided, using a two-sided 
(adjusted for the interim) weighted log-rank test stratified by histology (squamous vs. non-
squamous)/ PD-L1 Status (positive vs. negative/unevaluable)/ ECOG Performance status (0 vs.
1)., as entered into the IVRS. The weighted log-rank test will use G (rho = 0, gamma = 1) weights, 
in the terminology of Fleming and Harrington10,11.
The unweighted hazard ratio (HR) and the corresponding 100(1-)% CI (adjusted for the interim) 
will be estimated in a stratified Cox proportional hazards model using randomized arm as a single 
covariate with the same stratification factors mentioned above.
The OS curves for each treatment group will be estimated using the Kaplan-Meier (KM) product-
limit method. Two-sided, 95% confidence intervals for median OS will be constructed based on a 
log-log transformed CI for the survivor function S(t) 12,13. 
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
28
Survival rates at 6, 12, 18, 24, 36, 48 months and at 5 year will also be estimated using KM 
estimates on the OS curve for each randomized arm. Minimum follow-up must be longer than
timepoint to generate the rate. Associated two-sided 95% CIs will be calculated using the 
Greenwood’s formula14 for variance derivation and on log-log transformation applied on the 
survivor function S(t)15. 
The status of subjects who are censored in the OS Kaplan-Meier analysis will be tabulated for each 
treatment group using following categories:

on-study (on-treatment and not progressed, on-treatment progressed, in follow-up);

off-study: (lost to follow-up, withdraw consent, etc.).
To examine the assumption of proportional hazards in the Cox regression model, in addition to 
treatment, a time-dependent variable defined by treatment by time interaction will be added into 
the model. A two-sided Wald Chi-square p-value of less than 0.1 may indicate a potential 
nonconstant treatment effect. In that case, additional exploratory analyses may be performed.
7.5.1.2
OS Sensitivity Analyses
The following OS sensitivity analyses will be performed. 

OS will be compared between treatment groups using a two-sided (adjusted for the interim) 
stratified regular log-rank test. 

OS will be compared between treatment groups using a two-sided (adjusted for the interim) 
unstratified regular log-rank test. 

OS will be compared between treatment groups using a two-sided (adjusted for the interim) 
stratified regular log-rank test, and using the strata as determined at baseline (CRF source). 
This analysis will be performed only if at least one stratification variable at IVRS and at 
baseline disagrees for at least 10% of the randomized subjects.

OS will be compared between treatment groups using a two-sided (adjusted for the interim) 
stratified regular log-rank test in the All Treated Subjects population, using arm as randomized. 
This analysis will be performed only if the proportion of randomized but never treated subjects 
exceeds 10% in any arm.

OS will be compared between treatment groups using a two-sided (adjusted for the interim) 
stratified regular log-rank test, but censoring in chemo arm, subjects at the subsequent use of 
anti PD(L)1.
Estimate of the hazard ratio, its two sided 100(1-)% CI (adjusted for the interim) and p-value will 
be presented.

OS distribution will be compared bewteen treatment groups using stratified log-rank test 
limited to the first 291 deaths. Kaplan-Meier curves will be produced and stratified HR along 
with the two sided 100(1-)% CI (adjusted for 291 deaths) will be computed.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
29
7.5.1.3
Consistency of Treatment Effect on OS in Subsets
To assess consistency of treatment effects in different subsets, a “forest” plot of the OS unstratified 
hazard ratio (and 95% CI) will be produced for the following subgroups. 

Age categorization (< 65, 65 - < 75, 75, ).

Gender (male, female).

Race (White, Asian, Other).

Chinese / Non-Chinese., based on country (Chinese = from China Mainland or Hong-Kong)

Baseline ECOG PS (0 vs. 1).

Smoking status (CURRENT/FORMER vs. NEVER SMOKED vs. unknown).

Histology (SQ vs. NSQ) - per CRF

PD-L1 status at baseline using 1% cutoff

Disease Stage at study entry (stage IIIB vs. stage IV/recurrent)

Time from initial diagnosis to randomization (< 1 year vs. other)).

Time from completion of most recent prior systemic therapy regimen to randomization: 
< 3 months, 3-6 months, > 6 months, unknown. 

Prior maintenance therapy (yes vs. no).

Best response to most recent prior regimen (responders (CR/PR) vs. non responders (SD vs. 
PD) vs. UTD/NA)

CNS metastases (yes/no).
If subset category has less than 10 subjects per treatment group, HR will not be 
computed/displayed. Number of events and median OS along with 95% CI will be displayed for 
each treatment group.
7.5.1.4
Multivariate Analysis
A multivariate stratified (by histology (squamous vs. non-squamous), PD-L1 Status (positive vs.
negative/unevaluable), ECOG Performance status (0 vs. 1) as entered in the IVRS) Cox model will 
be fitted to assess the treatment effect on OS when adjusted for potential prognostic factors. The 
following potential prognostic factors will be included in the model.

Time from initial diagnosis to randomization (< 1 year (yes vs. other))

Age categorization (< 65, 65)

Gender (Male vs. Female)

Smoking status (yes vs. no or unknown)

Disease Stage at study entry (stage IIIB vs. stage IV/recurrent)
HR and 95% CI will be provided for treatment variable and all covariates. Descriptive p-values 
will be provided.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
30
7.5.1.5
Subject Follow-up for OS
The minimum follow-up will be reported. The minimum follow-up is defined as the time interval 
between the last patient’s randomization date and the clinical cutoff date.
The extent of follow-up defined as the time between randomization date and last known date alive 
(for subjects who are alive) or death date (for subjects who died) will be summarized descriptively 
(median, min, max) for all subjects randomized.
The currentness of follow-up, defined as the time between last OS contact (i.e., last known date 
alive or death date) and data cut-off date, will be summarized by treatment group. Subjects who 
died before data cut-off date will automatically have zero value for currentness of follow-up. For 
subjects with last known date alive after data cut-off date, they will have zero value for currentness 
of follow-up as well. The currentness of follow-up will be categorized into the following 
categories: 0 days, 1-3 months, 3-6 months, 6-9 months, 9-12 months and months. 
7.5.1.6
Follow-up Therapy
Subsequent therapies will be summarized and listed.

Subsequent Therapy

Immunotherapy (anti-PD1, anti PDL1, anti-CTLA4 and other Immunotherapy, by drug 
name)

Targeted Therapy (ALK/EGFR Tyrosine kinase inhibitors, VEGFR Inhibitors, other, by 
drug name)

Chemotherapy by drug name

Other investigational agent by drug name

Surgery

Radiotherapy

Any combination of the above

By Subject Listing of Subsequent Therapy
7.5.1.7
Analysis of Survival by Tumor Response
Survival by response category will be analyzed by arm using the landmark method17. Subjects still 
on study at the landmark time will be separated into two response categories according to whether 
they have responded before that time. This will assess whether survival from the landmark depends 
on the subject's response status at the landmark. Subjects who go off protocol (e.g. subjects who 
die) before the time of landmark will be excluded from the analysis.
The survival curves from Week 9, Month 4, Month 6, Month 8, Month 12, by response status, for 
each randomized arm will be produced using the KM product-limit method. Two sided, 95% 
confidence intervals for median OS will be constructed based on a log-log transformed CI for the 
survivor function S(t).
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
31
7.5.1.8
OS Analysis at time of TTF analysis
OS won’t be analyzed at time of interim analysis of TTF.
7.5.2
Objective Response Rate
7.5.2.1
Primary Analysis of ORR
BOR will be summarized by response category for each treatment group. ORR will be computed 
in each treatment group along with the exact 95% CI using Clopper-Pearson method18.
An estimate of the difference in ORRs and corresponding 95% CI will be calculated using CMH 
methodology and adjusted by the same stratification factors as for primary analysis of OS.
In addition, the stratified (source: IVRS) odds ratios (Mantel-Haenszel estimator) between the 
treatments will be provided along with the 95% CI. The difference will be tested via the Cochran
Mantel-Haenszel (CMH) test using a two-sided, 5% level.
To assess consistency of treatment effect on ORR in different subsets, ORR will be computed 
across the same subsets as defined in the OS analysis, including squamous and non-squamous 
subgroups, PD-L1 positive and PD-L1 negative protein expression subgroups, and Chinese and 
non-Chinese subgroups (see Section 7.5.1.3).
7.5.2.2
Sensitivity Analyses of ORR
If one stratification variable at IVRS and at baseline (CRF) disagrees for at least 10% of the 
randomized subjects, similar analysis of ORR as primary analysis will be performed using the 
strata as determined at baseline.
7.5.2.3
Duration of Objective Response
Duration of response in each treatment group will be estimated using KM product-limit method 
for subjects who achieve PR or CR. Duration of stable disease will also be estimated in each 
treatment groups using KM product-limit method for subjects with SD as best response. Median 
values along with two-sided 95% CI will be calculated. Summary statistics will be computed 
constructed based on a log-log transformed CI for the survivor function S(t).
7.5.2.4
Time to Objective Response
Summary statistics of time to objective response will be provided for each treatment group for 
subjects who achieve PR or CR. 
To assess further tumor response kinetics, time to response will be analyzed using the KM 
methology, for all randomized subjects. Kaplan-Meier curve will represent the cumulative rate of 
response over time. For the non-responders, time to response will be censored at the maximum 
time of response + 1 day of all subjects in their respective treatment group. Cumulative Response 
Rates will be tabulated for Week 9, Month 4, 6, 8, and 12, and overall Response Rate will be 
provided for each treatment group.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
32
7.5.2.5
ORR Analysis at time of TTF analysis
At the TTF analysis, BOR will be summarized by response category for each treatment group. 
ORR will be computed in each treatment group along with the exact 95% CI using Clopper-
Pearson method. Population for analysis will be the TTF population. Additionally analyses will be 
repeated using the Chinese subjects among the TTF population, and ORR will also be assessed by 
histology and, by PDL1 status at baseline (using cutoff at 1%, 5% and 10%) . TTR and DOR will 
be evaluated for responders (i.e. subjects with confirmed CR or PR) of the TTF population.
7.5.3
Progression Free Survival
7.5.3.1
Primary Analysis of PFS
PFS for each treatment arm will be estimated using Kaplan-Meier product limit method and 
graphically displayed. A two-sided 95% CI for median duration will be constructed based on a 
log-log transformed CI for the survivor function S(t).
The comparison of PFS distribution will be performed via a stratified log-rank test at two-sided, 
5% level. In addition, the stratified hazard ratios between treatment groups will be provided along 
with the 95% CI. 
PFS rates at 6, 12, 18, 24, 36, 48 months and at 5 year will also be estimated using KM estimates 
on the PFS curve for each randomized arm. Minimum follow-up must be longer than or equal to 
timepoint to generate the rate. Associated two-sided 95% CIs will be calculated using the 
Greenwood’s formula14. 
The source of progression (death vs. progression) will be summarized by treatment group.
The status of subjects who are censored in the PFS Kaplan-Meier analysis will be tabulated for 
each treatment group using following categories:

Never treated

On-study (on treatment, in follow-up) 

Off-study: (lost to follow-up, withdrew consent, other).

Received subsequent anti-cancer therapy

No baseline tumor assessment
To assess consistency of treatment effect on PFS in different subsets, a “forest” plot of the PFS 
unstratified hazard ratio (and 95% CI) will be produced for the same variable as in the OS analysis.
7.5.3.2
Sensitivity Analyses of PFS
Sensitivity analyses of PFS will also be performed using the following modification of PFS 
primary definition.

PFS will be compared between treatment groups using the strata as determined at baseline
(CRF source). This analysis will be performed only if at least one stratification variable at 
IVRS and at baseline disagrees for at least 10% of the randomized subjects.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
33

PFS accounting for assessment after subsequent therapy subjects will be defined similarly to 
the primary definition except that events (progression or death) and tumor assessments that 
occurred on or after subsequent anticancer therapy will be taken into account.

PFS accounting for missing tumor assessment prior to PFS event (progression or death). This 
analysis will be performed only if at least 20% of events have missing prior tumor assessment. 
It will apply the following restriction to the primary definition: If the elapsed time between the 
PFS event and the last on-study assessment immediately prior to the event (or randomization 
date if no on-study scan) is two or more missed visits (more than 12 weeks + 10 days), the 
subject will be censored at his last tumor assessment prior to the PFS event (or randomization 
date if no on-study scan).

PFS accounting for assessment after on-treatment palliative radiotherapy on skin, bone or 
CNS non-target lesions. This analysis is similar to the primary analysis except that no 
censoring will occur for on-treatment palliative radiotherapy.
7.5.3.3
PFS Analysis at time of TTF analysis
PFS won’t be analyzed at time of interim analysis of TTF.
7.5.4
Hierarchy for Key Secondary Efficacy Endpoints
In order to preserve an experimental-wise type I error rate at 5%, a pre-planned hierarchy for key 
secondary ORR and PFS endpoints will be applied when interpreting the statistical significance of 
treatment comparisons. The hierarchical ordering of the key secondary endpoints is as follows:
1) Objective Response Rate 
2) Progression-Free Survival
The statistical testing will be carried out using the following sequential procedure:

If superiority of OS is demonstrated at interim or final OS analysis or if consistency of 
treatment effect in OS with global data is demonstrated at OS final analysis , the secondary 
endpoint with the highest ranking in the hierarchy will be tested (ORR in this case). If the p-
value of ORR is statistically significant at 5% level, the second highest ranking endpoint in the 
hierarchy will be tested (PFS in this case) and the p-value of PFS will be provided. If the p-
value of ORR is not statistically significant at 5% level, then no further statistical testing 
regarding the other secondary endpoint (i.e., PFS) will be conducted. Estimates (medians and 
HR) and their 95% CI will be provided for PFS regardless of the outcome of ORR testing. 

If not, then no further statistical testing regarding the secondary endpoints will be conducted. 
However estimates along with their 95% CI will be provided for those (i.e. medians and HR, 
rates and odds ratio).
7.5.5
Other Efficacy Analyses
The following subject-level graphics will also be provided by treatment group as randomized: 

For the responders only, time courses of the following events of interest will be graphically 
displayed: tumor response, tumor progression, last dose received, and death.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
34

For response evaluable subjects, a waterfall plot showing the best reduction in target lesion 
will be produced. 
7.5.6
TTF Interim Analysis
A Time to Treatment Failure (TTF) interim analysis is planned after the first ~380 randomized 
subjects have been followed for at least 8 months (TTF population). This is projected to occur 
approx. 16 months after study initiation. 
The DMC will review the safety and efficacy data from the TTF interim analysis. There is no alpha 
spending nor penalty for TTF analysis: this interim analysis is considered as a bridging strategy. 
If TTF is statistically significant at 1-sided 0.025 level, study conduct, study population, exposure, 
safety (including death summary) and ORR will be described (no formal comparison) using the 
TTF population (see section 7.5.2.5 ) .
Regardless of TTF is positive or negative, study will continue until the planned OS interim/final
analysis.
The distribution of TTF will be compared in the two randomized arms via a 1-sided, weighted log-
rank test (unstratified). The one-sided weighted log-rank p-value will be reported using G (rho = 
0, gamma = 1) weights, in the terminology of Fleming and Harrington10,11. The FH method (with 
rho=0 and gamma=1) leads to a loss of power if treatment effect is not delayed but higher power 
starting with approximately a 2 month delay in treatment effect and increases as the delay 
increases. Distribution of TTF will also be tested using regular (unweighted) log-rank test.
The hazard ratio (HR) and the corresponding 2-sided 95% CI upper bound will be estimated in an 
unstratified cox proportional hazards model using randomized arm as a single covariate. The TTF 
curves for each treatment group will be estimated using the Kaplan-Meier (KM) product-limit 
method. Two-sided, 95% confidence intervals for median TTF will be constructed based on a log-
log transformed CI for the survivor function S(t) 12,13. 
7.5.6.1
Sensitivity Analyses
The following TTF sensitivity analyses will be performed. 

Sensitivity analysis will be conducted 

1-ignoring events of treatment discontinuation for reason due to patient preference (subject 
withdrew consent, subject lost to follow up) or physician withdrawal (subject no longer 
meets study criteria, administrative reason by sponsor)

2-censoring the TTF at randomization for subjects who were randomized but never treated.

TTF KM curves by treatment group will be produced for Chinese subjects from the TTF 
population (HR and 95% CI, median TTF and 95% CI will be presented)
7.5.7
OS Interim Analysis
A formal interim analysis for superiority of OS in subjects who were randomized to nivolumab vs. 
subjects who were randomized to docetaxel will be performed on all randomized subjects when at 
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
35
least 291 deaths have been observed (approximately 76% (291/382) of the total number of deaths 
required for the final analysis).
This OS comparison will be tested using the interim monitoring feature of EAST software based 
on a generalization of the Lan-DeMets error spending function approach using an O’Brien-
Fleming stopping boundary to reject H0, controlling for a two-sided overall of 5%. For example, 
if exactly 291 deaths are in the locked database at the interim analysis, H0would be rejected if the 
p-value from the log-rank test is p < 0.020. If the number of deaths is not exactly 291 at the time 
of the interim analysis, the nominal critical point and value of both the interim and final analyses 
will be calculated based upon the observed information fraction. 
The DMC will review the safety and efficacy data from the interim analyses and will determine if 
the study should continue or should be stopped. If the trial is stopped for superiority at the interim, 
the p-value will be considered as the final OS result. All secondary endpoint analyses will be tested 
at that time. The p-values from these analyses will be considered as the final results. See Section 
7.5.4 for type I error control for secondary endpoints.
If the study continues beyond the interim analysis and exactly 382 deaths are in the locked database 
at the final analysis, H0 would be rejected if the p-value from the log-rank test is 
p < 0.044. All events in the database at the time of the lock will be used. If number of final events 
exceeds the number specified per protocol, final boundary will not be recalculated using updated 
information fraction at interim.
7.6
Safety
Safety analyses will be performed by treatment group “as treated”. The primary population at 
theTTF analysis will be the Treated subjects among TTF population. The population at the formal 
OS analyses will be the all treated population. 
7.6.1
Deaths
See Core Safety SAP
7.6.2
Serious Adverse Events
See Core Safety SAP
7.6.3
Adverse Events Leading to Discontinuation of Study Therapy
See Core Safety SAP
7.6.4
Adverse Events Leading to Dose Delay of Study Therapy
See Core Safety SAP
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
36
7.6.5
Adverse Events
See Core Safety SAP
7.6.6
Adverse Events by Subgroups
See Core Safety SAP
7.6.7
Multiple Events
See Core Safety SAP
7.6.8
Adverse Events of Special Interest
See Core Safety SAP
7.6.9
Clinical Laboratory Evaluations
The analysis population for each laboratory test is restricted to treated subjects who underwent that 
laboratory test.
7.6.9.1
Hematology
See Core Safety SAP
7.6.9.2
Serum Chemistry
See Core Safety SAP
7.6.10
Vital Signs and Pulse Oximetry
See Core Safety SAP
7.6.11
Immunogenicity Analysis
Nivolumab arm only. See Core Safety SAP
7.6.12
Pregnancy
By-subject listing of pregnancy tests results will be provided 
7.6.13
Clinical Safety Program (CSP)
See Core Safety SAP
7.7
Pharmacokinetics
Pharmacokinetics analyses will be performed on nivolumab arm only. 
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
37
The concentration vs. time data obtained in this study will be combined with data from other 
studies in the clinical development program to refine a population PK model. This model will be 
used to evaluate the effects of ethnic as a categorical covariate and possibly other covaraites on 
the PK of nivolumab and to determine measures of individual exposure (such as steady-state peak, 
trough, and time-averaged concentration). Model determined exposures may be used for exposure-
response analyses of selected efficacy and safety end points. Results of population PK and 
exposure-response analyses will be reported separately.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.0
Approved
930109491
3.0
v






Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
40
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8
CONVENTIONS
The following conventions may be used for imputing partial dates for analyses requiring dates:

For missing and partial adverse event onset dates, imputation will be performed using the 
Adverse Event Domain Requirements Specification19. 

Missing and partial Non-Study Medication Domain dates will be imputed using the derivation 
algorithm described in 4.3.3 of BMS Non-Study Medication Domain Requirements 
Specification20.
For death dates, the following conventions will be used for imputing partial dates:
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
41

If only the day of the month is missing, the 1st of the month will be used to replace the missing 
day. The imputed date will be compared to the last known date alive and the maximum will be 
considered as the death date.

If the month or the year is missing, the death date will be imputed as the last known date alive. 
If the date is completely missing but the reason for death is present the death date will be 
imputed as the last known date alive 
For date of progression, the following conventions will be used for imputing partial dates:

If only the day of the month is missing, the 1st of the month will be used to replace the missing 
day*.

If the day and month are missing or a date is completely missing, it will be considered as 
missing.

In case of the date of death is present and complete, the imputed progression date will be 
compared to the date of death. The minimum of the imputed progression date and date of death 
will be considered as the date of progression.

For other partial/missing dates, the following conventions may be used:

If only the day of the month is missing, the 15th of the month will be used to replace the 
missing day.

If both the day and the month are missing, “July 1” will be used to replace the missing 
information.

If a date is completely missing, it will be considered as missing.
The following conversion factors will be used to convert days to months or years: 
1 month = 30.4375 days and 1 year = 365.25 days.
Duration (e.g. time from first diagnosis of NSCLC to first dosing date, duration response, and time 
to response) will be calculated as follows:
Duration = (Last date - first date + 1)
All statistical analyses will be carried out using SAS (Statistical Analysis System software, SAS 
Institute, North Carolina, USA) unless otherwise noted.
9
CONTENT OF REPORTS
All analyses describe in this SAP will be included in the final Clinical Study Report. All analyses 
will be repeated for subset of subjects from China for the China CSR. Refer to the Data 
Presentation Plan for mock-ups of all tables and listings.
3.0
Approved
930109491
3.0
v


Statistical Analysis Plan
CA209-078
BMS-936558
Nivolumab
42
10
DOCUMENT HISTORY
Table 10-1:
Document History
Version 
Number
Author(s)
Date
Description
1.0
Christine 
Baudelet
20Dec2016
Initial version 
2.0
Christine 
Baudelet
01Mar2017
Changes related to Amendment 03
1.2 Schedule of Analyses: timing of Interim and final 
analysis of OS and TTF IA revised
2.4 Protocol Amendments: amendment 03 added
4.1 Primary Endpoint: statement about crossover rate 
and treshold for consistency removed 
4.2.3
Time to Treatment Failure: definition of TTF 
endpoint refined. Description of the sensitivity 
analyses removed as described in section 7.5.6
5 Sample Size and Power: required number of events at 
OS IA/FA revised, comparison of power with the 
weighted vs regular log rank test provided, power as 
function of the cross over rate provided
6.3 Populations for Analyses: TTF population: 
description revised
7.5.1.1
Primary Analysis of OS: 2 step hierarchical 
testing added at OS IA. Weighted log rank test added.
7.5.1.2
OS Sensitivity Analyses: regular log-rank test 
added, sensitivity analysis limited to required number 
of events for OS IA: number of events revised
7.5.6
TTF Interim Analysis: number of randomized 
patient to be included in TTF interim analysis revised. 
DMC review added.
7.5.6.2
TTF Sensitivity Analyses: section revised
7.5.7
OS Interim Analysis: required number of 
events at OS IA/FA revised
Other changes:
Table 4.2.2-1:
Censoring Scheme for Primary 
Definition of PFS: censoring rule when no baseline 
tumor assessment revised (no death condition 
removed)
7.5.1.8
OS Analysis at time of TTF interim analysis: 
analysis by histology added
2.1
Christine 
Baudelet
02May2017
Changes related to Protocol Amendment 04
Analyses of OS/PFS for TTF population at time of TTF 
interim analysis removed 
Definition of TTF endpoint refined
3.0
Approved
930109491
3.0
v